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ABSTRACT 
Members of the angucycline group of antibiotics are produced by different Streptomyces 
species and share common structural feature – the four-ring aglycon frame organized in a 
planner manner. Simocyclinone D8 is a potent inhibitor of the DNA gyrase supercoiling 
activity. It is the highly complex hybrid antibiotic, which comprises four parts that are coming 
from three pools of primary metabolism: angucyclic and linear polyketides, deoxysugar 
moiety and aminocoumarin. Although a hypothesis explaining simocyclinone biosynthesis 
has been previously proposed, little was proven in vivo due to the genetic inaccessibility of 
the producer strain. Three new D-type simocyclinones (D9, D10 and D11) produced by 
Kitasatospora sp. and Streptomyces sp. NRRL-24484, as well as their biosynthetic gene 
clusters, have been identified. The gene inactivation and expression studies have disproven 
the role of a modular polyketide synthase (PKS) system in the assembly of the linear 
dicarboxylic acid. Instead, the new stand-alone ketosynthase genes were shown to be involved 
in the biosynthesis of the tetraene chain. Additionally, the gene responsible for the conversion 
of simocyclinone D9 into D8 had been identified. Also biosynthetic gene cluster involved in 
the biosynthesis of another angucyclic polyketides grecocyclines from Streptomyces sp. Acta 
13-62 was identified and cloned. Grecocyclines have unique structural moieties such as a 
dissacharide side chain, an additional amino sugar at the C-5 position and a thiol group. 
Enzymes from this pathway may be used for the derivatization of known active angucyclines 
in order to improve their desired biological properties. 
  
   
 
ZUSAMMENFASSUNG  
Zugehörige zur Antibiotika Gruppe der Angucycline werden von verschiedenen Streptomyces 
Arten produziert und weisen strukturelle Gemeinsamkeiten, wie den planaren 4-Ring Aglykon 
Rahmen auf. Simocyclinon D8 ist ein starker Gyrasehemmer und verhindert damit das 
Supercoiling der DNA. Es ist ein hochkomplexes Hybrid Antibiotikum, das aus 4 Teilen, die 
aus 3 Gruppen des Primärstoffwechsels kommen, besteht: angucyclische und lineare 
Polyketide, Desoxyzuckerteile und Aminocoumarin. Obwohl kürzlich eine Hypothese 
aufgestellt wurde, die die Biosynthese von Simocyclinonen erklärt, ist in vivo aufgrund der 
genetischen Unzugänglichkeit des produzierenden Stammes nur wenig nachgewiesen. Drei 
neue D-Typ Simocyclinone (D9, D10, D11), produziert von Kitasatospora sp. und 
Streptomyces sp. NRRL-24484, sowie deren biosynthetische Gencluster wurden identifiziert. 
Die Gen Inaktivierungs- und Expressionsstudien haben die Rolle eines modularen 
Polyketidsynthasesystems (PKS) beim Zusammenfügen der linearen Dicarboxylsäure 
widerlegt. Stattdessen wurde gezeigt, dass die neuen eigenständigen Ketosynthase Gene an 
der Biosynthese der Tetraenkette beteiligt sind. Darüber hinaus wurde das für die 
Umwandlung von D9 in D8 verantwortliche Gen identifiziert. Auch das biosynthetische 
Gencluster, das an der Biosynthese eines anderen angucyclischen Polyketids, Grecocyclin von 
Streptomyces sp. Acta 13-62, beteiligt ist, wurde identifiziert und geklont. Grecocycline haben 
einzigartige strukturelle Reste wie die Disaccharid-Seitenkette, einen zusätzlichen 
Aminozucker am C5 Atom und eine Thiolgruppe. Enzyme dieses Wegs können für die 
Derivatisierung bekannter aktiver Angucycline verwendet werden um deren gewünschte 
biologische Eigenschaften zu verbessern.  
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I. INTRODUCTION 
1. Polyketides as a source for new therapeutics 
The polyketides are one of the most remarkable classes of natural products, distributed among 
bacteria, fungi, plants and animals. Few thousands of polyketides have been discovered till 
date from different sources. They exhibit vast structural and functional diversity, in addition 
to broad spectrum of biological and pharmacological activities. These secondary metabolites 
have been successfully implemented in medicine and agriculture, as they demonstrate 
antibiotic (tetracycline, erythromycin), anticancer (daunorubicin), anticholesterol (lovastatin), 
antifungal (griseofulvin, nistatin), antiparasitic (avermectin), insecticide (pamamycin, 
nonactin) and immunosuppressive (rapamycin) properties [1] (Figure 1).  
Today many polyketides and their derivatives are available on the market. Total sales of the 
more than 40 polyketide medicines reach more than 20 billion US $ a year, close to the total 
sales of protein therapeutics [2]. Because of their industrial potential and importance, 
intensive efforts have been made in finding novel polyketides since the middle of the 20
th
 
century.  
In order to deal with increasing development of the multidrug-resistant microorganism and 
the lack of the effective therapy for many severe diseases, discovering of the new natural 
products with improved properties is extremely urgent. The polyketides are one of the most 
promising niches due to their fascinating structural diversity that gives rise to the broad 
spectrum of biological activities.  
2. Discovery of the polyketide biosynthetic pathways 
Original function of polyketides in their native environment is so far not clear in all cases. 
They are believed to function as pigments, virulence factors, as molecules of defense or 
signaling molecules [3]. However, all of them share one common feature – the way how they 
are synthesized. Despite their structural differences, they are mainly derived from the acetic 
acid – one of the simplest building blocks in the nature. Intriguingly, the vast structural and 
functional diversity of polyketides results from the controlled assembly of some of the 
simplest building blocks in nature – acetate and propionate [3].  
In 1893 Collie and Myers isolated a first polyketide – orcinol, while attempting to prove the 
structure of dehydroacetic acid. Later that year James N. Collie coined the term “polyketide” 
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and proposed that orcinol and related compounds most probably are synthesized by repetitive 
condensation or polymerization reactions [4]. Later this hypothesis was proven 
experimentally by A. Birch and coworkers. Birch was studying biosynthesis of the aromatic 
polyketide 6-methylsalicylic acid (6-MSA) in fungi Penicilum patulum. He used isotopically 
labeled acetate and showed that 6-MSA is formed from four acetate units. With the advent of 
the modern molecular biology techniques in the second half of the 20
th
 century, it became 
possible to analyze how polyketides are made within the living cell.  
   
  
 
   
Figure 1. Examples of polyketide secondary metabolites 
 
Actinorhodin, a blue pigment produced by S. coelicolor, was the first polyketide understood 
in “genetic and molecular biological” terms [5]. Through series of experiments, the genes 
responsible for the actinorhodin biosynthesis were identified and later sequenced. Using DNA 
Erythoromycin 
antibiotic 
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recombinant technology it was possible to clone DNA fragment, able to complement all 
classes of actinorhodin non-producing mutants of S. coelicolor. Furthermore, a heterologous 
expression of the cloned DNA in S. parvulus, directed the biosynthesis of the blue pigment 
[6]. The sequences of established actinorhodin proteins showed high homology with the 
enzymes from fatty acid biosynthesis. 
3. Biochemistry of polyketides biosynthesis  
3.1. Polyketide biosynthesis vs. fatty acid biosynthesis 
The two biosynthetic pathways – fatty acid biosynthesis and polyketide biosynthesis are 
closely related and share common features – pool of simple precursors that are used to build 
the growing polyketide chain, such as acetyl-CoA and malonyl-CoA and the type of enzymes 
that are employed for chain assembly [3, 4]. In general, both, polyketides and fatty acids are 
assembled by successive rounds of decarboxylative Claisen condensation between an 
activated acyl starter unit and malonyl-CoA derived extender unit [3]. The simplest set of 
enzymes that is sufficient to build the polyketide chain involves β-ketoacylsynthase (KS), 
which catalyses condensation and phosphopantethienylated acyl carrier protein (ACP) or 
coenzyme A (CoA), which serve as an anchor for the growing chain. Optionally, malonyl-
acetyl transferase (MAT) might transfer the building blocks from the coenzyme A pools to the 
ACP. The result of the condensation is a generation of ACP-bound β-ketoacylthioester. The 
phosphopantethiene functions in ACP as a flexible arm that carriers the growing chain and 
delivers it to the enzymes that are modifying nascent polyketide. After every chain elongation 
the keto ester can be reduced to an alcohol by ketoreductase (KR), dehydrated to alkine by 
dehydratase (DH) and alkine can be hydrogenated by an enoyl reductase (ER) to yield fully 
saturated acyl backbone. During the fatty acid biosynthesis (performed by FAS – fatty acid 
synthase) successive cycles lead to a chain of the required length (14, 16 or 18 carbon atoms). 
The chain is released by the thioesterase enzyme (TE). All FASs have the same set of 
components – KS, ACP, KR, DH, ER, MAT and TE and typically catalyze a full reductive 
cycle after each elongation. In contrast, during polyketide chain assembly, modification of the 
keto group is optional and can be completely excluded. If the reduction of the keto group is 
skipped, it will be present in the polyketide; when no functional DH is present, alcohol is 
incorporated into the chain and skipping of the enoyl reductase reaction will yield unsaturated 
chain. Polyketide biosynthesis differs from fatty acid biosynthesis in many other ways. For 
example, polyketide synthase can utilize much broader spectrum of the biosynthetic building 
blocks (e.g methylmalonyl-CoA, hydroxymalonyl-CoA, ethylmalonyl-CoA and others), 
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whereas FASs uses only – malonyl-CoA. The utilization ofvarious starter and extender units, 
the optionality of the keto group downstream modifications,the introduction of a chirality and 
variations in the cyclisation of the polyketide chain can yield a fascinating complex 
polyketide [3].  
Based on the architecture pattern and mode of action PKSs are classified on different types. 
Type I PKSs are gigantic polypeptides, that comprise a certain number of linear arrange and 
covalently fused functional modules. Type II PKS refers to a dissociable of discrete and 
typically monofunctional domains. Chalcone synthase, or type III PKS, is a homodimeric 
protein that is not depended on ACP and acts directly on CoA-activated substrate. In addition, 
PKSs are categorized as iterative or noniterative, depending on whether each module 
catalyzes one or more rounds of elongation (Table 1).  
Table 1. Types of PKSs 
 
    
PKS ACP Strater unit Extender unit Organisms 
Type I modular 
    
 noniterative  cis-AT Yes various various Bacteria, protists 
 noniterative trans-AT Yes various various Bacteria, protists 
 Iterative  Yes various Malonyl-CoA Fungi, some 
bacteria 
 
Type II (iterative) Yes various Malonyl-CoA Bacteria 
Type III (iterative) No various Malonyl-CoA Plants, bacteria, 
fungi 
PKS-NRPS hybrids Yes Various, 
amino acids 
Malonyl-CoA, 
amino acids 
 
Bacteria, fungi 
3.2. Modular polyketide synthases 
The erythromycin synthase (6-deoxyerythronolide B synthase, DEBS) from 
Saccharopolyspora erythraea is the prototypical PKS for polyketide biosynthesis. Since the 
DEBS genes were cloned, there was an explosive growth of PKS sequences discovery. The 
approx. number of assembly line polyketides sequences available in NCBI database is more 
than 1000 [7], nevertheless, DEBS is still one of the most favorable model for scientists to 
study the details and mechanisms of polyketide biosynthesis. The first DNA sequences and 
analyses of the erythromycin biosynthetic gene cluster have been published in 1990th, 
simultaneously by two groups [8-11]. The first macrolide intermediate during erythromycin 
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biosynthesis is 6-deoxyerythronolide B (6-dEB). Three gigantic genes - eryAI, eryAII and 
eryAIII are responsible for the biosynthesis of 6-dEB. They encode three multienzyme 
polypeptides –DEBS 1, 2 and 3, respectively (~ 350 kDa each). Interestingly, the DEBS 
proteins are relatively small, compared to those, involved in biosynthesis of, for example, 
rapamycin, rifamycin and nystatin [4]. 
Each DEBS is made of two modules (DEBS 1 – modules 1 and 2, DEBS 2 – modules 3 and 4 
and DEBS 3 – modules 5 and 6). In addition, DEBS 1 harbors loading domain (LD) and 
DEBS 3 – TE. Loading domain of DEBS 1 consists of AT and ACP and accepts the starter 
unit – propionate, whereas TE is responsible for the release of the polyketide chain and its’ 
subsequent cyclisation into the lactone ring. Each module contains three domains for 
catalyzing elongation reaction – KS, AT and ACP and a variable set of domains involved in 
the reduction steps. The growing polyketide chain is bound to the synthases throughout the 
entire biosynthetic process (Figure 2).  
 
Figure 2. Domain organisation of the erythromycin polyketide synthase. Putative domains 
are represented as circles.  
 
To generate 6-dEB, one propionyl-CoA, six methylmalonyl-CoA units and six NADPH are 
required. The erythromycin biosynthesis is initiated by a propionyl-CoA uptake from the 
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primary metabolism pool and transfering it onto the loading module.The propionyl moiety is 
passed to the first module that simultaneously picks up (2S)-methylmalonyl-CoA from the 
cell environment. Aftewards, methylmalonyl-CoA is decarboxylated and attached to the 
propionyl anchored on the ACP of the module 1. This chain is then passed downstream with 
the incremental addition of precursors at each module of the assembly line, resulting in the 
linear heptaketide intermediate that will be off-loaded and cyclized.  6-dEB should be further 
decorated to form the mature erythromycin molecule. Usually, the polyketides are prepared in 
a “skeleton” form and later are derivatized through various kinds of modification reactions 
(hydroxylation and sugar incorporation for 6-dEB) to give the final product.  
Sometimes the order of domains in the modular PKSs may not correspond to the polyketide 
pattern. The rapamycin polyketide synthase (RAPS) represents one of the first example [12]. 
RAPS comprises three large polypeptides – RAPS 1 (~900 kDA, 4 modules), RAPS 2 (~1 
MDa, 6 modules) and RAPS 3 (660 kDa, 4 modules). Modules 3 and 6 of RAPS contain KR 
and DH domains (plus ER domain in module 3) that are nominally active, but functionally 
redundant. There is a chance that these domains were disabled in the way that is not visible 
from the primary sequence, or, perhaps they are functional but sites of their action are 
modified in the post-translational events. Mismatch between PKS sequence and the 
polyketide pattern was observed in other cases as well [4].  
3.3. Type I iterative PKS 
Type I iterative polyketide synthases are  close “relatives” of the modular PKSs. Type I 
iterative PKSs have thesimilar protein architecture, as modular PKSs, however, the single 
module in this case acts iteratively – reusing domains in a cyclic fashion [13]. AviM, involved 
in biosynthesis of avilomycin, was the first type I iterative PKS discovered in bacteria [14]. It 
comprises KS, AT, DH and ACP domains typical for type I PKS. At first, AviM was treated 
not as iterative type I PKS from bacteria, but rather as exception from type II PKS paradigm 
[13].  
3.4. Type II PKSs 
Type II PKS are involved in a biosynthesis of natural products that give rise to a number of 
clinical useful drugs and promising drug candidates. Type II PKS – derived polyketides are 
structurally diverse and are classified as anthracyclines, angucyclines, aureolic acids, 
tetracyclines, tetracenomycins, pradimicin-type polyphenols, and benzoisochro-manequinones 
[15]. Type II PKS, or so-called “minimal” PKS, are comprised of several individual enzymes, 
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each encoded by a separate gene. A standard set of enzymes includes two ketosynthase units 
(KSα and KSβ) and an ACP [16-19]. Almost in all gene clusters “minimal” PKS genes are 
grouped into a typical KSα/KSβ/ACP operon [15]. Genes encoding enzymes that are involved 
in further modification of the nascent linear polyketide chain (cyclases, aromatases and 
ketoreductases), usually, are clustered in a close proximity to the PKS genes. Further 
modifications of the poly-β-keto intermediate usually include hydroxylation, methylation and 
glycosylation.  
In contrast to type I PKSs which may employ a great variety of starter and extender units, 
type II PKSs usually use acetyl-CoA and malonyl-CoA, respectively. KSα and KSβ are highly 
similar, however only KSα catalyze C-C bond formation through Claisen condensation. KSβ 
(or chain length factor, CLF) is deficient for cysteine in its active center, which is crucial for 
the polyketide assembly. Despite the mutation in the active center, it was shown that KSβ 
plays an important role in the polyketide chain elongation, as it is a primary determinant of a 
polyketide chain length and is generating acetyl KS after the decarboxylation of malonyl-ACP 
[15, 20]. Since the genes encoding MCATs are absent in most of the type II PKS gene 
clusters, there has been an ongoing debate regarding the transfer of the malonyl extander units 
to the PKS. It was proposed that an endogenous MCAT is recruited from fatty acid 
biosynthesis. An alternative model is a self-malonylation of ACP, as it has been demonstrated 
in vitro. During the biosynthesis KS and CLF form a heterodimer and the protein cleft keeps 
the nascent poly-β-keto intermediate extended in the way, where highly reactive keto groups 
are separated and probably contact KSα-KSβ mainly as enols [15]. A typical length of 
polyketides synthesized by type II PKS is either 16, 20 or 24 C atoms. The length of the 
polyketide chain is controlled by the protein cavity formed by KS and CLF. Khosla and 
coworkers [21] have demonstrated that regions defining chain length are located at the 
interface of the dimer. It was suggested that the residues 109, 112 and 116 in the actinorhodin 
CLF serve as a gatekeepers at the KS/CLF tunnel and reducing the length of this residues 
allows two more extension cycles. Additionally, interactions of KS/CLF with other proteins 
have effect on the polyketide chain length [21]. Other components of type II PKS complex 
have influence on the chain length as well, for example disruption of an aromatase/cyclase 
from the oxytetracycline (otc) gene cluster lead to the production of novel, shorter, 
polyketides. Similar effect was shown for whiE, act, and hedamycin (hed) [22-24]. Also KRs 
from actinorhodin and hedamycin biosynthetic gene clusters are able to modulate chain length 
specificity of KS-CLF [22]. In conclusion, it seems that not only CLF but the entire type II 
PKS complex determines the polyketide chain length.  
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3.5. Priming for type II PKS 
In most cases aromatic PKS are primed by decarboxylation of malonyl-CoA to yield an 
acetyl-KS intermediate, which is subsequently elongated by the minimal PKS [15]. However, 
many type II PKS deviate from decarboxylation mechanism and are primed with non-acetate 
units [25]. Two alternative pathways are involved: presence of the monofunctional acyl-CoA-
ligase (ACL) and AT, which are responsible for the activation and transfer of the starter unit 
to the “minimal” PKS and involvement of the additional KSIII (and ACP) for biosynthesis 
and attachment of the short-chain fatty acids [25].  
The first mechanism of the alternative mechanism for type II PKS priming was intensively 
studied for enterocin, where biosynthesis is primed with benzoyl-CoA that is formed from 
phenylalanine via β-oxidative route and oxytetracycline, where malonamate is activated and 
transferred to the minimal PKS [25-27].  
Scenario, where KSIII is implicated in the biosynthesis of primer unit was discovered for 
daunorubicin, frenolicin, R1128 and others. Daunorubicin and doxorubicin gene clusters 
contain two additional PKS elements – FabH-like KS and AT [28, 29]. It was suggested that 
KSIII catalyzes first condensation between malonyl-CoA and propionyl-CoA to yield β-keto 
ester, as in fatty acid biosynthesis. Later the diketide would be loaded on the minimal PKS by 
AT. Hutchinson and Strohl groups, in independent studies, showed that dps PKS exhibit 
relaxed starter unit specificity to acetyl-CoA in the absence of the KSIII [30, 31].  
In general, presence of KSIII (and additional ACP) in the type II PKS gene cluster is a good 
indication for priming with non-acetate unit. However, there are exceptions as well, for 
example during the biosynthesis of the polyketide with the anticancer activity – hedamycin 
[22]. 
3.6. Pamamycin and nonactin – polyketide biosynthesis beyond the paradigm 
There are several exception from the PKSI/PKSII paradigm. The most striking are 
ketosynthases involved in the biosynthesis of nonactins and pamamycins. Typically, succinate 
is not used as a building block by PKSs as it cannot directly participate in Claisen 
condensation, however feeding experiments clearly demonstrate that there are at least two 
natural products – pamamycin and nonactin, known to utilize succinate as a building block 
[32]. Pamamycins and nonactin are a group of macrodiolide antibiotics of the streptomycetes 
origin with a number of biological activities [32, 33]. Pamamycins are composed of two 
asymmetrical parts – hydroxy acid small and hydroxy acid large, while nonactin of four 
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molecules of enantiomeric nonactic acid [32, 34]. Studies using the 
13
C labeled precursors 
showed a direct incorporation of 3-oxoadipate into the nonactin and utilization of acetate and 
succinate as building blocks for its assembly [35]. Despite the structural evidence, molecular 
mechanisms of their biosynthesis remained unclear for a long time. The gene cluster for the 
biosynthesis of nonactin (non) contains five unusual KS that were classified as non-iterative 
type II PKS based on sequence similarity despite the lack of ACP [33, 34]. Pamamycin gene 
cluster (pam) share a high degree of homology with the non gene cluster, it harbors genes 
encoding seven discrete KS enzymes and one ACP (pamC). Deletion of pamC shifted 
pamamycin biosynthesis toward the accumulation of lower molecular weight compounds, 
indicating that PamC takes part in the delivery of starter units, as described above. All KSs in 
the pam cluster, except for PamA, exhibit active site triad typical for type III PKS. PamA was 
shown to participate in the first condensation step between succinate and malonyl- or 
methylmalonyl-CoA to yield 3-oxoadipyl-CoA, which represents an intermediate between the 
secondary and primary metabolism. Interestingly, 3-oxoadipyl-CoA and 2-methyl-3-
oxoadypil-CoA have to be rotated by acyltransferase PamB to further participate in the 
biosynthetic pathway. The resulting 4-oxoadipyl-CoA and 5-methyl-4-oxoadipyl-CoA are 
used as extenders for a Claisen condensation facilitating the incorporation of succinate and the 
starter units most probably are supplied as ACP-esters. Small and large hydroxy acids, which 
are synthesized in the following steps, later are re-activated by an acyl-CoA ligase, PamL and 
the closure of the pamamycin macrodiolide ring is perfomed by PamJ and PamK KSs that 
catalyze an unusual C-O condensation reaction (Figure 3). The function of PamA was proven 
in in vitro and in vivo studies and so far is a first studied enzyme responsible for the 
incorporation of succinate into a polyketide molecule [32].  
4. Simocyclinone D8 
Simocyclinone D8 (SD8) was isolated in 2000 from the mycelium extract of S. antibioticus 
Tü6040, collected in Iguaçu, Argentina [36]. SD8 is a unique natural hybrid antibiotic, as it 
consists of four different moeities that are comming from at least three primary metabolites 
pools [37]. Angucyclic polyketide is joined with the aminocoumarin part through the D-
olivose sugar and the polyunsaturated linear polyketide (Figure 4). The aromatic polyketide 
core is characterised by a large number of unusually placed hydroxyl groups and an epoxy 
group placed between C12a and C6a. D-olivose is acetylated at 4-OH position and linked to 
the tetraene chain is attached to its 3-OH group. The aminocoumarin moeity is halogenated at 
C17’’ position and linked to the tetraene side chain via an amid bond.  
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PamA PamB 
PamD 
PamE 
PamF 
PamG 
PamOMN 
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PamY 
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CoASH 
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PamJ 
PamK 
R1, R3, R4 = Me, Et 
R2, R5 = H, Me 
R = Me, Et, Pr 
 
Figure 3. Proposed pathway for the biosynthesis of pamamycin 
 
Beside SD8, S. antibioticus also produces other simocyclinones that can be considered as 
intermediates in the SD8 biosynthesis. These simocyclinones are divided into four types: 1)  
A-type simocyclinones consist of an aromatic polyketide moiety; 2) B-simocyclinones with 
PamOMN 
PamS 
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A-type  
B-type  
C-type  
D-type  
D-olivose is attached to the angucycline; 3) C-type simocyclinones - angucyclic polyketide 
plus deoxysugar plus tetraene chain and 4) D-type is a full molecule with the four functional 
parts. 
 
Figure 4. Simocyclinone D8 
 
4.1. Biosynthesis of simocyclinone 
SD8 biosynthetic gene cluster from S. antibioticus Tü6040 was reported by the groups of 
Bechthold [38] and Heide [39] and revealed 49 ORFs. The genes responsible for the 
biosynthesis of the aromatic polyketide (simA genes) show high similarity to the angucycline 
encoding genes from various gene clusters. A set of the minimal PKS genes and “auxiliary” 
genes (simA1-simA5, simA11) has been identified as well as genes for ketoreductases and 
oxygenases (simA6-simA10, simA12) that are involved in the modification of the nascent 
polyketide chain. The deduced amino acid sequence of SimA13 shares high similarity with 
P450 hydroxylases and is one of the candidates to be involved in the formation of the epoxy 
group in the angucyclic polyketide (personal communications). All simA genes are clustered 
together, except simA13, which is located in the different locus. The simB-series genes are 
involved in the formation and the attachment of the D-olivose moiety. The deoxyhexose 
biosynthesis starts from the activation of glucose-1-phosphate by NDP-D-glucose synthase 
(SimB1) with the subsequent dehydratation (SimB2 and SimB3) and ketoreduction (SimB4 
and SimB5). SimB7 is the glycosyltransferase attaching the D-olivose moiety to the 
angucycline and SimB6 is the acetyltransferase involved in the acetylating of the glycosylated 
angucycine. Several simocyclinones from B-, C- and D-series carry not acetylated D-olivose, 
indicating that incorporation of an acetyl group take place after the attachment of the 
deoxysugar to the aglycon. Notebly, the simB genes are not placed together – simB1, simB2, 
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simB3 and simB7 are located on the one end and simB4, simB5 and simB6 on the other end of 
the cluster. The simD1-simD6 genes encode enzymes involved in converting of L-tyrosine to 
aminocoumarin. It was suggested that L-tyrosine is activated by covalent binding to a 4-
phospho-pantetheinyl cofactor of SimD6 (SimH) similar way as during the novobiocin 
biosynthesis [39, 40]. Subsequently L-tyrosine is modified to the β-keto intermediate by 
SimD1 and SimD2, and afterwards is oxidatively cyclased by SimD3 yielding the 
aminocoumarin part. An amid bond between the aminocoumarin and the octatetraene 
dicarboxylic acid moiety in SD8 is formed by SimD5 (SimL). In vitro studies on SimL done 
by the groups of Heide [41] and Walsh [42] demonstrated the SimL relaxed specificity to 
structurally diverse substrates what was successfully applied to generate a novel novobiocin 
analogue. simD4 (the only simD gene located elsewhere in the sim cluster) is highly similar to 
the halogenases and presumably preforms the formation of the chlorinated SD8. simX1 
(simY), located between simD1 and simD2 in the sim gene cluster, is a MbtH-like protein, 
found in many secondary metabolites gene clusters [43]. When the sim cluster was published 
simX1 was annotated as the gene of an unknown function [38]. However, later Boll et al., [43] 
demonstrated that SimH (SimD6) and its analogues from other aminocoumarin biosynthetic 
gene clusters, require MbtH-like proteins for their catalytic activity in a molar ratio 1:1. In the 
absence of MbtH-like proteins activity of the tyrosine-adenylating enzymes was lowered by 
99.0 – 99.8%.  
Three ORFs of the sim cluster encode large, multifunctional type I PKSs [38]. SimC1A 
contains three modules (one loading module and two extension modules), while SimC1B and 
SimC1C have only one extension module each (Figure 5). The domains number and order in 
SimC1A-SimC1C PKSs do not perfectly correspond to the observed polyketide pattern. 
Activities of the KR and DH domains are predicted to be required for the biosynthesis of the 
tetraene chain, but the module II does not contain a DH domain, and there are no DH and KR 
domains in the module IV. The ER domain from the module III is not needed for the 
octatetraene dicarboxylic acid formation and the AT-specificity to the methylmalonyl 
substrates in modules I and IV is not consistent with the polyketide side chain structure [38]. 
However, as mentioned above, similar observations have been made for other natural product 
clusters as well. A number of genes encoding enzymes, which might be involved in the 
tailoring reactions on the assembled polyketide chain, have been identified in the sim cluster. 
Feeding experiments with [1,3-
13
C2]-  and  [2-
13
C]malonic  acid  confirmed that angucyclic 
polyketide is built from 10 acetate units and the  octatetraene dicarboxylic  acid  derives  from  
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five  acetate  units,  starting from  the  left side  (C-10”) [37]. Also, biosynthesis of 
simocyclinone in an 
18
O2 rich atmosphere showed signal shifts for C-6a, C-12b, C10”and 
C17a” positions, in accordance to the proposed ways of the aminocoumarin and the tetraene 
chain formation [44]. 
 
Figure 5. Proposed model for the tetraene chain biosynthesis in S. antibioticus Tü6040 
 
Two transporter (simEx1, simEx2) and three regulatory (simReg1, simReg2 and simReg3) 
genes have been identified in the sim cluster [38]. SimReg1 is a key regulator of the 
simocyclinone biosynthesis, as it activates the transcription of the simocyclinone structural 
genes, transporter genes, regulatory gene simReg3 and its own transcription [45]. SimReg2 
(SimR) and SimEx1 (SimX) resemble the TetR/TetA repressor-efflux pump pair and are 
involved in simocyclinone efflux and resistance. The simX promoter is directly repressed by 
SimR, which binds to two operator sites in the simR-simX intergenic region [46]. SimR was 
shown to dissociate from the intergenic regions in the presence of the SD8 [46-49]. The 
operator of SimReg2 partially overlaps with the DNA-binding region of SimReg1upstream to 
the start codon of simX, indicating the competition between SimReg1 and SimReg2 for  
binding to the simX promoter (PSEx1) [45]. Bechthold and co-workers suggested the following 
preliminary model for the regulation of simocyclinone biosynthesis and export. When the 
concentration of simocyclinone or its intermediates is low, SimR binds to the simX regulatory 
region and its transcription is repressed. At the same time SimReg1 activates expression of the 
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structural sim genes and thus the simocyclinone biosynthesis. SimR is released from the simX 
promoter when the concentration of simocyclinone increases, allowing SimReg1 to bind to 
the PSEx1. This activates the simX expression and efflux of simocyclinone from the cell. This 
mechanism couples the biosynthesis of simocyclinone to its export [45]. 
4.2. Simocyclinone D8 – DNA gyrase inhibitor 
SD8 is a potent inhibitor of the DNA gyrase supercoiling and has activity against gram-
positive bacteria, certain clinical isolates of Escherichia coli and distinct cytostatic activities 
against human tumor cell lines and [36, 50].  
DNA topoisomerases are enzymes that modulate DNA topology to maintain a chromosome 
superstructure and integrity [51]. These enzymes are divided in two types depending on  their 
mechanism of action which can be implemented through braking one (type I) or two (type II) 
strands of DNA. The DNA gyrase belongs to the type II topoisomerases and is the only one 
among this type capable of catalyzing DNA supercoiling, in the reaction driven by ATP 
hydrolysis [52].  
The DNA gyrase consists of two subunits, GyrA (97 kDa in E.coli) and GyrB (90 kDa in 
E.coli) that form a heterodimer. The GyrA subunit is involved in the interaction with DNA, 
and contains tyrosine in the active-site responsible for DNA cleavage, while the ATPase 
active site is located in the GyrB. There are two mechanisms of DNA gyrase inhibition by the 
antibacterial drugs: gyrase poisoning, or stabilization of the covalent enzyme-DNA complex 
and inhibition of the gyrase enzymatic activity [52]. Ciprofloxacin is an example of the 
cleavage-complex stabilizing agent, and novobiocin is a compound that inhibits the ATPase 
activity of the gyrase is an example of catalytic inhibitors. Novobiocin was the first 
aminocoumarin, which was introduced into the human anti-infective therapy in 1964 under 
the name Albamycin ® and used for the treatment of Staphylococcus aureus infections, 
including MRSA [53]. Four of five natural aminocoumarins discovered, novobiocin, 
clorobiocin, coumermycin and simocyclinone are antibiotics that target DNA gyrase, but they 
do so in the entirely different ways [53]. The “classical” aminocoumarins – novobiocin, 
clorobiocin, coumermycin and their derivatives inhibit the gyrase ATPase reaction by 
competing with ATP for binding to GyrB. Their binding site lies in the 24-kDa terminal sub-
domain of GyrB and overlaps with the ATP-binding site, preventing ATP binding. 
Specifically, the binding site of the adenine ring of ATP overlap the binding site of the 
noviose sugar of aminocoumarins [52]. 
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Surprisingly, despite carrying the aminocoumarin moiety, SD8 does not target the ATP-
binding site of GyrB, but binds to the N-terminal domain of GyrA, and prevents its interaction 
with DNA [54, 55]. The interaction between DNA gyrase and SD8 have been well studied, 
including two crystal structures of a complex formed between a 59-kDa [54] and 55-kDa [56] 
N-terminal domain fragment of the E. coli GyrA subunit. Analysis of the GyrA59-SD8 
complex revealed two binding pockets that separately accommodate the aminocoumarin and 
the angucycline parts of SD8, forming a cross-linked GyrA59 tetramer in the crystal. 
Additional analyses were performed to prove that it was not a crystallographic artifact [54]. A 
new crystal structure of SD8 with GyrA55 was generated to further explain the mechanism of 
the DNA gyrase inhibition by this antibiotic. The conformation of SD8 in GyrA55-SD8 was 
significantly different to that observed in GyrA59-SD8, first of all because SD8 was bound 
entirely within one GyrA55 homodimer. The angucycline part was shifted to a position where 
it spans the interface between the two GyrA monomers, whereas the aminocoumarin binding 
pocket is essentially the same as observed before, but its orientation is different. Also, no 
additional electron density adjacent to the angucycline, which was modeled as Mg
2+
 in the 
GyrA59-SD8 complex, has been identified. The observed position of SD8 across the dimer 
interface “staples” it closed, preventing conformational changes that need to occur to allow 
DNA binding. Through the evaluation of point mutants, which were generated earlier to probe 
GyrA-SD8 interactions,  Maxwell and co-workers have shown, that the new structure is more 
likely to be representative of the mode of action of SD8 on DNA gyrase [56].  
Interestingly, another binding site for SD8 in GyrB was proposed by Sissi et al., [57]. 
Additional binding was seen on the GyrB47 domain lacking ATP- and coumarin-binding site, 
probably affecting the enzyme’s interface and impairing DNA binding. Later, Maxwell and 
cowerkers [56], based on the different affinity of SD8 to GyrA and GyrB have suggested that 
the interaction between SD8 and GyrB may be an in vitro artifact, manifesting in the absence 
of GyrA. 
SD8 show potency against both the E. coli and S. aureus gyrase, but not topoisomerases IV 
[52]. IC50 value for SD8 was calculated as at least two times lower than that for novobiocin 
and approximately seven times lower than that for ciprofloxacin [55]. SD8 also exhibit potent 
antiproliferative activity against certain cancer lines, where its target appears to be human 
topoisomerase II (Topo II) [52]. Interestingly, SD8 was shown to inhibit the relaxation 
activity of human topoisomerase I (Topo I) [58]. This observation was unexpected as unlike 
human Topo II, human Topo I doesn’t have any structural similarities to the gyrase. The 
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inhibition effect of SD8 on human Topo I and II are essentially identical in the relaxation 
assays. The IC50 value of SD8 on human Topo I was approximately 2-fold higher than that of 
clinical drug camptothecin, whereas the IC50 value of SD8 for human Topo II was 
approximately 2-fold lower than that of etoposide [58]. 
Fluoroquinolones and aminocoumarins are the only two classes of the gyrase inhibitors, 
which have been introduced into clinical anti-infective therapy. Over the years 
fluoroquinolones like ciproflaxicin have become one of the most successful antibacterial 
agents. However, there usefulness is becoming limited by the spread of fluoroquinolone-
resistant bacteria [53]. Coumarins are potent inhibitors of gyrase with the limited resistance, 
as mutations in GyrB subunit show loss of enzymatic activity due to their proximity to the 
ATPase active site. On the other hand, their clinical success is limited by eukaryotic toxicity, 
poor activity against Gram-negative bacteria and low solubility. Therefore, searching for a 
new gyrase inhibitors is of a great interest. SD8 as a potent gyrase inhibitor with the novel 
mode of action may serve as a useful lead compound for the development of new antibacterial 
and anticancer drugs. 
5. Transformation-associated recombination in yeast 
Nowadays more than 11000 secondary metabolite gene clusters from Actinobacteria are 
available in the databases, the vast majority of which are “orphans” that synthesize products 
of yet unknown structure [59]. Heterologous expression of the orphan biosynthetic gene 
clusters is a possibility to explore the Actinobacteria biosynthetic potential. Heterologous 
expression has been used to discover new compounds by screening genomic libraries, to 
analyze natural product biosynthesis using genetic engineering and to confirm the clustering 
of secondary metabolite biosynthetic genes [60]. Natural product gene clusters may reach up 
to 100kb in size and even more, but cosmid and fosmid library inserts are restricted in size of 
approximately 40 kb and further manipulations are needed to assemble the entire biosynthetic 
pathway on a single vector from the multiple cosmids [61]. 
Transformation associated recombination (TAR) approach is an alternative, based on the 
homologous recombination to selectively capture a locus of interest from the DNA pool [62]. 
In the TAR protocols the “capture” vector with the short homology arms to the sequence of 
interest is cotransformed with the genomic DNA into the yeast Saccharomyces cerevisiae. 
TAR cloning in yeast takes advantage of its natural very efficient recombination activity – the 
capture vector arms and the homologous target DNA undergo recombination to yield a stable 
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plasmid containing the genomic region of interest [63-65].  Such plasmids are maintained as  
circular yeast artificial chromosomes (YACs) and are capable of carrying inserts up to 1 Mb 
[66]. Originally TAR was developed to facilitate cloning of large genomic DNA fragments 
without necessity to construct and screen genomic libraries. However, the scope of this 
methodology was extended, showing that it could be used for direct cloning of the 
biosynthetic pathways, reassembling eDNA-derived clones into a single construct and even 
for the assembly of a 1,077,947 bp functional synthetic genome from 1078 1-kb cassettes [63, 
64, 66, 67].  
Moore and coworkers [63] in 2014 have successfully adapted the TAR-based approach for the 
capture of a silent 67-kb biosynthetic pathway from the genomic DNA of a marine 
actinomycete. The followed heterologous expression of this gene cluster led to discovery of 
the novel antibiotic taromycin A. TAR enables straightforward and specific capture of a target 
biosynthetic gene cluster, without the size limitations or time consuming and laborious 
generation and screening of genomic libraries. Furthermore, it is a simple but efficient 
strategy for the discovery, characterization and modification of the natural products from 
bacteria that are hard to manipulate under the regular laboratory conditions. 
6. Outline of this work 
The purpose of this work was to explore molecular basis of biosynthesis of two angucyclic 
antibiotics: simocyclinone and grecocycline.  
Two new producer strains for simocyclinones, Kitasatospora sp. and Streptomyces sp. NRRL 
B-24484, have been identified using genome mining, leading to purification and structure 
elucidation of novel D-type simocyclinones. The genomes of the producing strains were 
sequenced and the simocyclinone biosynthetic gene clusters identified.  A comparison of the 
newly identified simocyclinone gene clusters with the previously published one provides 
several important and surprising insights into the biosynthesis of these complex natural 
products. Moreover, the development of genetic tools for the producing Kitasatospora strain 
allowed characterization of genes involved in the biosynthesis of the tetraene.  
In addition, transformation-associated recombination in yeast had been successfully employed 
for cloning and heterologous expression of the grecocycline biosynthetic gene cluster. Unique 
glycosyltransferase, oxygenase and thioesterase involved in grecocycline biosynthesis had 
been identified. 
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II. RESULTS 
1. New simocyclinones: surprising evolutionary and biosynthetic insights  
Abstract 
Simocyclinone D8 has attracted attention due to its highly complex hybrid structure and the 
unusual way it inhibits bacterial DNA gyrase by preventing DNA binding to the enzyme. 
Although a hypothesis explaining simocyclinone biosynthesis has been previously proposed, 
little was proven in vivo due to the genetic inaccessibility of the producer strain. Herein, we 
report discovery of three new D-type simocyclinones (D9, D10 and D11) produced by 
Kitasatospora sp. and Streptomyces sp. NRRL B-24484, as well as the identification and 
annotation of their biosynthetic gene cluster. Unexpectedly, the arrangement of the newly 
discovered biosynthetic gene clusters is starkly different from the previously published one, 
despite nearly the identical structures of D8 and D9 simocyclinones. The gene inactivation 
and expression studies have disproven the role of a modular polyketide synthase (PKS) 
system in the assembly of the linear dicarboxylic acid. Instead, the new stand-alone 
ketosynthase genes were shown to be involved in the biosynthesis of the tetraene chain. 
Additionally, we identified the gene responsible for the conversion of simocyclinone D9 into 
D8. 
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Introduction 
Simocyclinones are a family of complex hybrid natural products from Streptomyces 
antibioticus Tü6040 (1). Simocyclinone D8 (1, SD8) shows the strongest activity against 
Gram-positive and Gram-negative bacteria and also has the ability to stop the proliferation of 
tumor cells (2, 3). It comprises a chlorinated aminocoumarin linked to an angucyclic 
polyketide via a tetraene linker and an acetylated D-olivose sugar. SD8 (1) inhibits DNA 
gyrase by preventing DNA binding to the enzyme (4-6). The crystal structure of 
simocyclinone bound to the enzyme revealed two binding pockets, one for aminocoumarin 
and one for the angucycline moiety. This unique mode of action on the validated drug target 
makes SD8 (1) an interesting candidate for drug development. However, the structural 
complexity of the molecule represents a major problem for medicinal chemistry’s ability to 
generate a library of simocyclinones derivatives with improved properties. Alternatively, 
biosynthetic pathway engineering can provide a platform for simocyclinone derivatization. 
This approach, however, requires the investigation and detailed elucidation of the 
simocyclinone biosynthetic pathway. The biosynthetic gene cluster responsible for SD8 (1) 
has been cloned and annotated by the Bechthold and Heide groups (7, 8). However, despite 
the extensive efforts of several laboratories, the simocyclinone biosynthetic pathway could 
not be engineered because of the genetic inaccessibility of the production strain. This did not 
allow researchers to use the power of metabolic engineering to decipher the simocyclinone 
biosynthetic pathway and to date only two enzymes have been characterizedSimD5 (SimL) is 
an amid-forming ligase that attaches the aminocoumarin to the tetraene chain (9-11)and 
SimC7 is an angucyclinone ketoreductase (12). 
In the present study, we report the genomic-driven identification and structure elucidation of 
novel D-type simocyclinones from Kitasatospora sp. and Streptomyces sp. NRRL B-24484. 
The genomes of the producing strains were sequenced and the simocyclinone biosynthetic 
gene clusters identified. A comparison of the newly identified simocyclinone gene clusters 
with the previously published one provides several important and surprising insights into the 
biosynthesis of these complex natural products. Moreover, the development of genetic tools 
for the producing Kitasatospora strain allowed us to characterize genes involved in the 
biosynthesis of the tetraene. 
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Results and Discussion 
Genomic based identification of the new simocyclinone-producing strains 
Access to the large and steadily increasing volume of genomic data enables rapid 
identification of bacteria species that harbor biosynthetic gene clusters that are responsible for 
the biosynthesis of a certain class of compounds. The genome mining/alignment of natural 
producers significantly helps in prioritizing which strain has the potential to synthesize the 
compound of interest or its derivatives. We have focused on the screening of simocyclinones 
producers due to their remarkable antibacterial activities and puzzlingly complex chemical 
structure. Two strains, K. sp. and S. sp NRRL B-24484, have been identified that carry sub-
clusters of genes in their genomes that are highly similar to those of the simocyclinone 
biosynthetic gene cluster from S. antibioticus Tü6040. Indeed, cultivation of K. sp. and S. sp 
NRRL B-24484 allowed us to isolate simocyclinone D9 (2, SD9), simocyclinone D10 (3, 
SD10) and simocyclinone D11 (4, SD11) (Figure 6, Figure S1). 
 
Figure 6. Structures of SD8 (1), SD9 (2), SD10 (3) and SD11 (4) 
The structure elucidation of the detected simocyclinones shows the minor differences in the 
A-ring of the angucycline sub-structure between the previously described SD8 (1) and newly 
isolated molecules. The arrangement of the other sub-structures (aminocoumarin ring, 
tetraene part, deoxysugar and acetyl moiety) in these hybrid molecules are identical (Chapter 
S1, Figures S1-S5c, Tables S1a-S3b)  
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Similarly to SD8 newly identified simocyclinones SD9 (2) and SD11(4) are able to inhibit the 
process of DNA gyrase supercoiling with 4 (2, determined IC50 value is 0.41 ± 0.031 µM) 
and 50 (4, determined IC50 value is 4.59 ± 0.5 µM) times lower activities than SD8 (1, 
determined IC50 value is 0.09 ± 0.018 µM) (Figure 7).  
 
Figure 7. Supercoiling assay with E. coli DNA gyrase in the presence of (A) SD9 (2) or (B) 
SD8 (1). Controls: (-) without enzyme; (+) untreated 
 
Comparison of the simocyclinone D9 (smc and sml) and simocyclinone D8 (sim) 
biosynthetic gene clusters 
Given the high similarity of the chemical pattern of SD8 (1) and SD9(2)/SD10(3)/SD11 (4), 
the corresponding gene clusters would be expected to be nearly identical, with few deviations. 
The identified smc (in K. sp.) and sml (in S. sp. NRRL B-24484) gene clusters are around of 
47,000 bp long and comprise 43 open reading frames (ORF) (Figure 8; Table 2). To simplify 
the description process we will refer mostly to the experimentally characterized smc 
biosynthetic gene cluster. Despite the high similarity between the smc and the sim genes, the 
overall architecture of both gene clusters has the significant differences. The most 
remarkably, three genes from the sim gene cluster encoding polyketide synthase type I 
(simC1A-simC1C) are missing from the smc gene cluster. Moreover, their homologs were also 
not found within the genome outside of the smc gene cluster, which again opened the question 
about the biosynthetic mechanism of the tetraene chain formation. 
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Figure 8. Simocyclinone biosynthetic gene clusters from S. antibioticus Tü6040 (sim), K. sp. 
(smc) and S. sp. NRRL B-24484 (sml). In yellow are labeled genes involved in 
aminocoumarin biosynthesis, blue – genes involved in deoxysugar formation, green – genes 
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responsible for the angucyclic core synthesis, pink – genes putatively involved in 
modification of the polyketide chain precursor, red – type I polyketide synthase genes, dark 
grey – regulatory genes, dark blue – efflux, pale grey – genes of unknown function, white – 
genes previously annotated as flanking in the sim cluster. Blue arrows indicate operons. 
 
The second remarkable difference between the sim and the smc gene clusters is found within 
the operons responsible for dTDP-D-olivose production. In S. antibioticus Tü6040, seven 
genes (simB1-simB7) involved in the biosynthesis of activated D-olivose have been identified. 
In contrast, two genes (smcB1 and smcB2 encoding dTDP-glucose synthase and dTDP-
glucose-4,6-dehydratase, respectively) are located approximately 900 kb downstream from 
the smc gene cluster.  
Interestingly, three genes (ORF123) that were reported in the sim cluster as flanking and not 
involved in the biosynthesis of simocyclinone are located inside the smc cluster. A 1044 bp 
gene that shows high similarity to different ketoreductases is located downstream from ORF3 
in the smc cluster. Furthermore, closer look at sim cluster, revealed a 289-bp truncation at the 
end of ORF3.  
The gene operon involved in angucycline biosynthesis is very similar to one within the sim 
gene cluster and consists of the following: 1) a minimal PKS gene set represented by smcA1, 
smcA2 and smcA3, which encodes alpha and beta ketosynthases (KSα and KSβ) and acyl 
carrier protein (ACP), respectively; 2) two cyclase encoding genes - smcA4 and smcA5; 3) 
three ketoreductase encoding genes – smcA6, smcA9 and smcA10; 4) two oxygenase encoding 
genes – smcA7 and smcA8; 5) one gene, smcA11, which is responsible for the activation of 
ACP with its phosphopantetheine arm; and 6) the gene encoding a decarboxylase, smcA12. 
We have not identified any homologues of the putative hydroxylase P450 encoding gene 
simA13 within the smc gene cluster. As mentioned above, an additional gene, annotated as 
ORF7, putatively involved in the modification of the angucycline moiety, has been identified. 
Its truncated form is present in the genome of S. antibioticus Tü6040 and flanks the sim gene 
cluster. The full-length ORF for this gene from the smc gene cluster shows 73% homology to 
the Aln4 ketoreductase encoding gene from the alnumycin biosynthetic gene cluster (13). 
Aminocoumarin is another characteristic part of the simocyclinone molecules.  
The genes from the smc gene cluster responsible for the biosynthesis of aminocoumarin are 
represented by smcD1, smcD2, smcD3, smcD4, smcD5, smcD6 and smcX1 and are nearly 
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identical to those from the sim gene cluster (7, 8). SD8 is halogenated at the C-8 position of 
the aminocoumarin ring, a reaction performed by the halogenase SimD4. The corresponding 
gene, smcD4, encoding the putative halogenase, has also been found within the smc gene 
cluster. 
K. sp. and S. antibioticus Tü6040 simocyclinone clustrome description (transcriptome of 
a gene cluster) 
To analyse the expression levels and the operon architecture of the smc gene cluster we 
performed RNA sequencing of K. sp. samples grown in two media: DNPM and NL-5.  
All the genes from the smc cluster showed good expression (within the top 16% of all genes, 
when dividing mean DNPM/NL5 read counts by gene length). Transcription of the smc 
cluster appears to start approximately 192 bp upstream from the annotated coding sequence 
(CDS) for smcD4 and comprises the following transcription units: 1) smcD4-smcEx2; 2) 
smcB6-smcC5; 3) smcX4-smcB3 and 4) reverse-strand smcReg2. Two more 
genes, smcB1 and smcB2, are not inside the cluster.  smcB2 represents an atypical transcript 
with a very short leader sequence and smcB1 is a leaderless transcript (Figure 8).  
The transcriptional start of orf1 in sim cluster is located between 50 and 41 bp upstream of the 
coding region and appear to have the transcription read-through till simC7. The following 
operons are represented by simX3-simC1A, simC2-simC5 and simEx1-orf6. The only gene 
transcribed from the reverse-strand is simReg2 (Figure 8). 
On average, smc cluster gene expression increased 8-fold in NL5 media compared to DNPM 
(Figure S10). Interestingly, these two media do not differ purely in the amount of synthesized 
simocyclinones. While K. sp. in NL5 does produce more simocyclinones by weight, only a 
few simocyclinone derivatives could be identified. On the other hand, in the DNPM medium, 
more type D simocyclinones (and also C precursors) are produced, though their total amount 
is lower than that in the NL5 medium. 
The RNA sequencing and analysis provides the exact and clear expression profiles of both the 
smc and sim gene clusters. The elucidation of the number of operons and their level of 
expression will enable the rational design and engineering of both clusters. Biosynthetic 
engineering of complex gene clusters is significantly simplified when the complete 
information about the promoters, terminators, transcriptional and translational starts is 
available. By describing and characterizing clustromes of the smc and sim gene clusters, we  
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also aim to initiate a new standard in biosynthetic gene clusters characterization. Availability 
of a clustrome description provides an excellent starting point for further engineering of 
biosynthetic gene clusters. 
  
Table 2. Deduced functions of ORFs in the simocyclinone cluster 
№ polypeptide aa Most similar protein  
(identity, %) 
acc. number predicted function 
1 SmcD4 488 SimC6;  S. antibioticus (91) AEU17894.1 putative halogenase 
2 SmcEx2 415 SimEx2; S. antibioticus (90) AEU17895.1 putative Na/H antiporter 
3 SmcReg2 246 SimReg2;  S. antibioticus (82) AF324838_17 TetR family transcriptional regulator 
4 SmcEx 542 Sim17; S. antibioticus (93) AAL15595.1  EmrB/QacA family drug resistance 
transporter 
5 SmcB6 488 SimB6; S. antibioticus (61) AAK06811.1 putative acetyl transferase 
6 SmcP 83 ORF1; S. antibioticus (82) AEU17883.1 putative acyl carrier protein 
7 SmcKSI 360 ORF2; S. antibioticus (71) AEU17884.1 putative 3-oxoacyl-ACP synthase I 
8 SmcKSII 433 ORF3; S. antibioticus (89) AEU17885.1 putative 3-oxoacyl-ACP synthase II 
9 ORF7 348 ChaN; S.chattanoogensis (76) AIU99206.1 aldo-keto reductase 
10 SmcB7 387 SaqGT5;  M. sp. Tu 6368 (58) ACP19370.1 C-glycosyltransferase 
11 SmcB5 253 SimB5; S. antibioticus (72) AEU17887.1 putative 4-ketoreductase 
12 SmcB4 324 SimB4; S. antibioticus (72) AEU17888.1 putative 3-ketoreductase 
13 SmcX5 318 SimX5; S. antibioticus (89) AEU17889.1 putative 3-oxo-ACP synthase 
14 SmcX7 258 SimX7; S. antibioticus] (55) AEU17890.1 conserved hypothetical protein 
15 SmcReg3 155 SimReg3; S. antibioticus (73) AEU17891.1 putative regulator MarR/SlyA family 
16 SmcC7 279 SimC7; S. antibioticus (72) AEU17892.1 putative hydroxylase/dehydratase 
17 SmcA7 510 SimA7; S. antibioticus (85) AAK06782.1 putative oxygenase 
18 SmcA4 109 SimA4; S. antibioticus (89)  AAK06783.1 putative cyclase 
19 SmcA1 423 SimA1; S. antibioticus (90) AAK06784.1 putative ketosynthase 
20 SmcA2 405 SimA2; S. antibioticus (86) AAK06785.1 putative ketosynthase 
21 SmcA3 90 SchP6; S. sp. SCC 2136 (71) CAH10115.1 putative acyl carrier protein 
22 SmcA6 262 SimA6; S. antibioticus (87) AAK06787.1 putative ketoreductase 
23 SmcA5 316 SimA5; S. antibioticus (83) AAK06788.1 putative cyclase/dehydrase 
24 SmcA8 497 Sim7;  S. antibioticus (76) AAL15585.1 oxygenase 
25 SmcA9 255 Sim7; S. antibioticus (92) AAL15585.1 ketoreductase 
26 SmcA10 191 SimA10; S. antibioticus (80) AAK06791.1 putative reductase 
27 SmcA11 222 Sim10; S. antibioticus (69)  AAL15588.1 Ppan-transferase 
28 SmcA12 529 SimA12;  S. antibioticus (91) AAK06793.1 putative decarboxylase 
29 SmcX2 72 Sim12; S. antibioticus (64)  AAL15590.1 hypothetical protein 
30 SmcC3 258 SimC3; S. antibioticus (68) AAK06795.1 thioesterase 
31 SmcC4 457 Sim14; S. antibioticus (86) AAL15592.1 dioxygenase 
32 SmcC5 455 Sim15; S. antibioticus (80%)  AAL15593.1 putative alcohol dehydrogenase 
33 SmcX4 318 Sim18; S. antibioticus (82)  AAL15596.1 predicted phosphohydrolase 
34 SmcC8 226 Sim19; S.antibioticus (72) AAL15597.1 putative Ppan-transferase 
35 SmcD3 236 SimK; S.antibioticus (61) AAG34182.1 reductase 
36 SmcD5 523 SimL; S. antibioticus (76) AAG34183.1 aminocumarin ligase 
37 SmcD6 101 SimD6; S. antibioticus (68) AAK06804.1 putative peptide synthase 
38 SmcD1 437 SimD6; S. antibioticus (68) AAK06804.1 cytochrome P450 
39 SmcX1 71 SimY; S. antibioticus (70) AAG34186.1 putative conserved protein MbtH 
40 SmcD2 274 SimJ1; S. antibioticus (82) AAG34187.1 3-ketoacyl-(ACP)-reductase 
41 SmcReg1 251 SimReg1; S. antibioticus (65)  AAK06808.1 OmpR/PhoB subfamily response 
regulator 
42 SmcC6 247 SimJ2; S. antibioticus (79) AAG34189.1 3-ketoacyl-(ACP)-reductase 
43 SmcB3 483 Sim20; S. antibioticus (82) AAL15606.1 dNDP-4-keto-6-deoxy-glucose-2,3-
dehydratase 
44 SmcB1 292 RmlA; K. kifunensis (89) ADO32599.1 glucose-1-phosphate dTDP-transferase 
45 SmcB2 326 RfbB;  K. kifunensis (92) ADO32598.1 dTDP-D-glucose-4,6-dehydratase 
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Functional analysis of the genes/enzymes putatively involved in tetraene side chain 
biosynthesis 
We decided to focus on the surprising absence of the simC1A, simC1B and simC1C genes, 
which have been proposed to be involved in tetraene chain formation, from the K. sp and S. 
sp. NRRL B-24484 genomes. We screened the K. sp. genome for the presence of the other 
PKSI encoding genes and identified a single putative type I PKS encoding gene. It includes 
one module, which contains an acyltransferase (AT), dehydratase (DH), enoyl reductase (ER), 
two ketoreductase (KR) domains and ACP, but lacks a β-ketosynthase (KS) domain. Directly 
upstream of this gene, and translationally coupled to type I PKS, a gene encoding a separate 
KS domain is located. Interestingly, the corresponding protein is approx. 200 amino acid 
residues longer than regular KS domains and 18 amino acids that are located in the C-
terminus show high similarity to the AT domain. The third gene in this complex encodes 
FabB, which is similar to β-ketoacyl synthase. Together these genes may provide a polyketide 
structure, although the order of the domains do not correspond to the tetraene pattern: 1) the 
ER domain would yield the fully saturated polyketide; 2) the KS domain encoding fragment is 
located outside the gene; 3) the number of domains is not sufficient for formation of the 
tetraene chain, unless this synthase acts iteratively.   
To determine whether this unusual type I PKS is involved in the biosynthesis of 
simocyclinones, we inactivated the corresponding gene via a single crossover. No change in 
the production of simocyclinones was observed in the ∆PKSI mutant, thus excluding its 
involvement in the biosynthesis of simocyclinones (Figure S6.). Obviously, the polyketide 
chain substructure of simocyclinones must be synthesized through the different route not 
involving type I PKS enzymes. 
Intrigued by these result, we checked whether the SimC1A-SimC1C encoding genes are 
involved in the biosynthesis of the tetraene chain of simocyclinones in S. antibioticus Tü6040. 
In the sim gene cluster, the simC1A, simC1B, simC1C genes, were proposed to be responsible 
for tetraene chain formation (7). However, the structure and order of the domains in SimC1A, 
SimC1B and SimC1C do not match the pattern of the polyketide chain within the SD8 
molecule (7). A simC1B mutant, in which KS domain encoding region was replaced by the 
hygromycin resistance cassette was generated (S. antibioticus ∆KS). To our surprise, 
inactivation of the KS domain of SimC1B ketosynthase did not influence SD8 (1) 
biosynthesis (Figures S8a, S8b), indicating that the expression of the SimC1B KS domain and 
likely the entire PKSI sub-cluster is not necessary for biosynthesis of SD8 (1) in S. 
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antibioticus Tü6040. Therefore, the hypothesis of tetraene biosynthesis that is based on PKSI 
involvement should be revised. 
To identify genes responsible for biosynthesis of the tetraene chain, the smc cluster was 
screened for new candidates. Three ketosynthase encoding genes (smcKSI, smcKSII and 
smcX5), which might take part in a polyketide biosynthesis, have been detected after careful 
re-annotation of both, sim and smc gene clusters. Their orthologs in the sim gene cluster were 
marked as ORF2, ORF3, and simX5 and suggested to not be involved in simocyclinone 
biosynthesis. However, the transcriptome of the smc and sim biosynthetic gene clusters 
clearly shows that the expression of the smcKSI, smcKSII and smcX5 (ORF2, ORF3 and 
simX5) genes is coordinated with the expression of other genes in both clusters.  
smcKSI and smcKSII encode proteins with high similarities to 3-oxoacyl-ACP-synthase I (57-
62%) and 3-oxoacyl-ACP-synthase II (79-82%), respectively. SmcKSII contains a typical 
Cys(191)-His(322)-His(357) amino acid motif in its active site, however, we could not 
identify this motif in SmcKSI. SmcX5 is highly similar to 3-oxoacyl-ACP-synthase III (KAS 
III, FabH), a key enzyme in fatty acid biosynthesis in plants and bacteria, which initiates the 
condensing process and uses acetyl-CoA as primer. Additionally, acyl carrier protein (ACP) 
homolog (smcP, ORF1) has been identified upstream from the smcKSI. Together, SmcP, 
SmcKSI, SmcKSII, and SmcX5 may form an enzyme complex that is necessary for 
octatetraene dicarboxylate biosynthesis. However, subsequent ketoreduction and dehydration 
reactions are required for the maturation of the tetraene chain.  
To check the involvement of SmcKSII in tetraene chain formation an in-frame deletion 
mutant was generated. No D-type molecules of simocyclinone have been detected in the crude 
extract of the obtained mutant, although several ions exhibiting the mass, UV/Vis spectrum 
and retention time typical for B-type simocyclinones (angucycline with the attached sugar 
unit) were observed (Figure S7.). 
SD9 (2) was easily detected after complementation of the ΔsmcKSII mutant with the intact 
smcKSII. Albeit, expression of the mutated gene encoding SmcKSII with amino acid 
substitutions in the active center didn’t restore simocyclinone biosynthesis, undoubtedly 
proving the importance of the presence of the catalytically active form of the SmcKSII 
protein.  
Based on the collected data, a proposed model for tetraene chain biosynthesis was created 
(Figure 9). To generate the decatetraene side chain with three ketosynthases, the assembly 
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should most probably start with a four-carbon unit (e.g., crotonyl-CoA, acetoacetyl-CoA) 
condensed to malonyl CoA with the help of SmcX5, the protein similar to the type KSIII.  A 
number of ketosynthases employ non-acetate starter units for the polyketide biosynthesis (14, 
15). Very often, incorporation of an alternative to acetate primer units involves KSIII and 
ACP components as described for frenolicin, daunorubicin and others (15-17).  
 
Figure 9. Proposed model for tetraene chain biosynthesis. In circles are marked genes and 
the function of their products that are involved in a particular biosynthetic step. 
 
SmcX5 contains cysteine, proline and histidine in its active center and thus may be a 
candidate for the initiation of tetraene chain formation. Two other ketosynthases SmcKSI and 
SmcKSII, together with ACP, should be involved in the extension of the linear polyketide. 
The SmcKSI/KSII pair may act as a heterodimer catalyzing a polyketide chain extension 
similarly to the KS/CLF type II PKS system. Several more reactions are necessary to form the 
fully maturated dicarboxylic tetraene acids – ketoreduction, dehydratation and incorporation 
of the second carboxy group. Most of the gene encoding proteins with the necessary 
enzymatic activities can be found within both sim and smc gene clusters. SimC6/SmcC6 is 
homologous to 3-oxoacyl-ACP-reductases and a higher identity with FabG4 from S. 
avermitilis MA-4680. The PKS KR domains also belong to the same family. Most likely, this 
enzyme is involved in the subsequent ketoreduction of the polyketide chain. We could not 
identify the gene candidate responsible for the dehydration reaction of the hydroxylated 
polyketide intermediate, therefore the involvement of dehydratase from fatty acid biosynthesis 
cannot be excluded. Finally, the second carboxy group could be incorporated by two 
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enzymes, SimC4/SmcC4 and SimC5/SmcC5, to the tetraene chain. The deduced amino acid 
sequence of the smcC4 encoding protein is similar to the carotenoid dioxygenases that 
catalyze the oxidative cleavage of carotenoids at various chain positions, thus leading to the 
formation of an aldehyde (18). The oxygen at the C-10 position of the tetraene indeed derives 
from molecular oxygen, as previously shown by feeding experiments (19). Newly generated 
aldehyde is oxidized to the carboxylic acid by SimC5/SmcC5 (aldehyde dehydrogenase) and 
later is attached to the sugar. The inactivation of both genes, simC4 and simC5, in S. 
antibioticus Tü6040 led to the complete cessation of SD8 production, with the corresponding 
accumulation of the B-type simocyclinones (angucycline with the deoxysugar attached) (20). 
Although the exact mechanism of the decatetraene dicarboxylic acid formation remains 
unclear at the moment and requires further deciphering, the scheme and enzymes involved 
seems to be plausible.  
Heterologous expression of smcP, smcKSI and smcKSII in S.albus  
Deduced amino acid sequences of SmcP, SmcKSI and SmcKSII are highly similar to ACP 
and two 3-oxoacyl-ACP-synthases, respectively. Together with KSIII homolog SmcX5 they 
may be involved in tetraene chain formation. To check their function smcP, smcKSI, smcKSII 
(pSmcTet) and smcX5 (pSmcX5) have been expressed in S. albus del10. Additionally, smcC8 
(encoding putative Ppan-transferase) or smcC8 + smcC3 (encoding thioesterase) were 
introduced into S. albus del10 carrying pSmcTet and pSmcX5. However, we couldn’t detect 
any precursors of octatetraene dicarboxylate biosynthesis. It may be because of (a) absence of 
the appropriate starter unit utilized by SmcX5 in the CoA-pool of S. albus; (b) difference in 
genes expression from different plasmids. 
In vitro assay with SmcX5 and SmcP 
To check if SmcX5 can perform first step of condensation between acetoacetyl-CoA and 
malonyl-ACP, appropriate proteins (KSIII – SmcX5 and SmcP - ACP) have been 
overexpressed in E. coli. In vitro assay was performed as following: 2.5µM ACP was 
incubated with 200µM Malonyl-CoA or Acetyl-CoA or Acetoacetyl-CoA in presence of Sfp-
synthase (New England Biolabs), 75mM HEPES and 10mM MgCl2 at 37 
o
C. After 1 hour of 
incubation 200µM substrate (malonyl-CoA, acetyl-CoA or acetoacetyl-CoA) and 0.1µM 
KSIII were added and incubated at 28 
o
C for another hour and analyzed with MS. Ions that 
correspond to apo-ACP (10.132Da) and holo-ACP with loaded malonyl (10.558Da), acetyl 
(10.514Da) or acetoacetyl (10.556Da) were detected (Figure 10). However, no ions that may 
indicate elongation step performed by SmcX5 have been identified. One of the reasons why 
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there was no reaction made by ketosynthase may be the low concentration of the protein. To 
solve this problem SmcX5 was concentrated ten times using Amicon microcon filter columns 
10k and used for another in vitro assay. However, no expected product was detected, even 
after change to phosphate buffer (0.7M K2HPO4, 0.3M KH2PO4) and adding 1mM TCEP. 
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Figure 10. A – ACP (SmcP), B – ACP loaded with malonyl-CoA, C – ACP loaded with 
acetoacetyl-CoA, D – ACP loaded with acetate-CoA. 
Inactivation of smcA7, smcA8 and smcA9 
Proteins encoded by smcA7, smcA8 and smcA9 show high similarity to two oxygenases and 
oxygenase-reductase, respectively. Homologs of these genes from other species take part in 
oxidizing of the nascent angucyclic core prior to its’ further decoration with sugars. SmcA7 is 
highly similar (70% identity) to UrdE from the urdamycin biosynthetic pathway, which 
performs C-12/C-12b hydroxylation of the angucycline. SmcA8 is shares 63% identity with 
ox domain of LndM, whereas SmcA9 is a putative 6-ketoreductase (70 % similarity with 
UrdM red domain). Three deletion mutants were generated via double-crossover – K. sp. 
∆smcA7h, K. sp.  ∆smcA8h and K. sp. ∆smcA9h (Figure 11). 
The functions of oxygenases in the decoration of the angucycline moiety  
The only difference between SD8 (1) and the newly identified SD9 (2) was in the substitution 
of the C1 position. In the SD8 (1) molecule the ketogroup is present, while in SD9 (2) it is 
reduced to hydroxyl, and in SD10 (3) it is dehydrated to form a double bond (Figure 1). In the 
smc gene cluster, we identified ORF7 as showing a high similarity to ketoreductases. The 
orthologous gene within the sim gene cluster is present in a truncated non-functional form. To 
determine if the structural difference between SD8 (1) and SD9 (2) is due to the function of 
this gene, ORF7 was heterologously expressed in S. antibioticus Tü6040. Unfortunately, we 
could not identify new derivatives of simocyclinones in the recombinant strain. For the next 
step, we replaced ORF7 with the hygromycin-resistance gene. However, the biosynthesis of 
SD9 (1) was completely abolished in this mutant. 
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Figure 11. Chromatograms of the HPLC-ESI/MS analysis of K. sp. mutants: A - ∆smcA7, B - 
∆smcA8, C - ∆smcA8 and the wild type – D.  
This demonstrated that the integration of the hygromycin resistance gene into the smc gene 
cluster disrupts the transcriptional/translational process of the operon and thus leads to the 
complete abolishment of the simocyclinone production. To avoid such an effect, we then 
generated a point mutation in ORF7 while leaving the rest of the cluster intact (Figure S9). 
This mutant was named K. sp. ORF7*. A characteristic feature of this mutant is the point 
mutations in the active center of the enzyme that result in a catalytically inactive protein. The 
K. sp. ORF7* mutant produces D-type simocyclinones. At least seven new peaks were 
identified in the crude extract obtained for this mutant. Four of the peaks are presumably 
angucyclines, and three peaks exhibit UV/Vis spectrum that are typical for D-type 
simocyclinones and show molecular ions in ESI-MS m/z = 874.17 [M+H]
+
, m/z = 914.33 [M-
H]
-
 and m/z = 930.39 [M-H]
-
 (Figure 12). Based on the MS/MS analysis and the retention 
time, the molecule with mass 931 was assigned to SD8 (Figure 13), suggesting that ORF7 is 
indeed involved in reduction of the ketogroup to a hydroxyl group in the C1 position of the 
angucycline moiety during simocyclinone biosynthesis. In addition, the compound with the 
molecular mass M = 873 was semipurified. The amount and purity do not allow for the 
generation of a high-quality 1D NMR spectra, so the structure determination was conducted 
from this semipurified fraction based on 2D NMR signals, which led to the structure of  
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Figure 12. Chromatograms of the HPLC-ESI/MS analysis of K. sp. ORF7* mutant crude 
extract. Arrows indicate peaks corresponding to simocyclinones. 5 – simocyclinone D5 (5, 
SD5), m/z = 874.17 [M+H]
+
; ? – D-type simocyclinone of unknown structure, m/z = 914.33 
[M-H]
-
; 1 – simocyclinone D8 (1, SD8), m/z = 930.25 [M-H]- 
 
simocyclinone D5 (5), which have been predicted before by Schimana et al. (21), but had not 
been detected experimentaly. SD5 (5) has the same angucycline as SD8 (1) with the intact 
carbonyl group at C-1 (Tables S4a, S4b; Figures S5a-S5c). The presence of the carbonyl 
group at C-1 in SD5 (5) undoubtedly demonstrated the function of ORF7 (Figure 14).   
We speculate that the enzymes most likely involved in the simocyclinone biosynthesis form 
the protein complex, which is then disturbed when one of the structural units is deleted. When 
the mutated form of the enzyme is physically present within the complex, the metabolic 
intermediates are passed from one enzyme to another through the intramolecular tunnel 
without its release into the solution. Such substrate channeling prevents the release of unstable 
intermediates and also makes the process faster and more efficient (22, 23). Therefore, 
deletions or substitutions of genes from biosynthetic gene clusters may lead to much lower 
production and accumulation of shunt products. Thus, by changing the gene inactivation 
strategy from very rough to more precise we were able to generate the first engineered D-type 
simocyclinone in the native producer. Our finding may partially explain the previous failures 
to generate D-type simocyclinones via biosynthetic engineering. In addition, the RNA 
sequencing and analysis provides the exact and clear expression profiles of both the smc and 
sim gene clusters. The elucidation of the number of operons and their level of expression will 
enable the rational design and engineering of both clusters. Biosynthetic engineering of 
complex gene clusters is significantly simplified when the complete information about the 
promoters, terminators, transcriptional and translational starts is available. By describing and  
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Figure 13. Comparison of the MS and MS/MS of D-type simocyclinone produced by K. sp. 
ORF7*, m/z = 930.39 [M-H]
-
 (A) and 1 (B). 
 
characterizing clustromes of the smc and sim gene clusters, we also aim to initiate a new 
standard in biosynthetic gene clusters characterization. Availability of a clustrome description 
provides an excellent starting point for further engineering of biosynthetic gene clusters. The 
three identified simocyclinone gene clusters (sim, smc and sml) are typical examples of the 
“bricks and mortar” evolution events postulated by Marnix et al. (24). These hybrid gene 
clusters are composed of several sub-clusters (bricks) and individual genes (the “mortar"). 
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Figure 14. Structure of simocyclinone D5 (5, SD5) 
  
During the evolution of the sim gene cluster from the smc gene cluster, substantial gene 
reorganization took place (deletion of the ORF7 function, gaining the deoxysugar biosynthetic 
genes and reorganizing the gene order). These cluster rearrangements led to the generation of 
SD8 (1), which is four times more active than SD9 (2) in vitro, which could have brought 
some selective advantages to its producer. The acquisition of two additional deoxysugar 
biosynthetic genes might help in the coordination of the gene expression within the sim gene 
cluster. It is not clear which selective advantages to S. antibioticus Tü6040 are brought by 
PKS I encoding genes, which are expressed, but are not necessary for SD8 (1) biosynthesis. In 
summary, the comparative and functional analysis of the smc, sml and sim gene clusters led to 
the decifering of the simocyclinone biosynthetic route (Figure 15).  
Conclusions 
The identification of several new simocyclinones and the cloning and functional analysis of 
the corresponding gene clusters provided new insights into the biosynthesis and evolution of 
these hybrid bioactive molecules. In particular, a surprising and new biosynthetic route for the 
biosynthesis of the decatetraene dicarboxylic acid has been detected. Based on bioinformatics 
analysis and the experimental data, the involvement of several stand-alone ketosynthases, but 
not the PKSI system as suggested previously, in the biosynthesis of the tetraene chain has 
been proposed. The genetic basis of the structural differences of SD8 (1) and the newly 
identified SD9 (2), SD10 (3) and SD11 (4) has been found. A structure-activity relationship 
study of simocyclinones clearly demonstrates the importance of the A-ring modifications for 
the activity of the entire molecule. The understanding of the biosynthetic pathway and the 
genetic accessibility of this new producer opens up the important possibility of generating 
novel analogs of these unique molecules. 
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Methods 
Genus affiliation 
To determine whether the new simocyclinone producing strain belongs to the genus of 
Streptomyces, 16S rDNA was sequenced and analyzed. It shows the highest similarity to 
Kitasatospora setae. One of the phenotypic criteria to distinguish between Streptomyces and 
Kitasatospora is the chemical composition of cell wall peptidoglycan (25). Diaminopimelic 
acid (DAP) in Streptomyces is present only in the LL-isoform, in contrast to the peptidoglycan 
of Kitasatospora that contains both LL- (in spores) and meso (in mycelia) isomers of DAP. 
Analysis of DAP from our new strain has revealed the presence of both LL- and meso isomers 
in the cell wall peptidoglycan, which proves the affiliation of the new strain with the 
Kitasatospora genus.  
Strains, growth conditions and media 
For standard purposes S. antibioticus Tü6040 and K. sp. and S. albus wild types and all 
mutants were grown on 2% manitol and 2% soy bean meal, pH 7.5, prepared as solid medium 
and tryptone soy broth (TS broth), prepared as liquid medium, at 28 
0
C. For the maintenance 
of the mutants, hygromycin or apramycin was added to a final concentration of 50 µg/ml. For 
simocyclinone production a liquid medium NL-5 (NaCl, K2HPO4, MgSO4×7H2O, glycerin 
and trace element solution, pH 7.2) and DNPM (4%  dextrin, 0,75% soytone, 0,5% baking 
yeasts and 2,1% MOPS, pH 6.8) were used. DNA manipulation was carried out in E. coli XL-
1 Blue MRF (Stratagene) and the non-methylating E. coli ET12567/pUZ8002 strain was used 
to drive conjugative transfer of non-methylated DNA to Actinobacteria as described 
previously(26). E. coli strains were grown on Luria-Bertani agar or liquid medium containing 
the appropriate antibiotic for selection. Vector pJET1.2 was from ThermoScientific 
(Darmstadt, Germany) and pKC1132, which carried the apramycin-resistance gene used for 
gene disruption, was from Eli Lilly and Company (Indianapolis, IN, USA). pKG1139, which 
contains gusA and apramycin-resistance genes and was used for gene disruption, was present 
in our laboratory (27).  
Simocyclinone production analysis and NMR 
For simocyclinone production 3 ml of 24-h old pre-culture was inoculated into 50 ml of NL-5 
or DNPM media and grown for 4 days at 30°C with agitation at 200 rpms. The culture broth 
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was extracted with ethylacetate, samples were evaporated, dissolved in 500 μl of methanol 
and subjected to LC-MS analysis.  
Standard measurements were performed on a Dionex Ultimate 3000 RSLC system using a 
BEH C18, 100 x 2.1 mm, 1.7 µm dp column (Waters, Germany). Separation was achieved by 
a linear gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 
600 µL/min at 45 °C. The gradient was initiated by a 0.5 min isocratic step at 5 % B, followed 
by an increase to 95 % B in 18 min to end up with a 2 min step at 95 % B before re-
equilibration under the initial conditions. UV spectra were recorded by a DAD in the range 
from 200 to 600 nm. MS data was acquired with an Amazon Speed 3D ion trap mass 
spectrometer (Bruker Daltonics, Germany) using the Apollo ESI source. Mass spectra were 
acquired in centroid mode ranging from 150 to 1500 m/z. 
High-resolution measurements were performed on a Dionex Ultimate 3000 RSLC system 
using a BEH C18, 100 x 2.1 mm, 1.7 µm dp column (Waters, Germany). Separation of a 1 µl 
sample was achieved by a linear gradient from (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA 
at a flow rate of 600 µL/min and 45 °C. The gradient was initiated by a 0.5 min isocratic step 
at 5 % B, followed by an increase to 95 % B in 18 min to end up with a 2 min step at 95 % 
B before re-equilibration under the initial conditions. UV spectra were recorded by a DAD in 
the range from 200 to 600 nm. The LC flow was split to 75 µL/min before entering the maXis 
4G hr-ToF mass spectrometer (Bruker Daltonics, Germany) using the Apollo ESI source. 
Mass spectra were acquired in centroid mode ranging from 150 – 2500 m/z at a 2 Hz scan 
rate. 
NMR spectra were measured using a Varian VNMR-S 600 MHz spectrometer equipped with 
3 mm triple resonance inverse and 3 mm dual broadband probes (
1
H, 
13
C, 2D NMR)  or a 
Bruker Avance III equipped with a 5 mm TCI cryoprobe (
1
H and 2D NMR). Solvent signals 
were used as internal standard (DMSO-d6: δH = 2.50 ppm, δC = 39.5 ppm; CD3OD: δH = 3.31 
ppm, δC = 49.0 ppm, CD3CN: δH = 1.93 ppm, δC = 1.28 ppm). NMR spectra in DMSO-d6 
were recorded atT = 35 °C and in CD3OD or CD3CN at T = 25 °C. 
Purification of SD5 
K. sp. ORF7* was cultivated in DNPM medium in shaking flasks, total volume 6 L at 30°C, 
200 rpm for 5 days. Mixture of culture broth and biomass was extracted with 6 L of 
ethylacetate (EtAc) and led to 615 mg of crude extract. The extract was purified on SPE 
cartridge (ACN 20%, 40%, 60%, 80%, 100%). The 60% ACN fraction (8 mg) contained the 
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compounds of interest and was further purified by HPLC (HTec C18 column, 250 × 10 mm, 5 
µm, A = H2O + 0.1% FA, B = ACN + 0.1% FA) with gradient starting from 5% B to 95% B 
in 28.2 min. Flow 5.8 ml/min, injection volume 40 µl of an MeOH extract (c = 5.3 mg/ml), 
detection wavelength λ = 420 nm. The isolate (0.2 mg) could be identified as new 
simocyclinone D 12. High resolution ESI mass spectra were measured using a Bruker Impact 
II mass spectrometer equipped with a Dionex RSLC UHPLC. 
Purification of SD9 and SD10 
K. sp. WT was cultivated in NL5 medium in shaking flasks with a total volume of 2 L at 
30°C, 200 rpm for 5 days. The biomass was decomposed in MeOH and later extracted with 
EtAc, which yielded 160 mg of the crude extract. The crude extract later was purified by the 
Hypha company using preparative HPLC-MS. One fraction (N1) contained SD9 and was used 
for NMR measurement. To obtain sufficient SD10 for structure elucidation, fraction N3 was 
further purified by HPLC (conditions identical to SD11 purification), which yielded 0.7 mg of 
the compound that was used for further measurements. 
General genetic manipulation and PCR 
Standard molecular biology procedures were performed as described previously (28). 
Isolation of plasmid DNA from E. coli and DNA restriction/ligation were performed by 
following the protocols of the manufacturers of the kits, enzymes, and reagents, Qiagen, 
Promega, NEB and ThermoScientific. PCR reactions were performed by using Phusion High-
Fidelity DNA polymerase (ThermoScientific) for complementation and expression 
experiments and DreamTaq polymerase (ThermoScientific) to verify mutants. Primers were 
purchased from Eurofins MWG Operon. The oligonucleotide primers that were used are listed 
in Table S5. 
Genome sequencing 
For the genome sequencing, genomic DNA was isolated from K. sp. as described before (29). 
Genome sequencing of the cultivated strain was performed using Illumina MiSEQ 
technology. High-molecular-mass DNA was extracted from the selected strain, and two 
libraries were created: an 8-kb mate-pair library, as well as a shorter-insert (~600bp) shotgun 
paired-end library. Reads of an approximate length 2x250 (before trimming) were obtained 
for both libraries. Newbler software version 2.8 was used for genome assembly. 
 
 II. RESULTS  
40 
 
RNA sequencing and analysis 
RNA sequencing was performed by Vertis Biotechnologie AG. Briefly, ribosomal RNA 
depletion of isolated total RNA was performed with Ribo-Zero Bacteria kit from Epicentre. 
The rRNA depleted RNA was fragmented with RNase III and 5'PPP structures were removed 
using RNA 5' polyphosphatase (Epicentre). Afterwards, RNA fragments were poly(A)-tailed 
using poly(A) polymerase. First-strand cDNA synthesis was performed using an oligo(dT)-
adapter primer and M-MLV reverse transcriptase. The resulting cDNA was amplified and 
purified, and fragments in the length range 250-350 bp were sequenced on an Illumina HiSeq 
2000 machine with 100-bp read length. For DNPM, we had 8987253 reads, and for NL5 we 
had 7433408 reads (only mapped using Novoalign V3.00.04 non-rRNA reads were counted). 
Differential expression analysis was performed with DeSeq package for the R statistical 
environment (30). 
We used the EDASeq R package for gene GC content and length bias control in K. sp. 
samples (31). Neither the bias plots nor the log-fold-change plots revealed significant 
dependencies between GC/length and read counts, and therefore no EDASeq normalization 
was applied. The ArrayQualityMetrics (32) quality report has not revealed any problems. 
DNA-sequencing and computer-assisted sequence analysis  
Nucleotide sequences were determined at GATC Biotech AG (Cologne, Germany) by using 
either standard primers (pJET1.2 Forw. and pJET1.2 Rev.) or customized, internal primers. 
Computer-assisted sequence analysis was performed with the Geneious software (Geneious, 
version 7.1.7). Database comparison was performed with the BLAST search tools on the 
server of the National Center for Bio-technology Information, National Library of Medicine, 
NIH (http://www.ncbi.nlm.nih.gov/).  
Intergenic conjugation between E .coli and K. sp., S. antibioticus Tü6040 or S. albus 
J1074 
Plasmids were transferred to K. sp., S. antibioticus Tü6040 or S. albus J1074 by intergeneric 
conjugation with E. coli. Spores from one plate were recovered by centrifugation, washed 
twice in fresh TS broth, and resuspended in TS broth (recipient culture). The E. coli donor ET 
12567 (pUZ8002) was grown at 37 °C for 16–18 h on LB agar plus apramycin (50 mg/ml) 
and kanamycin (30 mg/ml). These donor cells were detached from the plate with a loop and 
resuspended in the recipient culture. Samples of this combination (500 µl) were plated on MS 
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medium (20 g/L, d-mannitol, 20 g/L soy flour, 18 g/L agar, pH 7.2). Plates were incubated at 
28 °C for 8–10 h and then covered with water (1 ml) that contained phosphomycin and 
apramycin at a final concentration of 200 mg/ml and 50 mg/ml, respectively, for selection of 
exconjugants. The incubation at 28 °C was continued for 3–5 days until exconjugants 
appeared. 
Construction of gene inactivation and complementation constructs  
For the generation of chromosomal mutants of K. sp and S. antibioticus Tü6040 by 
homologous recombination, the gene disruption plasmids were constructed as described 
below. To inactivate smcKSII, two flanking homologous sequences, 2.5 kb each, were 
appropriately inserted into the EcoRI-EcoRV and MunI-XbaI digest pKG1139 to yield 
plasmid pKGKSIIFR. Primers were used to introduce EcoRI, EcoRV and MunI, StuI, XbaI 
restriction sites to both homologous fragments. A unique StuI restriction site was inserted into 
the forward primer of the second homologous shoulder. The hph gene was amplified by PCR, 
using pIJ10700 as a template, and cloned into ploxLERE plasmid, which was previously 
digested with BamHI/MfeI and blunted with Klenow Fragment. Primers were used to 
introduce BamHI and MfeI into the hph gene. Here, hph, flanked by two loxP sites, was cut 
out from ploxLEREhph after restriction enzyme treatment with EcoRV and ligated into StuI 
pKGKSIIFR to generate plasmid pKGKSIIΔ.  
To inactivate PKSI-encoding gene, the internal fragment (3 kb) was inserted into the HindIII–
XbaI sites of pKC1132 to yield inactivation vector pKCPKSΔ. To generate the cassette for 
ORF7 inactivation, 3 kb-long DNA regions upstream and downstream from ORF7 were 
amplified with PCR. DNA restriction sites were artificially introduced into homologous 
regions using primers. A downstream homologous fragment (ORF7r) was treated with EcoRV 
and EcoRI and ligated with the pKG1139 vector prior digested with EcoRI and EcoRV, to 
yield plasmid pKGORF7r. MfeI, SspI and StuI restriction sites were introduced into the 3’ end 
of ORF7r. The upstream homologous region was treated with XbaI and StuI and ligated into 
pKGORF7R digested with XbaI/StuI to generate pKGORF7RF. hph flanked by two loxP sites 
was cut out from ploxLEREhph after restriction treatment with EcoRV and ligated into SspI 
treated pKGORF7RF to generate plasmid pKGORF7Δ. To generate the plasmid for site-
directed mutagenesis, ORF7* was cloned into pKGORF7rf, to give pKGORF7*rf. Primers 
were used to introduce nucleotide mutations into ORF7 and the MfeI restriction site into the 5’ 
and StuI into 3’ ends of the gene. Later, the hph gene with two loxP sites was ligated into 
pKGORF7*rf, which resulted in plasmid pKGORF7*. To delete the KS-domain of SimC1B 
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in S. antibioticus Tü6040 pKGKSΔ was constructed. Two homology shoulders (2.5 kb each) 
were fused using overlapping PCR and cloned into pJET1.2 (pJET1.2KSFR). Primers were 
used to insert a unique SspI restriction site between the two shoulders and StuI restriction sites 
at the ends of the fused construct. As in the case of pKGKSII, the hph gene flanked by two 
loxP sites was cloned into SspI pJET1.2KSFR. The resulting inactivation construct (two 
homology sequences and hygromycin-resistance gene) was excised from pJET1.2KSFR using 
StuI and cloned into EcoRV-treated pKG1139. For the generation of the plasmid that was 
used for ΔsmcKSII strain mutant complementation, smcKSII was amplified by PCR using 
Phusion polymerase. Suitable restriction sites (XbaI and EcoRV) were artificially introduced 
upstream and downstream of the gene. In addition to the XbaI restriction site, the forward 
primer also includes a synthetic 21p promoter (33) and a ribosomal binding site. After 
digestion with XbaI and EcoRV, the fragment was ligated into the pKC1139 (34) plasmid. 
This yielded the complementation plasmid pKCKSIIcom. To generate the expression vector 
pKGKSII*, smcKSII was amplified by PCR with two sets of primers that included point 
mutations. Suitable restriction sites (XbaI and EcoRV) were introduced upstream and 
downstream from the gene, using primers. The forward primer also contained the 21p 
promoter. The 1.1 kb PCR-fragment was digested with XbaI and EcoRV and ligated into a 
pKG1139 vector treated with EcoRV/XbaI, to generate pKGKSII*com. 
pKGsmcA7∆. To inactivate smcA7, two flanking homologous sequences, 2.5 kb each, were 
appropriately inserted into the EcoRI-EcoRV and MunI-XbaI digest pKG1139 to yield 
plasmid pKGA7FR. Primers were used to introduce EcoRI, EcoRV and MunI, SspI, XbaI 
restriction sites to both homologous fragments. A unique SspI restriction site was inserted into 
the forward primer of the second homologous shoulder. The hph gene was amplified by PCR, 
using pIJ10700 as a template, and cloned into ploxLERE plasmid, which was previously 
digested with BamHI/MunI. Primers were used to introduce BamHI and MunI into the hph 
gene. Here, hph, flanked by two loxP sites, was cut out from ploxLEREhph after restriction 
enzyme treatment with EcoRV and ligated into SspI pKGA7FR to generate plasmid 
pKGsmcA7Δ.  
pKGsmcA9Δ. To inactivate smcA9, pKGsmcA9∆ vector was constructed as pKGsmcA7Δ. 
pKGsmcA8∆. Left part of the simA8 gene and its flanking region were amplified from the 
chromosome of K. sp. using primer pair simA8-11F and simA811R (Table S5). Obtained 2.3 
kb DNA fragment digested with EcoRI and EcoRV, which cloning sites were incorporated 
into primers, was cloned into respective sites of the pKG1139 vector. This generated 
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pKGA8F. Right part of the simA8 gene and region flanking it were amplified using simA8-
21F and simA8-21R primers (Table S5) from the chromosome of K. sp. The amplified 2.2 kb 
DNA fragment was digested with EcoRV and HindIII, which recognition sites were 
introduced into primers, and cloned into respective sites of pKGA8F. As a result the 
pKGA8FR plasmid with the unique EcoRV site in the coding region of the simA8 gene was 
obtained. The plasmid pKGA8FR was hydrolyzed with EcoRV and ligated with hygromycin 
resistance cassette hyg that was obtained as a PvuII fragment from pIJ10700 (Table S5). This 
yielded pKGsimA8∆.  
Plasmids used for the heterologous expression were constructed as described below 
pSmcX5. To generate the expression vector pSmcX5, smcX5 was amplified by PCR. Suitable 
restriction sites (HindIII and XbaI) were introduced upstream and downstream from the gene, 
using primers. Also forward primer was carrying 21p promoter. To obtain suitable shuttle 
vector, pALHimar was treated with HindIII/XbaI and 8.5kb-fragment was eluted from the 
agarose gel (done according to the manufacturer, Promega). 1 kb PCR-fragment was digested 
with HindIII and KpnI and ligated into pAL vector, to generate pSmcX5. 
pSmcC8 and pSmcC8C3. Expression vector pSmcC8 was obtained by cloning 750-bp PCR 
fragment containing smcC8-coding region from the K. sp. chromosome into pTOS vector 
treated with HindIII/XbaI. Forward primer was used to introduce 21p promoter, RBS 
(ribosome binding site) and XbaI restriction site. Restriction site HindIII was introduced into 
the 3’ end of the reverse primer. To generate pSmcC8C3, pSmcC8 was digested with 
BglII/XbaI and 1-kb PCR fragment that contains smcC3 placed under the control of A9 
promoter (introduced by forward primer together with RBS and XbaI restriction site) was 
cloned.  
pSmcTet. To obtain suitable shuttle vector, pUWLCre was treated with KpnI/XbaI and 8kb-
fragment was eluted from the agarose gel (done according to the manufacturer, Promega). 2.7 
kb DNA fragment containing smcP, smcKSI and smcKSII was amplified in PCR reaction 
under the standard conditions. Forward primer was used to introduce 21 promoter and KpnI 
restriction site. XbaI restriction site was introduced in reverse primer. Obtained PCR-product 
was treated with XbaI and KpnI and subsequently ligated into pUWL vector digested with 
KpnI and XbaI to yield pSmcTet. 
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Generation of chromosomal mutant strains of K. sp. and S. antibioticus Tü6040 
For the generation of all deletion mutants, single crossover mutants were screened for loss of 
vector-resistance as a consequence of a double crossover event. Deletions within the genes 
were confirmed by PCR. 
Topoisomerase assays 
Assays were performed as described before (35). Commercial kits from Inspiralis (Norwich, 
UK) were used to test anti-gyrase activities of compounds. For standard reactions, 0.5 µg of 
supercoiled plasmid incubated with 1 unit of enzyme in the presence of different 
concentrations of compounds at 37°C for 30 minutes. Reactions with no enzyme and a 
standard reaction in presence of 5% (v/v) DMSO served as controls. Reactions were quenched 
by the addition of DNA gel loading buffer with 10% SDS (w/v). The samples were separated 
on 0.7% (w/v) agarose gel and DNA was visualized using ethidium bromide. All reactions 
were repeated at least three times. 
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2. Amycomycins C and D, new angucyclines from Kitasatospora sp. 
Abstract 
Two new angucycline compounds containing O-glycosylated 6-deoxy-a-L-talose were 
isolated from Kitasatospora sp. The compounds were elucidated based on spectroscopic 
methods including UV, HRESIMS, and NMR. A feeding experiment using alizarin led to the 
conversion of alizarin to a monoglycosylated product with high efficiency, which allows 
isolation of the sugar after hydrolysis and determination of the absolute configuration of the 
sugar. 
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Introduction 
While screening for new secondary metabolites two new angucyclines with an unusual O-
glycosylation pattern were isolated from K. sp. and named amycomycin C (6) and D (7) due 
to their structural relationship to amycomycin B [1]. NMR studies revealed that the attached 
6-deoxyhexose was the rare 6-deoxy-a-talose which is also a part of the lipopolysaccharides 
and polysaccharides found in the outer cell membrane of Gram-negative 
bacteria [2-4]. Only a few natural secondary metabolites from bacteria are known to contain 
6-deoxy-a-talose as the substructure. These natural products are talosin A and B [5], 
phenazoviridin [6], and some acyl- and aryl-a-glycosides from Streptomyces sp. GöM1 [7]. 
Moreover to the best of our knowledge C-1-O-glycosylation has been described only for 
benzanthrin A and B as well as for amycomycin B in the literature [1, 8], while the 
glycosylation of angucyclines at position C-6 is reported only for the antibiotic TAN-1085 
[9]. A feeding experiment using alizarin led to the O-glycosylation of alizarin (8), from which 
the sugar could be hydrolyzed, isolated, and determined as 6-deoxy-a-L-talose (Figure 16). 
 
Figure 16. 6-Deoxy-α-L-talopyrranosides from K. sp. 
 
Results and discussion 
Amycomycins 
HRESI(+)MS revealed m/z = 613.1918 [M+H]+ for 6 and m/z = 467.1335 [M+H]+ for 7, 
which led to the molecular formula C31H32O13 (6) and C25H22O9 (7). The chemical shifts 
of the protons and carbons in the 1D NMR spectra for 6 and 7 show high similarity. Therefore 
the structure elucidation is discussed in detail for 1 and only differences for 7 are highlighted. 
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The ESI(+) mass spectrum of 6 showed two fragments m/z = 467.1 [M–(6-deoxyhexose)+H]+ 
and 321.1 [M–(2*(6-deoxyhexose))+H]+ which correspond to the splitting of two sugar units. 
The NMR spectra of 6 show 3 methyl groups, 16 methin groups, and 12 quaternary carbons 
(Table 3). Moreover two sugars are visible and the aglycone was identified as an 
angucyclinone based on NMR data. 
Table 3. NMR data for 6-7 (500 MHz, 25 °C, MeOD)  
 1 2 
Pos. δC δH (J in Hz)
 [a] δC
[b] δH (J in Hz)
 [a] 
1 155.2  155.9  
2 113.6 7.26 d (1.1) 113.2 7.15 s 
3 143.4  144.2  
3a 22.2 2.52 s 22.9 2.48 s 
4 121.2 7.32 s (br) 121.2 7.22 s (br) 
4a 140.4  142.9  
5 118.5 7.75 s (br) 119.0 7.42 s 
6 153.6  158.6  
6a 125.7  139.6  
7 189.2  194.7  
7a 117.3  117.3  
8 162.8  163.8  
9 124.2 7.24 dd (8.4, 1.0) 125.0 7.27 d (8.3) 
10 137.7 7.69 dd (8.4, 7.6) 139.6 7.75 dd (8.3, 7.6) 
11 118.3 7.46 dd (7.6, 1.0) 119.8 7.50 d (7.6) 
11a 137.0  138.9  
12 187.9  188.1  
12a 141.4  141.4  
12b 117.5  117.5  
1’ 101.3 5.59 d (1.5) 101.8 5.57 s (br) 
2’ 71.8 3.86 ddd (3.1, 1.5, 1.5) 72.4 3.87 ddd (3.3, 1.5, 1.5) 
3’ 67.5 3.94 dd (3.2, 3.1) 68.2 3.94 dd (3.3, 3.3) 
4’ 74.2 3.71 ddd (3.2, 1.7, 1.5) 74.8 3.72 dd (3.3, 1.5 ) 
5’ 69.9 4.15 d (6.7) 70.5 4.16 q (6.6) 
6’ 17.0 1.28 d (6.7) 17.6 1.28 d (6.6) 
1’’ 100.8 5.81 d (1.5)   
2’’ 71.9 4.12 ddd (3.2, 1.7, 1.5)   
3’’ 67.2 4.34 dd (3.4, 3.2)   
4’’ 74.3 3.75 ddd (3.4, 1.7, 1.8)   
5’’ 70.0 4.06 q (6.7)   
6’’ 16.9 1.21 d (6.7)   
[a]
 coupling constants for 1’-6’’are extracted from 1D-TOCSY (600 MHz, CD3OD)
, [b]
 assignment based on 
HSQC and HMBC. 
 
The angucycline ring A is substituted by a methyl group at C-3 and flanked by aromatic 
protons, as shown by the small coupling constant J2-H,4-H = 1.1 Hz and the HMBC signals C-
2/3a-H3, C-4/3a-H3, C-3a/2-H, and C-3a/4-H. The connectivity between ring A and B is 
indicated by the quaternary carbons δC = 117.5 (C-12b) and 140.4 ppm (C-4a) with HMBC 
signals C-4a/4-H and strong m-couplings C-12b/2-H, C-12b/4-H, and C-12b/5H which 
established the assignment of C-12b. Ring B showed connectivity with ring A through the 
HMBC signal C-5/4-H. The quinone structure of ring C was identified from the significant 
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carbonyl chemical shifts (δC = 187.9 and 189.2 ppm). The connection of ring C with ring B 
was represented by the HMBC signal C-6a/5-H. Ring D showed a phenolic hydroxyl group 
and an AMX spin system through the COSY cross peaks (9-H/10-H and 10-H/11-H) and 
coupling constants J9-H,10-H = 8.5 Hz and J10-H,11-H = 7.6 Hz. The NOE-signals (3´-H/11-H, 11-
H/3´-H, and 10-H/2-H) between the aromatic proton of AMX spin system at δH = 7.46 ppm in 
ring D and the sugar unit attached at ring A defined the orientation of ring D with the OH 
group at C-8 (δC = 162.8 ppm). HMBC signals C-8/9-H and C-8/10-H supported the phenolic 
hydroxyl group at C-8. The HMBC signals C-7a/H-11, C-11a/H10, and C-12/11-H highlight 
the connection of ring C and D. One of the remaining quaternary carbons (δC = 141.4 ppm) 
was signed to be C-12a due to comparison with literature values [10, 11]. Thus, the aglycone 
structure was determined as 6-hydroxytetrangulol [12]. The angucycline core is di-O-
glycosylated at C-1 and C-6 as shown by the HMBC signals C-1/1´-H and C-6/1´´-H in 
combination to the chemical shifts of C-1 (δC = 155.2 ppm) and C-6 (δC = 153.6 ppm). The 
1H NMR signals at δH = 5.82 and 5.59 ppm corresponding to δC = 100.8 and δC = 101.3 ppm, 
respectively indicated two anomeric protons from O-glycosylated saccharides (Table 3). Their 
small coupling constants J1´-H,2´-H and J1´´-H,2´´-H = 1.5 Hz indicate α-sugars. This was 
supported by the carbon–proton coupling constant 1JC-10/10-H = 171.8 Hz [13]. 2D NMR data 
(COSY, HSQC, and HMBC) identify both saccharides as 6-deoxyhexoses (Table S3). All 
coupling constants in the sugar units (determined from 1D-TOCSY experiments) were smaller 
than 
3
JH,H = 6.7 Hz; thus no diaxial 3JH,H couplings were observed, so these sugars could not 
be either rhamnose or fucose [14, 15]. In addition sugar proton chemical shifts and w-
coupling 2´-H/4´-H (J2´-H,4´-H = 1.5 Hz) and 2´´-H/4´´-H (J2´´-H,4´´-H = 1.7 Hz) indicated these 
sugars to be 6-deoxy-a-talose (Figure 17) [6]. This assumption was supported by the NOE 
signals between the 3´-H/5´-H which determined the chair conformation of the saccharides 
(Figure 17) [7]. A boat conformation could be excluded through the NOE signals between the 
3´-H/5´-H and 3´-H/11-H. 
 
Figure 17: Selected coupling constants and NOE signal determine the chair conformation of 
the 6-deoxy-α-talopyranoside unit 
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NOE signals for 3´-H/11-H, 11-H/3´-H, and 1´-H/2-H indicated the orientation favored by 
saccharide A and the ROESY signal 5- H/1´´-H indicated the favored orientation of α-
saccharide B (Figure 18). 
 
Figure 18. Selected COSY, HMBC, and NOE signals for 6 
 
HRESI(+)MS showed a m/z = 467.1330 [M+H]
+
 for 7 leading to the molecular formula 
C25H22O9. The molecular formula and the MS fragment m/z = 321.1 [M–(6-
deoxyhexose)+H]
+
 indicated only one sugar to be present in 7. Comparison of NMR data of 6 
and 2 led to the assumption, that the same aglycone and the same sugar are present in 6 and 7. 
The HMBC signal C-1/10-H (δC = 155.9 ppm/δH = 5.57 ppm) and ROESY 2-H/1´-H signal 
(δH = 7.15 ppm/5.57 ppm) determined C-1-O-glycosylation of the angucycline. Moreover the 
deep-field shift of carbon C-6 in 7 (δC = 158.6 ppm) in comparison with 6 (δC = 153.6 ppm) 
indicates the free C-6-OH-group. 
 
2-O-α-L-Talosyl-1,2-hydroxyanthraquinone 
To prove the glycosylation potential of K. sp. a feeding experiment with alizarin was done 
which led to the new compound 8. HRESI(+)MS of 8 shows a molecular ion m/z = 387.1085 
for [M+H]
+
 that fits to the assumed molecular formula C20H18O8 for a monoglycosylated 
alizarin. The fragment m/z = 241.0514 [M–(6-deoxyhexose)+H]+ indicates the splitting of the 
attached sugar. 
NMR data of the aglycone are in good agreement with alizarin as the substructure (Table 4). 
O-glycosylation of alizarin at C-2 was proved by the HMBC signal C-2/1´-H and ROESY 
cross peak 3-H/1´-H. The aglycone free hydroxyl group must be in position C-1 showing a 
typical chemical shift of δH = 12.66 ppm. The NMR data determined that the 6-deoxysugar 
was 6-deoxy-α-talose like in 6 and 7. Unfortunately the superposition of protons 2´-H, 3´-H, 
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and 5´-H in a multiplet at δH = 3.85 ppm, does not allow to determine sugar conformation 
based on proton–proton coupling or via NOESY/ROESY. Therefore, additional NMR 
measurement was performed in CDCl3 with drops of CF3COOD, which led to sufficient 
separation of 2´-H, 3´-H, and 5´-H (Table S6) allowing further NMR measurements (Table 
S6) and proving the sugar to be 6-deoxy-α-talose. 
Table 4. NMR data for 3 (500 MHz, 25 °C, DMSO-d6) 
Pos. δC δH (J in Hz)
  COSY[a] HMBC[a] 
1 152.4   3-H 
2 149.8   1’-H, 3-H, 4’-H 
3 121.8 7.63 d (8.5) 4-H 1J 
4 120.1 7.72 d (8.5) 3-H 3-H 
4a 126.2   3-H,  
5 126.8 8.18 m 6-H 1J 
6 135.2 7.93 m 5-H 1J, 8-H 
7 134.3 7.93 m 8-H 5-H, 1J 
8 126.6 8.23 m 7-H 1J 
8a 133.3    
9 188.6   8-H 
9a 116.5   4’-H 
10 180.9   5-H, 4-H 
10a 132.9   6-H, 5-H, 8-H 
1’ 99.1 5.73 s (br)  (2’-H, 3’-H), 1J, (2’-OH) 
2’ 70.0 3.85 m 2’-OH 3’-OH, 2’-OH, 1’-H, 4’-
H,  
3’ 65.0 3.85 m 3’-OH (4’-H) (2’-H), 4’-H, 4’-OH, 3’-
OH, 2’-OH, 1’-H 
4’ 72.0 3.59 d (6.5) 4’-OH, (3’-H,  
4’-H) 
3’-H, 5’-H, 6’-H3, 4’-OH, 
3’-OH 
5’ 68.5 3.85 m 6’-H3, (4’-H) 6’-H3, 4’-OH, 1’-H, 
1J 
6’ 16.6 1.09 d (6.4) 5’-H 1J, 5’-H, (4’-H) 
1-OH  12.66 s (br) /  
2’-OH  5.39 d (7.0) 2’-H  
3’-OH  5.12 d (6.0) 3’-H  
4’-OH  5.02 d (6.5) 4’-H  
[a]
 weak signals in brackets. 
After hydrolysis of 3 in methanolic HCl, methyl 6-deoxy-a-talopyranoside (3.9 mg) was 
isolated. Comparison of the optical rotation value in H2O [α]D = – 87 (c 2 mg/ml, 20 °C) and 
MeOH [α]D = – 101 (c 2 mg/ml, 20 °C) with the literature values confirmed L-configuration 
of the 6-deoxy-α-talose [6, 7]. From this experiment we could conclude that the sugars in 1 
and 2 are 6-deoxy-α-L-talose, too. 
Amycomycins C and D and monoglycosylated alizarin in comparison with alizarin were 
screened against a small panel of Gram-positive and Gram-negative bacteria (Table S2). 
Amycomycin C (6) displayed no remarkable activity, whereas the monoglycosylated 
amycomycin D (7) revealed a slight increase in activity against Staphylococcus aureus 
Newman, Pichia anomala, Mucor hiemalis (MIC = 9.21 µM), and E. coli ToIC (MIC = 14.6 
µM). The monoglycosylated alizarin is slightly more active than its aglycone, to mention here 
is the activity against E. coli ToIC (MIC = 9.11 lM). Unusual is the fact that the genes 
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responsible for glycosylation could not be found within the gene cluster for angucycline 
biosynthesis. 
In summary we isolated and characterized three new 6-deoxy-α-L-talopyranosides from K. sp. 
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3. Draft genome sequence of Kitasatospora nimpheas 
Actinobacteria are of great importance for biotechnology as the source of diverse natural 
products, including anticancer agents, antibiotics and others [1]. Kitasatospora genus together 
with Streptacidiphilus and Streptomyces constitute Streptomycetaceae family within the 
phylum of Actinobacteria [2]. For a long time the status of genus Kitasatospora has been a 
matter of a debate [2-5]. Based on distinct clades of sequences of both 16S rRNA genes 
and16S-23S gene spacers Zhang et al. could strongly suggest that Kitasatospora and 
Streptomyces are separate genera [5]. Also, there are clear phenotypic differences between 
Kitasatospora and Streptomyces. Cell wall peptidoglycan of Kitasatospora contains both LL- 
and meso-diaminopimecil acid (DAP); in contrast, the peptidoglycan of streptomycetes 
contains only LL isomer of DAP. More recently, it was shown that Kitasatospora strains do 
not contain genes for the developmental proteins BldB and WhiJ, and for the actin-like 
cytoskeletal protein Mbl. Another feature of kitasatosporae is the loss of cell division 
activator SsgA and its transcriptional activator SsgR in some species [2]. Furthermore, 
tetracycline producer “Streptomyces viridifaciens” DSM 40239 merits species status within 
Kitasatospora taxon [2]. 
Eight genomes of Kitasatospora strains are available on the web site of NCBI 
(http://www.ncbi.nlm.nih.gov/genome) today [2, 6, 7]. Here we report draft genome sequence 
of new Kitasatospora nimpheas, which was found recently to produce new angucycline 
antibiotics amicomycins C and D [8]. 
Genomic DNA of the strain was isolated and sequenced using two Illumina MiSEQ libraries – 
4 914 332 short-insert (paired-end, PE) and 6 576 880 long-insert (mate pair, MP) read pairs. 
PE insert size was 597.4 with a standard deviation of 179, MP insert size was 8 841.7 with a 
standard deviation of 2 210.4 (as reported by the Newbler v2.8 genome assembly software). A 
total of 843 contigs (8 398 185 bases) were assembled, including 612 large contigs (8 353 677 
bases, N50 contig size 26 kbp). The final assembly resulted in 27 scaffolds (8 511 455 bases 
total), with most of the genome being in scaffold 1 (8 353 987 bases). The genome was then 
annotated using prokka [9]. The K. nimpheas genome has average GC content of 73.5%. The 
analysis of K. nimpheas genome revealed that its chromosome contains 7536 predicted 
protein coding sequences, and 98 predicted tRNA genes.  
Using antiSMASH tool [10] we were able to estimate the potential of K. nimpheas to produce 
secondary metabolites. Preliminary data indicates the presence of 27 putative gene clusters for 
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the biosynthesis of different secondary metabolites on the main scaffold. Among predicted 
gene clusters, 6 encode terpenes, 2 – NRPS, 2 are involved in biosynthesis of siderophores, 2 
are type II PKS (one of them have been identified to encode amicomycin biosynthetic 
machinery), 1 is type III PKS and 1 is a hybrid type I PKS-hlgks-teprene cluster.  
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4. Cloning and heterologous expression of the grecocycline biosynthetic gene cluster 
Introduction 
Actinobacteria is a potential source of secondary metabolites with diverse chemical scaffolds 
and interesting biological activities. 43% of microbial biologically active compounds were 
isolated from Actinobacteria, especially the excellent producers of the genus – Streptomyces 
[1]. The implementation of Actinobacteria biosynthetic potential involves the expression of 
orphan secondary metabolite gene clusters in heterologous host. Therefore, construction of 
vectors carrying entire biosynthetic gene clusters is of high interest.  
Nowadays cosmid vectors are routinely used for genomic libraries constructions, they can 
accommodate between 31kb and 44 kb of foreign DNA. However, gene clusters encoding 
secondary metabolites may have size over 100kb i and cosmid vectors capacity is simply not 
great enough to deal with such large DNA segments. There are several alternatives of 
replicons capable to accommodate larger DNA insertions: P15a, RK2 and F1 (BAC). P15a is 
a low copy (about 15 copies of vector per cell) replicon from E. coli [2]. Its utility in 
maintaining large DNA constructs was demonstrated in the assembly of 62.4 kb large 
epothilone biosynthetic gene cluster [3]. RK2 replicons belong to the IncP incompatibility 
group and have been used for metagenomics library constructions [4]. Vectors constructed 
from this replicon function in numerous Gram-negative bacterial species and have been 
transferred to Gram-positive bacteria, yeast and mammalian cells [5, 6]. Bacterial artificial 
chromosome (BACs) and P1 artificial chromosomes (PACs)-derived libraries are good 
alternative to cosmid libraries when handling of large DNA fragments is needed. PACs that 
combine features of BACs and bacteriophage P1 vectors can carry inserts in size from 60kb to 
150kb, whereas BACs are capable of cloning and propagating of large DNA fragments up to 
700 kb (with an average insert size 150 kb). Though, construction of BAC-derived libraries 
requires special equipment, is time-consuming and expensive.  
During the past years transformation-associated recombination (TAR) in yeast was 
successfully applied to assemble and clone large DNA fragments, including secondary 
metabolite gene clusters [7-10]. Originally TAR method was developed for cloning of large 
genomic fragments without having to construct and screen genomic libraries [11]. This 
approach relies on homologous recombination between DNA of interest and short (~ 60 bp) 
“capture arms” of the TAR-vector. Advantage of the method is elimination of in vitro 
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enzymatic reactions such as restriction and ligation and reducing the amount of DNA 
handling.  
Herein, we report successful assembly and heterologous expression of 35-kb long 
grecocycline biosynthetic gene cluster (gre) using TAR method. Fragments of the gene cluster 
were obtained using PCR and transformed into S. cerevisiae together with the “capture” 
vector, resulting in the construct, carrying the entire gene cluster. The obtained construct was 
successfully expressed in S. albus. 
Results 
Grecocycline biosynthetic gene cluster identification and description 
The Streptomyces sp. Acta1362 draft genome contains 8,710,318 base pairs with an average 
GC content of 71% and includes 8,026 open reading frames. Using antiSMASH we have 
predicted 41 potential biosynthetic gene clusters, containing two type II PKS clusters [12]. As 
grecocyclines contain sugar units (Figure 19), the presence of genes encoding for 
glycosyltransferases and deoxysugar biosynthesis are expected within the biosynthetic gene 
cluster. Indeed, three glycosyltransferases were identified in one of type II PKS gene cluster, 
along with genes required for the deoxysugars biosynthesis, genes encoding post-PKS 
tailoring enzymes, regulatory and transporter genes. Altogether they compose the putative 
grecocycline biosynthetic gene cluster (gre cluster) that comprises 32 predicted open reading 
frames (ORF) (Figure 20, Table 5).  
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Figure 19. Structures of grecocylines A (A), B (B) and C (C). 
 
There are several genes involved in the angucycline formation and maturation: 1) the type II 
PKS gene set is represented by greA1, greA2 and greA3 encoding alpha and beta 
ketosynthases (KSα and KSβ) and acyl carrier protein (ACP), respectively; 2) two cyclase 
encoding genes - greA4 and greA5; 3) three ketoreductase encoding genes – greA6, greV and 
greO; 4) four oxygenase genes – greM2, greE, greL and greD; 5) one gene, greA7, which is 
responsible for the activation of ACP with its phosphopantetheine arm; and 6) the gene 
encoding a decarboxylase, greN. Interestingly, greD is the only one transcribed on the 
antisense strand. An additional gene that is encoding enzyme presumably acting on the 
angucyclic core of the grecocyclines is greTh. The deduced amino acid sequence of GreTh is 
highly similar to thioesterases and may be involved in formation of the thiol group in 
grecocycline B. 
 
Figure 20. Grecocycline biosynthetic gene cluster (gre) from S. sp. Acta 13-62. In yellow 
are labeled genes encoding type II PKS, orange – genes involved in angucycline formation, 
blue – genes involved in biosynthesis of rhodinose and α-tolyposamine, dark blue – genes 
encoding glycosyltransferases, pink – gene encoding putative thioesterase, green – efflux, 
red – regulatory genes. Dashed arrow indicates formation of shunt product grecocycline C. 
 
Two different deoxysugars are attached to the angucycline: L-rhodinose and L-tolyposamine. 
Eleven of thirty-two genes are encoding enzymes that are involved in biosynthesis and 
transfer of sugars to the polyketide. The genes greG, greH, greS, greT, greQ, greZ1 and 
greZ3 encode enzymes that are involved in the formation of NDP-rhodinose from D-glucose-
1-phosphate. Additionally, greJ encodes NDP-hexose-4-aminotransferase that probably 
transfers aminogroup to the hexose to form L-tolyposamine.  
Grecocyclines contain three sugar units and an equal number of glycosyltransferase encoding 
genes was identified in the gre cluster – GreGT1, GreGT2 and GreGT4. greGT2 encodes a 
protein that is homologous to SaqGT5 and UrdGT2 [13, 14] and may be involved in  
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Table 5. Deduced function of ORFs in the grecocycline biosynthetic gene cluster 
Polypep
tide 
aa Similar protein Acc. number Identity Proposed function 
GreR1 216 PgaR1; Streptomyces sp. PGA64 AHW57766.1 68% transcriptional regulator 
GreA4 110 LndF; Streptomyces globisporus 
JadI; Streptomyces venezuelae 
AAU04837.1 
AAO65345.1 
82% 
81% 
polyketide cyclase  
GreA1 354 PgaA; Streptomyces sp. PGA64  AAK57525.1 85% ketosynthase alfa 
GreA2 405 PgaB; Streptomyces sp. PGA64 AAK57526.1 73% ketosynthase beta 
GreA3 92 PgaC; Streptomyces sp. PGA64 AAK57527.1 72% acyl carrier protein 
GreA6 262 PgaD; Streptomyces sp. PGA64 AAK57528.1 87% ketoreductase 
GreA5 315 UrdL; Streptomyces fradiae 
PgaL; Streptomyces sp. PGA64 
AAF00205.1 
AAK57529.1 
79% 
74% 
aromatase 
GreM2 794 PgaM; Streptomyces sp. PGA64 AAK57530.1 67% two-domain mono-oxygenase 
GreEx 503 PgaJ; Streptomyces sp. PGA64 AAK57531.1 53% transporter 
GreA11 236 OvmF; Streptomyces antibioticus CAG14972.1 63% 4'-phosphopantetheinyl 
transferase 
GreN 515 PgaI; Streptomyces sp. PGA64 AAK57534.1 84% acyl-CoA carboxylase, beta-
subunit 
GreEx2 391 uncultured soil bacterium V167 ACX83629.1 59% putative major facilitator 
transporter 
GreTH 305 Streptomyces roseoverticillatus WP_030366371.1 63% thioesterase 
GreE 498 PgaE; Streptomyces sp. PGA64 AAK57522.1 97% monooxygenase 
GreO 199 UrdO; Streptomyces fradiae AAF00220.1 62% reductase 
GreZ3 341 PgaZ3; Streptomyces sp. PGA64 AHW57779.1 45% TDP-hexose-4-ketoreductase 
GreJ 384 PgaC1; Streptomyces sp. PGA64 AHW57776.1 80% TDP-hexose-4-aminotransferase 
GreZ1 200 PgaZ1; Streptomyces sp. PGA64 AHW57777.1 74% TDP-hexose-3,5-epimerase 
GreG 356 PgaG; Streptomyces sp. PGA64 AHW57786.1 75% TDP-hexose synthetase 
GreH 337 PgaH1; Streptomyces sp. PGA64 AHW57787.1 83% TDP-hexose-4,6-dehydratase 
GreQ 435 PgaQ; Streptomyces sp. PGA64 AHW57788.1 86% TDP-hexose-3,4-dehydratase 
GreS 465 PgaS; Streptomyces sp. PGA64   AHW57789.1 71% TDP-hexose-2,3-dehydratase 
GreT 328 PgaT; Streptomyces sp. PGA64 AHW57790.1 66% TDP-hexose-3-ketoreductase 
GreV 254 LanV; Streptomyces cyanogenus AAD13552.1 62% Reductase homolog 
GreK 497 SaqE; Micromonospora sp. Tu 6368 ACP19351.1 68% putative oxygenase 
GreGT2 379 SaqGT5; Micromonospora sp. Tu 6368 ACP19370.1 59% glycosyltransferase 
GreGT4 425 Lcz36; Streptomyces sanglieri ABX71153.1 54% glycosyltransferase 
GreGT1 392 SaqGT3; Micromonospora sp. Tu 6368 ACP19364.1 59% glycosyltransferase 
GreD 217 FrnE; Streptomyces roseofulvus AAC18100.1 56% DSBA oxidoreductase 
GreR2 118 Streptomyces sp. CNH287 WP_027750658.1 59% HxlR family transcriptional 
regulator 
GreL 227 Actinoplanes missouriensis WP_014442785.1 40% putative monooxygenase  
GreEx3 542 Streptomyces sp. W007 WP_007448654.1 95% MFS transporter 
 
attachment of L-rhodinose  to the C-9 position of the aglycon similar to urdamycins and 
saquayamycins. Probably, GreGT1 is responsible for introduction of second L-rhodinose unit, 
as it is highly similar to SaqGT3, SaqGT4, LanGT1 which are responsible for the extention of 
an oligosaccharide chain in angucyclines [13-15]. To our knowledge, grecocyclines are the 
first angucyclines that carry the sugar moiety in C-5 position of the angucyclic core. 
Furthermore, α-tolyposamine is a very rare deoxysugar in natural products, so far it was found 
only in BU-4514N from Microtetraspora sp. [16]. We presume that GreGT4 is transferring 
aminosugar to the C-5 position of grecocyclines. The deduced amino sequence of GreGT4 
share 54% with Lcz3 from the lactanomycin gene cluster and 50% identity with UrdGT1a 
involved in urdamycin biosynthesis [17, 18]. As mentioned above, greL encodes 
 II. RESULTS  
63 
 
G
re
co
cy
cl
in
e 
B
 
G
re
co
cy
cl
in
e 
A
 
G
re
co
cy
cl
in
e 
C
 
+
 + 
+
 
1
0
 a
ce
ta
te
 
G
lu
co
se
-1
-p
h
o
sp
h
a
te
 
G
re
J 
G
re
Z
1
 
Z
3
 
G
re
T
h
 
G
re
Z
1
 
Z
3
 
G
re
G
H
 
S
T
Q
 
G
re
G
H
 
S
T
Q
 
G
re
L
 
G
re
M
2
 
E
V
K
 
G
re
N
 
D
O
 
G
re
A
1
-
A
3
 
G
re
A
4
-
A
6
 Gr
eG
T
2
 
G
re
G
T
4
 
G
re
G
T
1
 
monooxygenase that doesn’t have a predicted function, and might be a potential candidate for 
hydroxylation of the aglycon at C-5 prior to the sugar attachment (Figure 21).  
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Figure 21. Proposed biosynthesis of grecocyclines. In circles are indicated enzymes 
putatively involved in particular biosynthetic steps. 
Two regulatory – greR1, greR2 and three transporter genes – greEx, greEx2 and greEx3 have 
been identified in the gre cluster. greR1 is located on the 5’ end of the gene cluster, and 
encodes protein with the similarity to transcriptional regulators from the OmpR family [19]. 
GreR2 is homologous to the HxlR family of transcriptional regulators. GreEx, GreEx2 and 
GreEx3 are similar to MFS transporters and probably are exporting grecocyclines out of the 
cell. 
All the attempts to generate the deletion mutants in S. sp. Acta 13-62 failed and therefore we 
decided to assemble the gene cluster for heterologous expression  
Grecocylcine gene cluster assembly in yeast 
To express the gene cluster in the heterologous host, we targeted appropriate DNA region for 
TAR cloning (Figure 22). Previous reports showed that short 40- to 70-bp DNA-specific 
targeting sequences were enough for successful TAR cloning [20]. The grecocycline 
biosynthetic gene cluster was split on three regions, R1, R2 and R3, overlapping with each 
other and with the shuttle vector (pCLY10) in 38 bp. The capture arms to the gre cluster were 
introduced into pCLY10 via PCR to generate pCLY10ol. Primers were designed to overlap 38 
bp of the 500 bp long region upstream from the gre cluster (forward primer) and 38 bp of the 
130 bp long region downstream from the cluster (reverse primer). Assembly of the gre cluster 
was done in two steps: 1) capture of R1 and R3 on the shuttle vector to give pR1R3; 2) 
capture of R2 on pR1R3 to give pGRE.  R1, R2 and R3 were amplified in PCR reaction with 
the primers carrying homologous arms to the adjacent DNA regions. After transformation of 
S. cerevisiae BY4742 cells with the mixture of obtained PCR-products (R1, R3 and 
pCLY10ol), positive clones were identified by PCR and confirmed by restriction mapping to 
give pR1R3. Later, linearized pR1R3 and R2 (R2.1 + R2.2) were transformed into yeast cells 
and resulted in pGRE – a construct carrying the entire gre biosynthetic gene cluster. The 44-
kb pGRE construct was stably maintained in E. coli. 
Heterologous expression of pGRE  
For the heterologous production, we chose S. albus, a model actinomycete commonly used as 
a biosynthetic host. pGRE was introduced by conjugative transfer from E. coli into the 
genome of  S. albus J1074. S. albus strain carrying pGRE (S. albus pGRE) produced a series 
of angucyclines, as revealed by ESI-MS analysis (Figure 23).  
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Figure 22. Strategy for assembling the grecocycline biosynthetic gene cluster using TAR. A 
– gre cluster divided on R1, R2 and R3; B – assembly of pR1.R3; C – assembly of pGRE. 
To determine the chemical structure of produced compounds, we cultivated S. albus pGRE in 
5 L to yield ~130mg of crude extract, from which we purified ten fractions which were 
analyzed by LC MS. Three compounds from fractions N4, N9 and N10 were assigned to 
known angucycline intermediates or shunt products, based on the UV/Vis spectrum shape and 
the accurate mass. The compound from fraction N4 is rabelomycin (m/z = 338.07863), 
fractions N9 and N10 contain dehydrorabelomycin (m/z = 320.06741) and tetrangulol (m/z = 
304.07257), respectively. No glycosylated products have been detected after the heterologous 
expression of pGRE. Althought no grecocyclines have been detected in the crude extracts via 
LC MS analysis it isobvious that the cloned biosynthetic gene cluster is responsible for 
grecocycline biosynthesis, since several known angucyclines were observed. To identify the 
reason why after the heterologous expression of cloned gre gene cluster no grecocyclines 
were produced we have sequenced the pGRE plasmid.pGRE was sequenced via primer 
walking, covering approximately 97,1% of the construct.  Analysis of the sequenced data 
revealed twenty six nucleotide substitutions.  
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Eight nucleotide substitutions were identified in the DNA region encoding GreM2. 
Inactivation of greM2 homologs in urdamycin and landomycin biosynthetic pathways led to 
accumulation of rabelomycin, tetrangulol and other shunt products [21, 22], preventing 
subsequent conversion of aglycon into the natural product. 
 
Figure 23. Chromatogram of the HPLC-ESI/MS analysis of S. albus pGRE. Arrows indicate 
ions corresponding to rabelomycin, dehydrorabelomycin and tetrangulol. 
 
To complement mutated region encoding greM2, native greM2 was placed under the control 
of the strong synthetic 21p promoter. The introduction of this construct into the S. albus 
pGRE strain did not change the spectrum of the compounds observed after the expression of 
only pGRE. It may be because of an unbalanced expression of greM2 and the rest of the gre 
cluster from different plasmids. 
Discussion 
During the decades actinomycetes have been the source or inspiration for the numerous 
pharmaceutically useful compounds, including antibiotics, immunosuppressive, 
antiproliferative and antiparasitic drugs [23]. Also, the rise of DNA sequencing technologies 
revealed the wealth of natural product biosynthetic gene clusters in the genomes of 
actinomycetes, most of which remain cryptic [24]. One approach to address cryptic/silent 
biosynthetic gene cluster is heterologous expression, however cloning of large natural product 
clusters still represent a challenge. Therefore, technics for large DNA fragments cloning are 
of great interest.  
Several techniques have been developed to get access to entire gene clusters for their 
subsequent expression e.g. sequence-independent (In-FusionTM, SLIC, Gibson isothermal 
assembly) and standardized restriction enzyme assembly protocols (BioBricks TM, 
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BglBricks, Golden Gate) [25]. For example, one-step in vitro recombination method (Gibson 
isothermal assembly) has a capacity to assemble and repair overlapping DNA molecules in a 
single isothermal step. This approach was used to assemble the complete synthetic 583-kb 
genome of Mycoplasma genitalium. The Gibson isothermal assembly is based on combination 
on 5’ T5 exonuclease activity combined with DNA polymerase and Taq DNA ligase. This 
method is simple, rapid and may be used for scarless assembly of a large number of DNA 
fragments in one step [26]. However, this approach is hardly applicable for DNA with high 
G/C content, due to the secondary structures that may occur in the single-stranded DNA 
overhangs, as it would compete with the required single-stranded annealing of neighboring 
assembly fragments. 
Another routine method widely used in laboratories is a Golden Gate Assembly, which offers 
seamless, multi-part DNA assembly [27]. This method uses single type II restriction 
endonucleases (for example BsaI) that cut outside their recognition sequence, allowing 4-bp 
overhangs that can be freely chose. Thus, assembly can be seamless between neighboring 
fragments, containing appropriate 4-bp termini. A major limitation in Golden Gate assembly 
may be presence of the selected type II recognition site (BsaI) in the internal sequence of 
DNA fragments to be assembled, additionally rather short 4-bp overhangs may limit a single 
multi-part assembly step when number of fragments to assemble becomes larger (greater than 
10) or if the fragment termini is characterized by extremely high or law GC% content. 
Furthermore, base-pair mismatching at similar overhangs had been reported [25]. 
TAR method has been a common protocol for manipulating DNA in yeast for over a decade, 
and like methods described above relies on overlapping sequences between the fragments to 
be cloned or assembled.  
In this study we used TAR method to assemble and heterologously express grecocycline 
biosynthetic gene cluster. The entire 36-kb gene cluster was successfully captured on the 
shuttle vector carrying short (38-bp) homologous shoulders. We did cluster assembly in two 
steps. The advantage of step by step method is very fast and effortless obtaining of all parts 
and their joining together. The excessive DNA fragments, which are coming when a genomic 
DNA mixture is used for transformation, may sufficiently reduce the recombination 
frequency. Hence, yeast transformation only with essential fragments may increase frequency 
of the correct assembly in a fold range.  
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On the other hand, using polymerases for generation of the building blocks gave rise to 
numerous mutations.  
The re-assembled gre gene cluster was expressed in S. albus. Undoubtedly, the angucycline 
compounds, which we have isolated, are produced after the expression of gre biosynthetic 
cluster from pGRE, since the host lacks type II PKS-encoding genes.  
Although no grecocycline have been detected after heterologous expression of the gre gene 
cluster we have isolated rabelomycin, dehydrorabelomycin and tetrangulol. This was 
expected, as they represent intermediates and shunt products during biosynthesis of 
angucycline polyketides [22, 28-30]. Also this data is in agreement with the mutations in 
greM2. The deduced amino acid sequence of GreM2 shows significant similarity to the 
bifunctional oxygynase-reductases from the landomycin (LndM2, LanM2, 59%), gaudimycin 
(PgaM, 67%) and jadomycin (JadF, 63%, partially) biosynthetic pathways. LanM2 and PgaM 
belong to short-chain alcohol dehydrogenases/reductases (SDRs) family and are translated as 
the two-domain flavoprotein oxygenase fusion with a separate C-terminal SDR [21, 31, 32]. 
LanM2 was shown to catalyze a thioesterase-like decarboxylative 2,3-dehydration of the 
ACP-tethered nascent angucycline generated by “minimal” PKS [32]. This reaction gives 
prejadomycin, which is recognized by further enzymes involved in the landomycins 
biosynthesis. The same reaction was proven in in vitro studies for JadF during one-pot 
defucogilvocarcin enzymatic biosynthesis, where its removal led to accumulation of 
rabelomycin [33]. Thus, accumulation of rabelomycin may be due to the lack of GreM2 N-
terminal oxidative activity. On the other hand, conversion of UWM6 into rabelomycin was 
observed after incubation with LanE [32]. LanE homolog in grecocycline biosynthetic gene 
cluster is represented by GreE (74% identity with LanE and 76% identity with PgaE). As a 
result rabelomycin may originate from UWM6, which is recognized as a substrate by GreE. 
Only the oxygenase domain of GreM2 is required to release angucyclic intermediate tethered 
to ACP. One amino acid substitution (A2T) was identified in sequence of greM2 encoding N-
terminal domain after sequencing of pGRE. This mutation occurred in the first amino acid 
after methionine and may not change enzymatic activity and folding of the GreM2 oxygenase 
domain. In contrast, three amino acid substitutions were identified in the reductase domain 
encoding sequence of greM2, would likely impair its catalytic activity. Therefore, we presume 
that mutated GreM2 may keep oxygenase activity and perform 2,3-dehydration of the ACP-
tethered angucycline to give prejadomycin. Later prejadomycin is recognized by GreE and (a) 
converted to dehydrorabelomycin or (b) in cooperation with GreV, produce tetrangulol. 
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Table 6. List of mutations introduced into the gre genes during amplification*. 
Protein Mutation Proposed function 
GreA5 A217T aromatase 
GreM A2T; R339C; 
G407C; P665L; 
R734C; E747G 
bifunctional oxygynase-reductase 
GreN I353V carboxylase 
GreK V79V**; 
K101K**; L387P;  
putrative oxygenase 
GreGT4 W22R glycosyltransferase 
GreGT1 A291A** glycosyltransferase 
GreD E147V DSBA oxidoreductase 
GreL P104T; R106Q putative monooxygenase 
GreEx3 I322F; A500V MFS transporter 
* - mutations in the intergenic regions are not included  
**  - nucleotide substitution do not influence amino acid sequence  
 
Other nucleotide substitutions were located in regions encoding GreA5, GreN, GreGT1, 
GreGT4, GreD, GreL and GreEx3 (Table 6). Two times nucleotide change did not influence 
amino acid sequence (in GreGT1 and GreK). Clearly, the mutation in greA5 did not have 
impact on the protein function; otherwise aromatic polyketides would not be formed. Most 
probably mutation in GreN (I353V) also does not influence the enzyme activity significantly. 
GreN is highly similar (~80%) to different acetyl-CoA carboxyltransferases. The orthologs of 
this enzyme have been identified in many gene clusters of secondary metabolites [14, 34, 35]. 
For example, acyl-CoA carboxylase JadJ, from the jadomycin biosynthetic pathway, is 
supplying malonyl-CoA for the polyketide biosynthesis. Its inactivation severely reduced 
jadomycin B production [34]. Isoleucine and valine are highly similar amino acids and their 
swapping may not influence folding and activity of the enzyme, additionally heterologous 
expression of pGRE resulted in a significant yield of angucyclines. Therefore, it was 
concluded that mutation in greN is not essential. As all other mutated enzymes/proteins are 
acting on the later stages of biosynthesis, it is impossible to predict if they had any impact on 
the protein function.  
In summary, TAR method is an efficient and rapid approach for assembling of large DNA 
molecules into one biosynthetic gene cluster and its heterologous expression, although the 
PCR derived mutations should be taken into account. Despite this, we believe that the cloned 
gene cluster is indeed involved in the biosynthesis of grecocycline in the native producer and 
several unique enzymes (specially GreGT4 and the sugar biosynthesis genes) will find their 
application in the derivatization of known active angucyclines via combinatorial biosynthesis.  
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Methods and Materials 
Strains, growth conditions and media 
For standard purposes S. sp. Acta 1362 and S. albus d10 wild types and mutant were grown 
on 2% manitol and 2% soy bean meal, pH 7.5, prepared as solid medium and tryptone soy 
broth (TS broth), prepared as liquid medium, at 28 0C. For maintenance of S. albus d10 
pGRE apramycin was added to a final concentration of 50 µg/ml. For production a liquid 
medium DNPM (4% dextrin, 0,75% soytone, 0,5% baking yeasts and 2,1% MOPS, pH 6.8) 
was used. DNA manipulations were carried out in E. coli BG2005 and the non-methylating E. 
coli ET12567/pUZ8002 was used to drive conjugative transfer of non-methylated DNA to 
Actinobacteria as described previously [36]. E. coli strains were grown on Luria-Bertani agar 
or liquid medium containing appropriate antibiotic for selection. pKG1139, which contains 
gusA and apramycin-resistance genes was used for heterologous gene expression, was present 
in our laboratory [37].  
General genetic manipulation and standard PCR 
Standard molecular biology procedures were performed as described previously [38]. 
Isolation of plasmid DNA from E. coli and DNA restriction/ligation were performed by 
following the protocols of the manufacturers of the kits, enzymes, and reagents, Qiagen, 
Promega, NEB and ThermoScientific. PCR reactions were performed by using Phusion High-
Fidelity DNA polymerase (Thermo Fisher Scientific) for complementation and expression 
experiments and DreamTaq polymerase (Thermo Fisher Scientific) to verify mutants. Primers 
were purchased from Eurofins MWG Operon. The oligonucleotide primers that were used are 
listed in Table S1. The oligonucleotide primers used to sequence pGRE are listed in Table S2. 
Gene complementation cassettes 
pUWLgreM2. To generate the expression vector pUWLgreM2, greM2 was amplified by 
PCR. Suitable restriction sites (XbaI and KpnI) were introduced upstream and downstream 
from the gene, using primers. Also forward primer was carrying 21p promoter. To obtain 
suitable shuttle vector, pUWLCre was treated with KpnI/XbaI and 8kb-fragment was eluted 
from the agarose gel (done according to the manufacturer, Promega). 2.4 kb PCR-fragment 
was digested with XbaI and KpnI and ligated into pUWL vector, to generate pUWLgreM2. 
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gre gene cluster assembly using TAR 
Homologous sequences to the gre cluster were introduced into pCLY10 via PCR. Primers 
were designed to overlap 38 bp of the 500 bp long region upstream from the gre cluster 
(forward primer) and 38 bp of the 130 bp long region downstream from the cluster (reverse 
primer). Prior to the PCR pCLY10 was treated with HindIII, obtained PCR-product was 
treated with DpnI for 3 hours. gre cluster was split into 3 parts: region 1, region 2 and region 3 
(R1, R2 and R3), each size in range from 10 to 14 kb (Fig. N.). R1 and R3 were chosen for 
the first step of the cluster assembly. Primers for R1 were designed to overlap with 38bp 
pCLY10 (forward primer) and R3 (reverse primer); R3-primers had 38-bp long overlaps with 
R1 (forward primer) and pCLY10 (reverse primer). Mixture of obtained PCR-products (R1, 
R3 and pCLY10) was transformed into Saccharomyces cerevisiae BG4742 (LEU) cells in 
concentration 100 ng each. After 4 days of incubation at 30 oC, transformants were picked 
from the plates, plasmid DNA was isolated and transformed into E. coli GB2005 cells. 
Verification of obtained constructs revealed pCLY10 carrying R1 and R3 regions (pCR1.R3). 
ScaI restriction site was introduced between R1 and R3 artificially using primers, thus giving 
possibility to introduce R2 into pCR1.R3. Due to the problems with PCR, R2 was split into 
two parts: R2.1 (5743 bp) and R2.2 (7586 bp), overlap between R2.1 and R1 was 110 bp, 
R2.2 and R3 49 bp, R2.1 and R2.2 41 bp. To amplify pCLY10, R1 and R3 MasterAmpTM 
Extra-Long PCR Kit from Epicentre was used, to amplify R2.1 and R2.3 polymerase from the 
kit was substituted with Phusion High-Fidelity DNA Polymerase from ThermoScientific. 
Mixture of R2.1, R2.2 PCR-products and pCR1.R3, treated with ScaI, was transformed into 
yeast cells. Transformants were picked from the plates after 4 days incubation at 30 °C, prior 
to plasmid DNA isolation, colony-PCR was done. Primers were specific to the DNA sequence 
that can be present only in a reassembled gene cluster construct. 22 positive clones were 
picked from 95 after PCR, 4 clones were selected randomly and plasmid DNA was isolated. 
After verification all four clones were positive for containing pR1.R3 reassembled with R2.1 
and R2.2 (pGRE). 
Conditions for amplification of R1, R2.1, R2.2, R3 and pCLY10 
To amplify pCLY10, R1, R2.1, R2.2 and R3 Master-AmpTM Extra-Long PCR Kit 
(Epicentre) was used: PreMix 4 for amplification R3 and R2.2, PreMix 8 for amplification R1 
and R2.1. Phusion High - Fidelity DNA (Thermo Fisher Scientific) polymerase was used to 
amplify R2.1 and R2.2, and Master-AmpTM Extra-Long Polymerase Mix (Epicentre) for R1 
and R3 amplification. 
 II. RESULTS  
72 
 
Transformation of yeast 
Yeast transformation was done as described before [39]. 
Isolation of plasmid DNA from yeast 
Plasmid DNA was isolated from the yeast cells using Wizard Plus SV Miniprep kit from 
Promega. 37,5 Units of Longlife Zymolyase (G-Biosciences, USA) were added to P1 buffer, 
samples were incubated at 37 C for 30-60 min. Further steps were done according to the 
manufacturer. 
Purification of compounds 
S. albus pGRE was cultivated in DNPM medium in shaking flasks, total volume 5 L at 30°C, 
200 rpm for 5 days. Mixture of culture broth and biomass was extracted with 5 L of 
ethylacetate (EtAc) and led to 120 mg of crude extract. The extract was purified by HPLC 
(HTec C18 column, 250 × 10 mm, 5 µm, A = H2O + 0.1% FA, B = ACN + 0.1% FA) with 
gradient starting from 5% B to 95% B in 28.2 min. Flow 5.8 ml/min, injection volume 40 µl 
of an MeOH extract (c = 5.3 mg/ml), detection wavelength λ = 420 nm.  
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III. DISCUSSION 
1. sim biosynthetic gene cluster 
Given the redundancy of biosynthetic gene clusters within actinobacteria genomes, we have 
screened the genomic database for availability of simocyclinone biosynthetic genes. Indeed, 
two strains - K. sp. and S. sp. NRRL B-24484 have been identified carrying the sub-clusters of 
genes in their genomes highly similar to those of simocyclinone biosynthetic gene cluster 
from S. antibioticus Tü6040. When both strains are cultivated in the production media, novel 
derivatives of the D-type simocyclinone can be detected in their production profiles. SD9, the 
major and the most active metabolite of K. sp. is usually produced along with minor SD10, 
SD11 and other D-type simocyclinones of unknown structure. Newly detected simocyclinones 
show structural deviation in the A-ring of the angucycline moiety. The arrangement of the 
other sub-structures – acetylated D-olivose, tetraene chain and aminocoumarin ring is 
identical between described before SD8 and newly isolated molecules. Based on the high 
similarity of the chemical pattern of SD8 and SD9/SD10/SD11, one can expect that 
corresponding gene clusters would be nearly identical with the few deviations. Surprisingly, 
despite the high similarity between the individual genes, the overall architecture of SD8 and 
SD9 gene clusters is organized in the substantially different ways.  
1.1 Analysis of the genes/enzymes putatively involved in the angucycline biosynthesis 
and modification  
Thirteen genes (smcC7, smcA7-smcA12) involved in the angucycline formation are organized 
in one operon within the smc cluster (smcA subcluster).  
The gene products of smcA1, smcA2 and smcA3 show significant homology to the type II 
iterative PKSs from different species. SmcA1 and SmcA2 resemble ketoacylsynthases and 
SmcA3 is the acyl carrier protein homologue; together they compose the expected “minimal 
PKS” set. SmcA1 contains typical catalytic triad Cys(169)-His(309)-His(346) and obviously 
catalyzes Claisen condensation; SmcA2 with the conserved glutamine residue in the active 
center is a CLF. Also, a typical LGyeS (39-43) phosphopantetheinyl binding sequence [70] 
has been identified within this protein. Phosphopantetheinyl transferase, necessary for ACP 
activation is encoded by smcA11 and is located downstream in the smcA subcluster. SmcA4 
and SmcA5 are putative cyclases showing 92% and 90% homology to the SimA4 and SimA5, 
respectively. Together with the product of smcA6 (putative ketoreductase with 90% and 87% 
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homology to pgaD and aurI), these proteins should generate UMW6, a common precursor of 
many angucycline polyketides. 
Angucyclic core of simocyclinones is highly oxidized with an epoxide group at the positions 
C-12a and C-6a and several other unusually placed hydroxyl groups. The enzymes 
responsible for thosedecoration of the polyketide aglycon belong to two families: NADPH-
dependent flavoprotein mono-oxagenases and short-chain alcohol dehydrogenases/reductases 
(SDR). Because of the significant sequences similarity of their proteins, function prediction 
based on the primary amino acid sequencing is challenging, thereby heterologous expression, 
gene-inactivation experiments or in vitro assays are required. Typically, the genes encoding 
oxygenases and reductases follow conserved order in the angucycline biosynthetic gene 
clusters and are forming a subcluster [71].   
Deduced amino acid sequence of SmcA7 has the high identity to UrdE (70%) and LanE 
(67%) from urdamycin (urd) and landomycin (lan) biosynthetic pathways, respectively. 
Recent studies have shown that purified UrdE and LanE can utilize prejadomycin (2,3-
dehydro-UWM6) as a substrate. UrdE catalyzed two consecutive NADPH/O2-dependent 
reactions – C-12 and C-12b hydroxylations, followed by 6-ketoreduction by UrdM to produce 
gaudimycin. In contrast, landomycins do not contain a hydroxyl group at C-12b and an 
incubation of LanE and LanV together with prejadomycin led to the  accumulation of 11-
deoxylandomycinone – an intermediate in landomycin biosynthesis. Thus, despite substantial 
sequence identity, LanE is making C-4a/C-12b dehydration that is promoted by LanV. Based 
on the structure of angucycline in simocyclinones, SmcA7 should follow “UrdE-pathway” 
during C-12b modification and introduce hydroxygroup (Figure 24). The ∆smcA7h mutant 
was accumulating 2,3-dehydro-UWM6 as a main product, confirming this hypothesis. Similar 
results were obtained in vitro for GilOI, which is the UrdE homologue in gilvocarcin (gil) 
biosynthesis. The removal of GilOI from the enzyme cocktail produced prejadomycin [72]. 
Most probably SmcA7 is performing two consecutive steps – C-12 and C-12b hydroxylations 
of prejadomycin, where the second intermediate is highly unstable and should be directly 
further modified by the following enzymes. In urd and pga/cab pathways these reactions are 
performed by UrdM and PgaM/CabV, respectively. 
UrdM and PgaM belong to the SDR family and are translated as the two-domain flavoprotein 
oxygenase fusion (ox domain) with a separate C-terminal SDR (red domain) [73, 74]. In 
contrast, CabV is an independent reductase not linked with oxygenase domain. In in vitro 
studies, the C-6 ketoreduction was catalyzed by UrdMred, whereas UrdMox domain was not 
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required for C-12b hydroxylation, despite the enzyme has been linked with the reaction before 
[71, 73]. Additionally, coupling of the second hydroxylation reaction performed by UrdE (or 
PgaE) to that of the SDR enzyme is a strict requirement, otherwise this reaction invariably 
leads to the product degradation [71, 72, 75].  SmcA9 shares 72% identity with PgaM and 
70% with UrdM and is a candidate for 6-ketoreductase reaction. However, SmcA9 doesn’t 
contain an ox domain and is approx. half-shorter from the N-terminal side. Inactivation of 
smcA9 did not lead to accumulation of prejadomycin, rabelomycin or any other intermediates 
or shunt products of the angucycline biosynthesis, indicating that biosynthesis diverted onto a 
degradation pathway and additionally proving dependence of the SmcA7 function on SmcA9. 
An accumulation of prejadomycin in the ∆smcA7 mutant and the change to the degradation 
pathway in the ∆smcA9 mutant suggest that the reaction sequence in simocyclinone 
biosynthesis is SmcA7-SmcA9 and two last reactions cannot be separated from each other 
similarly to the urd and pga/cab pathways. 
 
Figure 24. Proposed pathway for the biosynthesis of an angucyclic part of simocyclinones. 
Upstream from smcA9 is located smcA8 encoding an oxygenase highly similar to JadF (jad, 
jadomycin biosynthetic pathway), and N-terminal domains of LanM2 and LndM2 from the 
landomycin biosynthesis in S. globisporus. JadF was shown to catalyze the 2,3-dehydratation 
on the ACP-tethered intermediate during prejadomycin biosynthesis in vitro, moreover it 
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catalyzes decarboxylation of the angucyclic intermediate and its hydrolysis from ACP. 
Removal of JadF from the enzyme cocktail during one-pot defucogilvocarcin enzymatic 
biosynthesis resulted in accumulation of rabelomycin. Rabelomycin is a shunt product in this 
pathway and was produced from UWM6 by aerial oxidation and spontaneous degradation 
[72]. Analysis of the K.sp. ∆smcA8h mutant revealed peak with the LC-MS and UV/Vis 
properties that are in agreement with rabelomycin, therefore, SmcA8 may play the same role 
during simocyclinone biosynthesis as JadF for jadomycin. The same was hypothesized for the 
ox domain of UrdM by Patrikainen et al [71]. 
Comparison of the putative product of smcA10 to proteins in the database suggests that it 
belongs to the NADF-dependent FMN reductases (62% identity to UrdO and 63% to SaqO). 
The exact function of SmcA10 remains unknown; presumably it may act as a reductase during 
the aromatic polyketide biosynthesis. SmcA12 is a putative methylmalonyl-CoA 
carboxyltransferase with amino acids identity 91% to SimA12 and may take part in providing 
acetyl-CoA building blocks for the angucycline biosynthesis.  
Any homologues of simA13, which encodes putative P450 hydroxylase, haven’t been 
identified in the smc gene cluster. This is interesting, because SimA13 could have been a 
candidate for introducing of the epoxy group into the angucycline moiety. Epoxy groups have 
been found in many bioactive secondary metabolites and may play a key role in their 
pharmacological properties [76]. Epoxides are usually introduced by enzymes of cytochrome 
P450 family, for instance, EpoK in epothilone (epo) [77] and HedR in hed [78] biosynthetic 
pathways. Flavoenzymes are also known to create an epoxide via oxygen transfer to a C–C 
double bond [76]. However, BLAST search against the smc cluster didn’t reveal any 
homologues of both groups of enzymes that may be involved in the epoxide formation. Thus, 
the origin of the epoxy group in the simocyclinones remains unclear. 
An additional gene, orf7, encoding oxidoreductase, has been identified in the smc cluster. The 
activity of the ORF7 in K. sp. determines the only structural difference between SD8 and 
SD9. The precise analysis revealed a truncated form of the corresponding gene in S. 
antibioticus Tü6040 genome. The orf7 homologue flanks the sim cluster and has not been 
annotated before. The full-length ORF for this gene from the smc cluster is highly similar to 
aldo-ketoreductases that reduce aldehydes and ketones to primary and secondary alcohols 
[79]. In order to check ORF7 involvement in reduction of the ketogroup to hydroxygroup in 
SD9 several attempts have been made. An interesting phenomenon was observed after several 
attempts to inactivate orf7. If orf7 was completely replaced with the hygromycin-resistance 
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gene, the strain did not produce simocyclinones of D-type. The mutant with the expected 
phenotype was observed after an inactivation of the catalytic center of the protein. The ORF7 
protein was present, but not able to catalyze reduction in the C-1 position. Probably, the 
enzymes involved in the simocyclinone biosynthesis form the protein complex, which is 
disturbed when one of the structural units is deleted. When the mutated form of the enzyme is 
physically present within the complex, the metabolic intermediates are passed from one 
enzyme to another through the intramolecular tunnel without its release into solution. Such 
substrate channeling prevents the release of unstable intermediates, also it makes the process 
faster and more efficient [80, 81]. Therefore, deletions or substitutions of genes from 
biosynthetic gene clusters may lead to much lower production and accumulation of shunt 
products. Furthermore, substrate channeling may explain why no new derivatives were 
detected after heterologous expression of the gene. 
Recently, SimC7 was proven to be angucyclinone ketoreductase, essential for antibiotic 
activity of simocyclinone [82]. In S. antibioticus Tü6040, simC7 is located separately from all 
other genes involved in angucycline biosynthesis. In contrast, simC7 homologue in K. sp. is 
flanking simA subcluster and is transcriptionally coupled to it.  
According to the transcriptome data, all genes involved in angucycline biosynthesis, including 
orf7, are located within one transcription unit. 
1.2. Analysis of the genes/enzymes putatively involved in D-olivose biosynthesis  
One of the remarkable differences between the sim and the smc gene clusters is found within 
the operons responsible for the dTDP-D-olivose production. In S. antibioticus Tü6040 seven 
genes (simB1-simB7) involved in biosynthesis of the activated D-olivose form two sub-
clusters, in K. sp. their homologs are scattered throughout the entire genome. smcB1 and 
smcB2 have been identified approximately 900 kb downstream from the smc gene cluster. 
SimB1 and SimB2 share 47,3% and 55% of identity with their homologs in K. sp., 
respectively. Downstream from smcB1 are located genes putatively encoding dTDP-4-
dehydrorhamnose-3,5-epimerase, glycosyltransferase, dTDP-4-hexulose reductase and 
acetyltransferase, together they constitute a set of genes required for L-rhamnose biosynthesis 
[83]. It is not unique example of recruiting of the sugar biosynthesis genes from the outside 
for the natural product formation [84-87]. For example, during the biosynthesis of 
elloramycin in S. olivaceus [84] and caprazamycin in Streptomyces sp. MK730-62F2 [85] 
four genes (NDP-glucose synthase, dNDP-glucose-dehydratase, 4-ketoreducatse and sugar 
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epimerase) involved in the biosynthesis of L-rhamnose are located in different chromosomal 
loci.  
All other genes requiredid for D-olivose biosynthesis are located within the smc gene cluster, 
but in the different order in comparison to their orthologs from the sim gene cluster. smcB7, 
smcB4 and smcB5 are forming a sub-cluster as in the sim cluster; smcB3 is located at the 3’ 
end and is the last gene in the smc cluster, whereas smcB6 is located separately. Products of 
these genes share 61% (SmcB6) to 82% (SmcB3) identity with their homologs from S. 
antibioticus Tü6040. Deduced amino acid sequence of SmcB7 has high similarity with the 
glycosyltransferases from saquayamycin (saq) and urd biosynthetic pathways. As only one 
glycosyltransferase has been identified within the smc cluster (as expected), SmcB7 should 
catalyze attachment of the deoxysugar to angucycline. SmcB6 is the acetyltransferase 
involved in the sugar decoration at 4-OH position (Figure 25).  
1.3. Analysis of the genes/enzymes putatively involved in aminocoumarin moiety 
biosynthesis 
smcD1, smcD2, smcD3, smcD4, smcD5, smcD6, smcD7 and smcX1 genes from the smc 
biosynthetic gene cluster are responsible for the biosynthesis of aminocoumarin and are 
nearly identical to those from the sim gene cluster [38, 39]. 
SmcD6 shows 57% similarity to NovH from the novobiocin (nov) biosynthetic pathway [88] 
and activates aminocoumarin precursor – L-tyrosine. Like SimD6, SmcD6 has an extra 400 
amino acids at the N terminus, which are highly similar to the non-ribosomal peptide synthase 
(NRPS) condensation domain [39]. This feature may point to evolutionary origin of SmcD6 
from NRPS or their common ancestor. SD9 is halogenated at the C-8 position of 
aminocoumarin ring; this reaction is performed by the putative halogenase SmcD4 (91% 
identity with SimD4) (Figure 24). The genes smcD3, smcD5, smcD6, smcD1, smcX1 and 
smcD2 are forming a sub-cluster close to the 3’ end of the smc cluster, whereas smcD4 is the 
first gene in the smc cluster from the 5’ end.   
1.4. Analysis of the genes/enzymes putatively involved in tetraene side chain biosynthesis 
The most pronounced difference between the two simocyclinone biosynthetic gene clusters 
(sim and smc) is the absence of the type I PKS encoding machinery in the smc cluster. 
Furthermore, no homologs of simC1A, simC1B and simC1C have been detected elsewhere in 
the genome of K. sp.  
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Figure 25. Proposed pathway for the biosynthesis of aminocoumarin (A) and D-olivose (B) 
 
A close analysis of the K. sp. genome revealed type I PKS encoding gene, however it’s 
inactivation didn’t have any impact on the simocyclinone production. Furthermore, the 
inactivation of simC1B gene does not influence SD8 biosynthesis supporting the idea of the 
alternative tetraene biosynthetic pathway. Therefore, the hypothesis of tetraene biosynthesis 
A B 
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that is based on type I PKS involvement should be revised. Careful re-annotation of the smc 
and sim gene clusters revealed three ketosynthase encoding genes (smcKSI, smcKSII and 
smcX5), which might take part in a linear polyketide biosynthesis. Interestingly, their 
orthologs in S. antibioticus Tü6040 were suggested to be not involved in simocyclinone 
biosynthesis and marked as flanking genes (orf2 and orf3) or genes of unknown function 
(simX5). However, the transcriptome of the smc and sim biosynthetic gene clusters clearly 
shows that the expression of the smcKSI, smcKSII and smcX5 (orf2, orf3 and simX5) genes is 
coordinated with the expression of other genes in both clusters.  
Indeed, the deletion of SmcKSII from this complex completely abolished the formation of D-
type simocyclinones and led to the synthesis of glycosylated angucyclines. To generate the 
decatetraene side chain with three ketosynthases, the assembly should most probably start 
with a four-carbon unit (e.g., crotonyl-CoA, acetoacetyl-CoA) unless one of the KS does not 
act iteratively. A number of ketosynthases employ non-acetate starter units for the polyketide 
biosynthesis [15, 25]. Very often, incorporation of an alternative to acetate primer units 
involves KSIII and ACP components as described for frenolicin, daunorubicin and others [25, 
89, 90]. 3-oxoacyl-ACP-synthase III (KAS III, FabH) homologs have been identified in both 
sim (simX5) and smc (smcX5) clusters. KAS III is a key enzyme in fatty acid biosynthesis in 
plants and bacteria; it initiates the condensing process and uses acetyl-CoA as a primer and 
malonyl-ACP as an extender unit. Nevertheless, some KAS III-like enzymes from different 
organisms can prime polyketide biosynthesis with different starter units [91]. FabH homologs 
have been found in some type II PKS gene clusters [28, 78, 89, 92-94]. In all cases, they are 
involved in the generation of the non-acetate priming unit for polyketide chain biosynthesis. 
SmcX5 contains cysteine, proline and histidine in its active center and thus may be a 
candidate for the initiation of tetraene chain formation. Interestingly, the feeding experiment 
with the [1-
13
C] labelled acetate did not show perfect incorporation of C-9’’ into the tetraene 
chain, which indirectly supports the idea of a non-acetate priming of this moiety [95]. Two 
other ketosynthases SmcKSI and SmcKSII, together with ACP, should be involved in the 
extension of the linear polyketide. Several more reactions are necessary to form the fully 
maturated dicarboxylic tetraene acids – ketoreduction, dehydratation and incorporation of the 
second carboxy group. Most of the gene encoding proteins with the necessary enzymatic 
activities can be found within both sim and smc gene clusters. SimC6/SmcC6 is homologous 
to 3-oxoacyl-ACP-reductases and a higher identity with FabG4 from S. avermitilis MA-4680. 
The PKS KR domains also belong to the same family. Most likely, this enzyme is involved in 
the subsequent ketoreduction of the polyketide chain. We could not identify the gene 
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candidate responsible for the dehydration reaction of the hydroxylated polyketide 
intermediate, therefore the involvement of dehydratase from fatty acid biosynthesis cannot be 
excluded. Finally, the second carboxy group could be incorporated by two enzymes, 
SimC4/SmcC4 and SimC5/SmcC5, to the tetraene chain. The deduced amino acid sequence 
of the smcC4 encoding protein is similar to the carotenoid dioxygenases that catalyze the 
oxidative cleavage of carotenoids at various chain positions, thus leading to the formation of 
an aldehyde [96]. The oxygen at the C-10 position of the tetraene indeed derives from 
molecular oxygen, as previously shown by feeding experiments [44]. Newly generated 
aldehyde is oxidized to the carboxylic acid by SimC5/SmcC5 (aldehyde dehydrogenase) and 
later is attached to the sugar. The inactivation of both genes, simC4 and simC5, in S. 
antibioticus Tü6040 led to the complete cessation of SD8 production, with the corresponding 
accumulation of the B-type simocyclinones (angucycline with the deoxysugar attached) [97]. 
Although the exact mechanism of the decatetraene dicarboxylic acid formation remains 
unclear at the moment and requires further deciphering, the scheme and enzymes involved 
seems to be plausible. 
1.5. Genes of regulation and self-resistance 
Three regulatory and two efflux genes were annotated in the smc gene cluster. SmcReg1 
shares 65% identity with SimReg1 and presumably is a master switch of the simocyclinone 
biosynthesis in K. sp. SmcReg2 and SmcEx1 form a TetR/TetA-like resistance pair, like 
SimR/SimX and show 82%/79% identity, respectively. SmcReg3 is highly similar to the 
MarR/SlyA transcription regulators involved in development of the resistance to multiple 
antibiotics, oxidative stress agents, oxidative stress, etc [98]. SmcEx2 is 90% identical to 
SimEx2 and is a putative Na
+
/H
+
 antiporter.  
1.6. Genes of unknown function 
Three genes of unknown function have been identified in the smc cluster – smcX2, smcX4 and 
smcX7. The gene smcX2 is located directly downstream of simA12 and both genes are 
translationally coupled . SmcX2 is a hypothetical protein with the acyl-CoA carboxylase 
epsilon subunit domain. Together with SmcA12 it may be involved in generation of malonyl-
CoA building blocks, used for the angucycline and tetraene biosynthesis. SmcX4 is a 
predicted metallophosphoesterase and SmcX7 is a hypothetical protein found in different 
Streptomyces species.   
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2. sml biosynthetic gene cluster 
The simocyclinone biosynthetic gene cluster from S. sp. NRRL B-24484 (sml gene cluster) 
has the same set of genes and architecture as the smc cluster. Both, the smc and sml cluster 
share 97% pairwise identity. 
2.1. Summary 
The three identified simocyclinone gene clusters (sim, smc and sml) are typical examples of 
the “bricks and mortar” evolution events postulated by Marnix et al. [99]. These hybrid gene 
clusters are composed of several sub-clusters (bricks) and individual genes (the “mortar"). 
During the evolution of the sim gene cluster from the smc gene cluster, substantial gene 
reorganization took place (deletion of the ORF7 function, gaining the deoxysugar biosynthetic 
genes and reorganizing the gene order). These cluster rearrangements led to the generation of 
SD8 (1), which is four times more active than SD9 (2) in vitro, which could have brought 
some selective advantages to its producer. The acquisition of two additional deoxysugar 
biosynthetic genes might help in the coordination of the gene expression within the sim gene 
cluster. It is not clear which selective advantages to S. antibioticus Tü6040 are brought by 
PKS I encoding genes, which are expressed, but are not necessary for SD8 (1) biosynthesis. 
3. Amicomycins 
One strain-many compounds (OSMAC) approach was described in 2000s by Zeeck and co-
workers to trigger productivity of a single microorganism through turning on cryptic or silent 
biosynthetic genes by varying accessible cultivation parameters (media composition, pH, 
temperature, oxygen supply, quantity and quality of light, bioreactor platform, addition of 
precusors or enzyme inhibitors) [100].  
Indeed, a fermentation of K. sp. under certain conditions led to isolation of two hitherto 
unknown polyketides – amicomycin C and D. Angucyclic nature of amicomycins suggests 
that their biosynthesis is directed by type II PKS genes. Preliminary data after the analysis of 
the K. sp. genome sequence with the secondary metabolites search tool antiSMASH 2.0 [101] 
indicates the presence of two type II PKS gene clusters. One of them is the simocyclinone 
biosynthetic gene cluster. Another type II PKS gene cluster shares 83% homology with spore 
pigment biosynthetic genes from different streptomycetes and is not involved in the 
biosynthesis of angucyclic polyketides. This observation suggests that amicomycins share 
biosynthetic route with the angucyclic core of simocyclinones.  
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Unusual is the fact that genes responsible for the glycosylation could not be identified within 
the cluster. Only one glycosyltransferase encoding gene (smcB7) has been identified in the 
smc cluster. SmcB7 is accepting D-olivose as a substrate and is forming C-C bond at C-9 
position of the aglycon. From the whole broad range of glycosyltransferases targeting 
aromatic polyketides, only UrdGT2 was shown to establish both C- and O-glycosidic bonds 
[102]. Furthermore, C-1-O-glycosylation has been described only for benzanthrin A and B as 
well as for amycomycin B in the literature [103, 104], while the glycosylation of angucyclines 
at position C-6 is reported only for the antibiotic TAN-1085 and the antitumor compound J-
124131 [105, 106]. It is rather unlikely that SmcB7 is accepting talose as a substrate and 
performs glycosylation at these unusual positions, since it shares the high homology to several 
glycosyltransferases attaching D-olivose via C-C bond. Additionally, 6-deoxy-α-talose is 
rather untypical sugar for secondary metabolites. 6-deoxy-talose has been identified in 
isoflavonol glycosides talosins A and B produced by K. kifunensis. It has been suggested that 
talosins are produced from exogenous genistein that is included in fermentation medium and 
K. kifunensis is decorating it with 6-deoxy-L-talose. Talosins A and B are antifungal agents 
and deoxy-sugar plays an import role in their biological activity [107]. The genes of talose 
biosynthesis in K. kifunensis have been cloned and their function proved in in vitro assay 
[108]. In K. kifunensis biosynthesis of 6-deoxy-talose is encoded within the biosynthetic gene 
cluster of the extracellular glycan. Four proteins (RmlAKkf, RmlBkkf, RmlCKkf and Tal) from 
this cluster are completing the biosynthesis of dTDP-6-deoxy-talose from dTTP, α-D-glucose-
1-phosphate and NAD(P)H. The homologs of the genes encoding these proteins have been 
identified in the genome of K. sp. RmlA in K. sp. is a glucose-1-phosphate 
thymidyltransferase with 89% identity to RmlAKkf and probably is activating α-D-glucose-1-
phosphate with dTTP. The next step – conversion of dTDP-D-glucose into dTDP-6-deoxy-D-
glucose-xylo-4-hexulose is performed by RmlB (dTDP-D-glucose-4,6-dehydratase, 92% 
identity to RmlBKkf), later it is recognized by dTDP-6-deoxy-D-xylo-4-hexulose-3,5-
epimerase RmlC (83% homology with RmlCKkf) and is modified to dTDP-6-deoxy-L-glucose-
lyxo-4-hexulose. At this step the sugar biosynthetic pathway is branching to give either dTDP-
6-deoxy-L-talose or dTDP-L-rhamnose. Tal from K. kifunensis is a NAD(P)H-dependent 
dTDP-6-deoxy-L-talose 4-dehydrogenase it is performing the last step in talose biosynthesis. 
Its homolog was identified in K. sp. and presumably is involved in the same reaction. The 
order of the talose biosynthetic genes in K. sp is the same as in K. kifunensis, however the 
overall architecture of the cluster is slightly different. In K. kifunensis three 
glycosyltransferase-encoding genes have been identified in the gene cluster of the 
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extracellular glycan biosynthesis – orf1, orf8 and orf11 (N-terminally truncated), in K. sp. two 
homologs of these genes (orf1and orf8) are present. The proteins encoded by orf1and orf8 
might be candidates for attaching of 6-deoxy-talose to the angucycline core of amicomycins. 
Production of individual secondary metabolites by Actinomycetes is sensitive to growth and 
media conditions. Changes in the microbial environment result in differential expression and 
transcription of certain genes and finally in a different metabolome. Thus, the fine control 
over genes expression can affect the chemical structure of the compounds produced from the 
same biosynthetic gene cluster, and a single compound should not be regarded as the sole 
product of a biosynthetic gene cluster. 
4. gre biosynthetic gene cluster 
Novel angucyclines - grecocyclines A, B and C have been isolated from S. sp. Acta1362 by 
Paululat et al [109]. Grecocyclines have unique structural moieties such as a dissacharide side 
chain, an additional amino sugar at the C-5 position and a thiol group. Grecocyclines are 
biologically active compounds – grecocycline A shows cytotoxic activity and grecocycline B 
inhibits protein tyrosine phosphatase 1B [109].  
4.1. Analysis of the genes/enzymes putatively involved in the angucycline biosynthesis 
and modification 
The genome scanning of the strain Acta1362 revealed a gene cluster (gre) responsible for the 
grecocycline biosynthesis that is approximately 36 kb long and comprises 32 ORFs. The 
genes that are required for the biosynthesis of the glycosylated angucycline have been 
identified within the gre cluster. The genes greA1, greA2 and greA3 encode KS, CLF and 
ACP, respectively. Three deduced proteins from the gre cluster, GreA4, GreA5 and GreA6, 
show similarity to cyclases and ketoreductase involved in UWM6 formation. GreA4 (82% 
identical with LndF) and GreA5 (79% identical with UrdL) are putative cyclases and GreA6 
encodes a putative ketoreductase (87% similarity to PgaD). The cluster also harbors genes 
encoding oxygenases and reductases that are probably involved in the biosynthesis of the 
grecocycline aglycon. Two deduced proteins of the gre cluster GreE and GreM2 have high 
similarity to oxygenases involved in angucycline formation [71]. GreE shares 76% identity 
with PgaE monooxygenase from the rubromycin gene cluster [110], whereas GreM2 is 
identical to bifunctional oxygenase-reductases – PgaM, SaqM, Sim7 [19, 39, 110]. Further 
genes involved in modifying steps on the polyketide are greV and greO (putatively involved 
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in reduction steps) (Figure 26). GreK shows high similarity to the putative oxygenase SaqE 
[19]. The grecocycline gene cluster harbors additionally two other oxygenases – greL and 
greD. Blast search didn’t reveal any conserved domains in GreL, it has 37-40% of identity 
with monooxygynases from different species without precise function identified. Deduced 
amino acid sequence of GreD shows high similarity to proteins from DsbA-FrnE family, 
which are presumed to be a thiol oxidoreductases and are involved in biosynthesis of 
frenolicin and nanaomycin [111]. Intrestingly, greD is the only one gene that is transcribed on 
the antisense strand. 
 
Figure 26. Proposed pathway for the biosynthesis of the polyketide part of grecocycline 
 
One of the unique features of the grecocycline B is a thiol group located at the C-6a position. 
The introduction of sulfur into the angucycline core was reported for WS009A and B, a potent 
endothelin receptor antagonists from S. sp. no. 89009. In this compound, C6a was substituted 
with N-acetylcysteine moiety [112], however no further studies on the biosynthetical origin of 
this group have been done. In the gre cluster, thioesterase-encoding gene (greTH), which 
might be involved in formation of the thiol group in grecocycline B has been identified.  
4.2. Analysis of the genes/enzymes putatively involved in biosynthesis of deoxysugars 
Two different deoxy sugars are attached to the angucycline: L-rhodinose and L-tolyposamine. 
Eleven of thirty-two genes are involved in the modification and transfer of the sugars to the 
polyketide moiety. First, D-glucose-1-phosphate is converted to NDP-D-glucose (GreG), then 
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4,6- and 2,3-dehydratation (GreH and GreS) and 3-ketoreduction (GreT) reactions yield NDP-
4-keto-2,6-dideoxy-D-glucose intermediate. The NDP-rhodinose is formed by subsequent 3,4-
dehydratation (GreQ), 3,5-epimerisation (GreZ1) and 4-ketoreduction (GreZ3). GreJ encodes 
NDP-hexose-4-aminotransferase that transfer an amino group to the hexose to form L-
tolyposamine (Figure 27). Grecocyclines contain three sugar units and equal number of 
glycosyltransferase encoding genes has been identified in the gre cluster – greGT1, greGT2 
and greGT4. All of them have significant similarity to different glycosyltransferases from 
saquayamycin, landomycin and urdamycin gene clusters [17, 19, 113]. greGT2 encodes a 
protein that is homologous to SaqGT5 and LanGT2 [17, 19]. SaqGT5 and LanGT2 where 
proven to catalyze first glycosylation step during biosynthesis of saquayamycin Z and 
landomycin A, respectively [19, 114]. LanGT2 transfers D-olivose to O-8 of the angucycline, 
in contrast SaqGT5 is involved in attachment of D-olivose to C-9. In grecocyclines, L-
rhodinose is attached to C-9 of aglycon, probably this reaction is mediated by GreGT2. 
GreGT1 may be responsible for introduction of the second L-rhodinose unit, as it is highly 
similar to SaqGT3, SaqGT4, LanGT1 and other O-glycosyltransferases [17, 19, 115]. SaqGT3 
and LanGT1 are iteratively acting glycosyltransferases, they attach two D-olivose units to the 
polysaccharide chains, whereas SaqGT4 is believed to transfer two L-rhodinoses to the 
pentasaccharide chain during biosynthesis of saquayamicn Z [19]. Deduced amino sequence 
of GreGT4 share 54% with Lcz3 from lactanomycin and 50% identity with UrdGT1a from 
urdamycin biosynthetic pathways [113, 116] and presumably is transferring the aminosugar to 
the polyketide. As mentioned above greL encodes monooxygenase that doesn’t have close 
homologs in other angucycline gene clusters, perhaps GreL is oxidizing aglycon in C-5 
position prior to sugar attachment.  
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Figure 27. Proposed pathway for the biosynthesis of D-rhodinose and α-tolyposamine  
4.3. Genes of regulation and self-resistance 
Two regulatory – greR1, greR2 and three transporter genes – greEx, greEx2 and greEx3 have 
been identified in the gre cluster. greR1 is located on the 5’ terminus of the gene cluster, and 
encodes protein with similarity to transcriptional regulators from the OmpR family [117]. 
Deduced amino acid sequence of GreR1 is very similar to JadR1 and LndI. Disruption of lndI 
caused complete loss of landomycin E production in S. globisporus, while its overexpression 
led to an increase in the antibiotic production [118, 119]. LndI is an autoregulator as it can 
bind to its own promoter region as well as to the promoters of the lnd structural genes [120]. 
Presumably, GreR1 plays the same role in the grecocycline biosynthesis. GreR2 is 
homologous to HxlR transcriptional regulators. GreEx, GreEx2 and GreEx3 are similar to 
MFS transporters and probably are transporting secondary metabolites through the cell 
membrane.  
4.4. Summary 
As mention above, presence of the aminosugar and a thiol group are unique features of 
grecocyclines. Incorporated into the natural product, sugars may sufficiently influence 
pharmacokinetic properties of the metabolite. For instance, L-desosamine of erythromycin is 
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essential for its binding with a target – 50S RNA [121]. Typically secondary metabolires are 
glycosylated with deoxysugars like D-olivose, L-rhodinose, L-mycarose and L-digitoxose 
[102]. α-tolyposamine, attached to the grecocycline aglycon, is a rare structural moiety, 
previously reported only for BU-4514N from Microtetraspora sp. [122]. It may become a 
unique building block for the derivatization of natural products via glycosylation.  
Furthermore, grecocyclines are the first angucyclines carrying the deoxysugar unit in the C-5 
position of the angucyclic core. Therefore, glycosyltransferases that are attaching sugar 
moieties into C-5 position may have a great potential for natural product combinatorial 
biosynthesis. 
During the evolution microbial secondary metabolites have been optimized for the biological 
functions useful to the producing organism. On the other hand, they have not necessarily been 
optimized for desirable drug properties and this can be improved by structural modifications. 
Combinatorial biosynthesis has been accepted as a useful tool to increase chemical 
functionality of natural products. Glycosylation, oxidation and halogenation are only few 
examples of the “decorating” reactions suitable for genetic engineering of polyketides. 
Enzymes encoded within the grecocycline biosynthetic pathway (GreTh, GreGT4, GreL) are a 
promising addition to the existing toolbox used for combinatorial biosynthesis. Their 
employment opens a possibility for generation of novel derivatives of known active 
polyketides, perhaps, with improved biological properties.
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Chapter S1. Identification of new D-type simocyclinones in K. sp. and S. sp. NRRL B-24484 
Information derived from the genome mining of the K. sp. and S. sp. NRRL B-24484 strains promised the production of simocyclinones similar to 
those produced by S. antibioticus Tü6040. Indeed, after HPLC-MS analysis of extracts from both strains, several peaks were identified with a UV 
spectra typical of D-type simocyclinones, as reported in the literature [5]. 
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HR ESI-MS of SD9 (2) showed that the molecular ion m/z = 932.2176 [M-H]
-
 (calculated mass: 932.2169 for [M-H]
-
), which indicated that 2 had 
the molecular formula C46H44NO18Cl. This formula and a molecular mass of M = 933 gmol
-1
 were not previously reported for any known 
simocyclinone. Compared to SD8 (1), the molecular weight of 2 is two mass units higher, thus leading to the assumption that it has the same basic 
structure as D8, where the hydration of one double bond or reduction the of one carbonyl group has occurred at the corresponding alcohol. Structure 
elucidation allowed us to determine that D9 (2) contained the same chlorinated aminocoumarin, the same tetraene unit and the same sugar, but with 
a modified angucycline unit, as compared to SD8 (1) (Figures S2a – S2e, Tables S1a, S1b). 
The angucycline part of 2 contains one carbonyl group, six methine groups (two aromatic, one double-bond and three aliphatic methines), one 
methylene group and nine quaternary carbons substituted with one methyl group, one epoxide, six hydroxy groups and one sugar. Ring A of the 
angucycline shows a double-bond in position C2-C3 substituted with a methyl group at C-3, neighboring a hydroxy methine at C-1 (δH = 4.63 / δC = 
73.0) and a methylene group at C-4 assigned by COSY 1-H / 2-H and HMBC signals C-12b / 2-H, C-2 / 3-H3, C-2 / 4-H2, and 3-C / 4-H2, C-4 / 2-H. 
This substitution pattern in ring A is described for SF2315B, which only differs from SD8 (1) by the presence of a proton in the C-12b position 
instead of a hydroxyl group. Thus, our NMR data are in good agreement with that reported for SF2315B [6]. Ring B contains a CH2-CH-OH unit in 
the C-5-C6-position assigned by HMBC signals C-4 / 5-H2, C-6a / 5-H2, C-4a / 5-H2 and C-12b / 5-H2, the angular carbons bear hydroxyl groups 
based on their carbon chemical shifts (δC-4a = 70.8 and δC-12b = 74.3). Ring C includes the one carbonyl group at C-12 (δC = 196.0), as proven by 
HMBC signal C-12 / 11-H, and one hydroxy-methine at C-7 indicated by HMBC crosspeaks C-11a / 7-H and C-7a / 7-H. The C-6a-C12a-epoxide 
between rings B and C is proven by the chemical shifts δC = 64.2 (C-6a) and δC = 65.6 (C-12a). Ring D is an aromatic ring with two protons, 10-H 
and 11-H, which are in ortho position to each other (J = 8.2 Hz). Moreover, a phenol group is at C-8 (δC = 152.2) and the sugar unit is attached at C-
9, which deduced from HMBC analysis. The sugar is determined as an α-sugar by the proton-proton coupling constant of J1’-H,2’-Hax = 11.2 Hz, 
which is a C-glycoside due to the carbon chemical shift of δC-1’ = 70.6 ppm. The protons 3’-H and 4’-H, 5’-H must be in axial positions, as shown 
by the coupling constants J2’-Hax, 3’-H = 10.4 Hz, J3’-H, 4’-H = 9.5 Hz and J4’-H, 5’-H = 9.5 Hz, and supported by ROESY crosspeaks 1’-H / 3’-H, 1’-H / 
5’-H, 3’-H / 5’-H. An acetyl group is attached at position C’-4, as proven by the HMBC signals C-7’ / 4’-H. Therefore, the sugar is 4-acetyl-α-
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olivose, as in SD8 (1). At position C-3’ a tetraene chain is attached via an ester group C-1’’, which was established from the HMBC correlation C-
1’’ / 3’-H and C-1’’ / 2’’-H and C-1’’ / 3’’-H. The configuration is proven to be E for the tetraene double bonds C-2’’ / C-3’’, C-4’’ / C-5’’, C-6’’ / 
C-7’’, C-8’’ / C-9’’ due to coupling constants J ~ 15  Hz (2’’-H / 3’’-H, 8’’-H / 9’’-H), J ~ 13.5  Hz (4’’-H / 5’’-H, 6’’-H / 7’’-H), and J ~ 11.6  Hz 
(3’’-H / 4’’-H, 5’’-H / 6’’-H, 7’’-H / 8’’-H) and ROESY signals (2’’-H / 4’’-H, 3’’-H / 5’’-H, 4’’-H / 6’’-H, 5’’-H / 7’’-H, 6’’-H / 8’’-H, 7’’-H / 9’’-
H). An aminocoumarin moiety is attached via an amide group C-10’’ as proven by HMBC signals C-10’’ / 8’’-H, C-10’’ / 9’’-H, C-10’’ / NH and 
C-12’’ / NH. The constitution is proven to be an aminocoumarin unit by comparison of NMR data to that of 1 which is supported by HMBC signals 
C-13a’’ / 13’’-OH, C-13a’’/ 14’’-H, C-14’’ / 13’’-OH, C-16’’ / 14’’-H, C-16’’ / 15’’-H, C-16’’ / 16’’-OH. The chloride is proven by the isotopic 
pattern of the molecular ion of 2 in the ESI mass spectrum. Finally, attached to the angucycline is the same substituent containing olivose, a tetraene 
chain and an aminocoumarin unit, as in SD8 (1), the new SD9 (2) only differs in ring A of the angucycline part of the structure  
The second isolated compound SD10 (3) shows the same molecular mass, 915 gmol
-1
, and formula, C46H42NO17Cl, as simocyclinone D7, but the 
structure determination proves that 3 is a new compound. Structure elucidation of 3 was conducted based on NMR measurements (
1
H, COSY, 
HSQC and HMBC) and again displays a modification of ring A in the angucycline moiety of the simocyclinone structure. Ring A consists of one 
endocyclic and one exocyclic double bond and a methylene group. The C-13 methylene group shows NMR signals δC = 114.4 corresponding to δH = 
4.98, 4.95, which is typical for an exocyclic double bond. This exocyclic double bond could be assigned to C-3-C-13 in conjugation with the second 
double bond C-1-C-2, which shows the protons H-1 and H-2 to be in Z configuration (J = 10.3 Hz). The position of the endocyclic double bond C-
1-C-2 could be deduced from HMBC signals C-2 / H-1, C-3 / H-1, C-5 / H-1, C-12b / H-1 and C-1 / H-2, C-3 / H-2, C-13 / H-2. The aliphatic 
methylene group is determined to be C-4 via HMBC crosspeaks C-3 / 4-H2, C-4 / 13-H3, C-4 / 5-H2 and C-5 / 4-H2. As this is the only difference in 
the structure between SD9 (2) and SD10 (3), the final structure elucidation is displayed in the Supplemental Information (Tables S2a, S2b; Figures 
S3a-S3c).  
The third isolated compound, SD11 (4), shows the same molecular mass M = 933 as D9 (1) in HR ESI MS m/z = 932.2103 [M-H]
-
, which results in 
the same molecular formula, C46H44NO18Cl. Detailed NMR analysis shows that only ring A is different in SD11 (4) (Tables S3a, S3b; Figures S4a-
 V. APPENDIX  
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S4c). Ring A consists of an endocyclic double bond at C1-C2 showing two doublets (J = 10.3 Hz) with typical double bond proton chemical shifts 
6.24 (H-1) and 5.67 (H-2), a C-4 methylene group and a quaternary carbon C-4 substituted by a hydroxyl and a methyl group. The angucyclic 
carbons bear hydroxy groups deduced from carbon chemical shifts δC = 70.5 (C-4a) and δC = 69.1 (C-12b). The constitution of ring A is determined 
from HMBC signals C-4a/H-1, C-4/4-H2, C-12b/H-2, C-2/4-H2, C-3/H-1, C-3/ 4-H2, C-13/2-H and C-13/ 4-H2. The rest of the structure is proven 
by COSY and HMBC spectra and is shown to be the same as SD9 (2) and SD10 (3). 
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Kitasatospora 
sp. 
culture broth, NL-5, 2L 
mycelium 
106 mg crude extract 
simocyclinone D9  
13.0 mg 
simocyclinone D10 
0,7 mg 
culture broth,NL-5,10L 
mycelium 
258.9 mg crude extract 
simocyclinone D11  
1,6 mg 
SiO2 
39.6 mg fraction 
culture broth,DNPM,6L 
mycelium 
615.0 mg crude extract 
simocyclinone D5 
0.2 mg 
DSC-18 
8.0 mg fraction 
ORF7 inactivation 
HPLC 
HPLC HPLC 
Figure S1: Fermentation and isolation of new simocyclinones from K. sp. 
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Table S1a 
Pos. C (J Hz) H (J Hz) COSY TOCSY HMBC H2BC ROESY 
1 73.0 4.63 s 2-H, (4-Ha, 4-Hb,13-H3) 2-H, (4-Ha, 4-Hb),13-H3   2-H 
2 123.2 5.18 s 1-H, (4-Ha, 4-Hb,13-H3) 2-H, 4-Ha, 4-Hb,13-H3 4-Ha, 4-Hb, 13-H3 1-H, 13-H3 1-H, 13-H3 
3 131.5    4-Ha, 4-Hb, 13-H3   
4 42.0 2.17 d (17.8, Ha) 
1.97 d (17.8, Hb) 
(1-H, 2-H), 4-Hb, 13-H3 
(1-H, 2-H), 4-Ha, 13-H3 
1-H, 2-H, 4-Hb, 13-H3 
1-H, 2-H, 4-Hb, 13-H3 
2-H, 5-H2, 13-H3  4-Hb, 5-H2, 6-H, (13-H3), 
4-Hb, (13-H3) 
4a 70.8    4-Hb, 5-H2   
5 38.5 1.93 6-H 6-H  6-H 6-H 
6 63.2 4.33 br s 5-H2 5-H2 5-H2 5-H2 5-H2, 4-Ha 
6a 64.2    5-H2   
7 65.3 5.70 d (6.3) 7-OH 7-OH  7-OH 7-OH, 8-OH 
7-OH  7.00 d (6.3) 7-H 7-H   8-OH 
7a 123.1    7-H, 8-OH, (10-H), 11-H   
8 152.2    (7-H), 8-OH, 10-H, (1’-H)   
8-OH  9.88     7-H 
9 133.1    8-OH, 11-H, 1’-H, 2’-Hax   
10 125.6 7.46 d (8.2) 11-H 11-H 11-H, 1’-H 11-H 11-H, (2’-Hax) 
11 117.8 7.19 d (8.2) 10-H 10-H  10-H 10-H 
11a 130.1    7-H, 10-H   
12 196.0    11-H   
12a 65.6       
12b 74.3    2-H, 5-H2   
13 22.3 1.56 s 1-H, 2-H 1-H, 2-H, 4-Ha, 4-Hb 2-H 1-H, 2-H 2-H 
1’ 70.6 4.97 d (11.2) 2’-Hax 2’-Hax, 3’-H, (4-H), 6-H3 10-H, 2’-Hax, 5’-H 2’-Hax 2’-Heq, 3’-H, 5’-H 
2’ 36.6 eq: 2.42 dd (11.0, 5.3) 
ax: 1.57 ddd (11.2, 11.0, 10.4)  
(1’-H), 2’-Hax, 3’-H 
1’-H, 2’-Heq 
2’-Hax, 3’-H, 4’-H, 5’-H, 6’-H3 
1’-H2’-Hax, 3’-H, 4’-H, 6’-H3 
 1’-H, 3’-H 1’-H, 2’-Hax, 3’-H 
10-H, 1’-H, 2’-Heq 
3’ 71.7 5.18 ddd (10.4, 9.5, 5.3) 2’-Hax, 2’-Heq, 4’-H 1’-H, 2’-Hax, 2’-Heq, 4’-H, 5’-H, 
6’-H3 
1’-H, 2’-Hax, 2’-Heq 2’-Heq, 4’-H 1’-H, 2’-Heq, 5’-H 
4’ 74.2 4.77 dd (9.5, 9.5) 3’-H, 5’-H 2’-Hax, 2’-Heq, 3’-H, 5’-H, 6’-H3 2’-Hax, 2’-Heq, 5’-H, 6’-H3 3’-H, 5’-H 2’-Hax, (5’-H), 6’-H3 
5’ 73.2 3.80 dd (9.5, 6.2) 4’-H, 6’-H3 3’-H, 4’-H, 6’-H3 1’-H, 6’-H3 4’-H, 6’-H3 1’-H, 3’-H, (4’-H), 6’-H3 
6’ 17.8 1.18 d (6.2) 5’-H 1’-H, 2’-Hax, 2’-Heq, 3’-H, 4’-H, 
5’-H 
4’-H 5’-H 4’-H, 5’-H, (8’-H3) 
7’ 169.7    4’-H, 8’-H   
8’ 20.5 2.02 s   1J   
*assignment not possible 
2D signals in brackets are week 
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Table S1a: NMR data of simocyclinone D9 (2), angucycline and sugar part. (600 / 150MHz, DMSO-d6, Temperature=35°C, solvent as internal 
reference) 
Table S1b 
Pos. C (J Hz) H (J Hz) COSY TOCSY HMBC H2BC ROESY 
1’’ 165.3    3’-H, 2’’-H, 3’’-H   
2’’ 121.5 6.00 d (15.5) 3’’-H 3’’-H, 4’’-H, 5’’-H, 6’’-H 7’’-H 4’’-H 3’’-H 4’’-H 
3’’ 144.5 7.28 dd (15.5, 11.5) 2’’-H, 4’’-H 2’’-H, 4’’-H, 5’’-H, 6’’-H, 7’’-
H, 9’’-H 
4’’-H, 5’’-H 2’’-H, 4’’-H 5’’-H 
4’’ 132.9 6.65 dd (13.3, 11.7) 3’’-H, 5’’-H 3’’-H, 5’’-H, 6’’-H, 7’’-H,8’’-H 2’’-H, 5’’-H 3’’-H, 5’’-H 2’’-H, 6’’-H 
5’’ 140.3 6.87 dd (13.3, 11.7) 4’’-H 2’’-H, 3’’-H, 4’’-H, 7’’-H, 8’’-H 3’’-H, 7’’-H 4’’-H 3’’-H 
6’’ 139.1 6.87 dd (13.6, 11.7) 7’’-H 2’’-H, 3’’-H, 4’’-H, 7’’-H, 8’’-H 4’’-H, 5’’-H, 7’’-H, 8’’-H 5’’-H, 1J 4’’-H 
7’’ 134.4 6.72 dd (13.6, 11.7) 6’’-H, 8’’-H 2’’-H, 3’’-H, 5’’-H, 6’’-H, 8’’-
H, 9’’-H 
5’’-H, 6’’-H, 8’’-H, 9’’-H 6’’-H, 8’’-H 9’’-H 
8’’ 141.1 7.31 dd (15.2, 11.6) 7’’-H, 9’’-H 2’’-H, 4’’-H, 5’’-H, 6’’-H, 7’’-
H, 9’’-H 
6’’-H, 7’’-H 7’’-H, 9’’-H 6’’-H 
9’’ 124.9 6.63 d (15.5) 8’’-H 2’’-H, 3’’-H, 4’’-H, 5’’-H, 6’’-
H, 7’’-H, 8’’-H 
7’’-H, 8’’-H 8’’-H 7’’-H, NH 
10’’ 166.2    8’’-H, 9’’-H, NH   
11’’ 158.8    NH   
12’’ 105.2       
13’’ 157.9    NH, 14’’-H   
13’’-
OH 
 10.27     14’’-H 
13a’’ 115.4    13’’-OH, 14’’-H, 15’’-H   
14’’ 119.6 7.25 s   13’’-OH 15’’-H, 1J 13’’-OH 
15’’ 115.9 7.25 s   1J 14’’-H, 1J 16’’-OH 
16’’ 151.0    13’’-OH, 14’’-H   
16’’-
OH 
 10.26     15’’-H 
17’’ 114.5    15’’-H   
17a’’ 145.6    14’’-H   
NH  9.84     9’’-H 
OH*  12.65, 9.84, 6.23, 5.32      
*assignment not possible 
2D signals in brackets are week 
 
 
Table S1b: NMR data of simocyclinone D9 (2), angucycline and sugar part. (600 / 150MHz,  DMSO-d6, Temperature=35°C, solvent as internal 
reference)  
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Figure S2a, related to Figure 2: UV, MS and 1D NMR spectra of simocyclinone D9 (2). (A) UV spectrum of 2. (B) ESI-MS (neg. mode) of 2. 
(C) 
1
H NMR spectrum of 2 (600 MHz, DMSO-d6, 35°C).  (D) 
13
C NMR spectrum of 2 (150 MHz, DMSO-d6, 35°C).
A 
 
B 
 
 
 
 
 
 
C 
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Figure S2b, related to Figure 2: 2D NMR spectra of  simocyclinone D9 (2). (A) COSY spectrum of 2 (600 MHz, DMSO-d6, 35 °C). (B) TOCSY 
spectrum of 2 (600 MHz, DMSO-d6, 35°C). (C) ROESY spectrum of 2.  (D) HSQC spectrum of 2 (600 MHz, DMSO-d6, 35°C).
A 
 
B 
 
C 
 
D 
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Figure S2c, related to Figure 2: 2D NMR spectra and structure elucidation of   simocyclinone D9 (2) . (A) HMBC spectrum of 2 (600 MHz, 
DMSO-d6, 35 °C). (B) H2BC spectrum of 2 (600 MHz, DMSO-d6, 35°C). (C) 2D NMR correlations in aminocoumarin part of 2. (D) 2D NMR 
correlations in tetraene part of 2. 
A 
 
 
 
B 
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Figure S2d: Structure elucidation of simocyclinone D9 (2). (A) 2D NMR correlations in amiocoumarin part of 2. (B) 2D NMR correlations in 
tetraene part of 2. (C) 2D NMR correlations in sugar part of 2. (D) 2D NMR correlations in angucycline part of 2.
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Figure S2e: Structure elucidation of simocyclinone D9 (2). 
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Table S2a 
 
Pos. C* H (J Hz) COSY HMBC 
1 130.7 6.10 d (10.3) 2-H 2-H 
2 130.8 6.22 d (10.3) 1-H 1-H, 4-H 
3 141.7   1-H, 2-H 
4 41.9 a: 2.75 d (14.2) 
b: 2.30 d( 14.2) 
4-Hb 
4-Ha 
2-H, 13-H2 
4a 70.2   1-H, 2-H, 4-Hb, 6-H 
5 33.5 a: 1.82 dd (15.0, 3.1) 
b: 1.75 d (15.0) 
5-Hb, 6-H 
5-Ha, 6-H 
4-Hb, 6-H 
6 65.0 4.49 d (3.1) 5-Ha, 5-Hb 5-Hb 
6a 67.3   6-H 
7 64.5 5.83 s br  6-H 
7a 125.7   7-H, 11-H 
8 154.1   7-H, 1’-H 
9 135.3   1‘-H 
10 126.7 7.53 d (8.4) 11-H  
11 119.8 7.62 d (8.4) 10-H  
11a 129.5   7-H, 10-H 
12 197.7   11-H 
12a 68.6   5-Hb, 6-H, 7-H 
12b 73.0   1-H 
13 114.4 4.98, 4.95  2-H, 4-Ha, 4-Hb 
1’ 72.7 4.99 d (11.2) 2’-Hax 10-H 
2’ 37.7 eq: 2.59 dd (12.6, 5.3) 
ax: 1.59 dd (12.3, 11.2) 
2’-Hax 
1’-H, 2’-Heq, 3’-H 
 
3’ 73.4 5.22 m 2’-Hax, 2’-Heq, 4’-H 2’-Heq, 4’-H 
4’ 75.7 4.85*** 3’-H, 5’-H 2’-Heq, 3’-H, 5’-H 
5’ 75.2 3.76 m 4’-H, 6’-H3 4’-H 
6’ 17.9 1.27 d (6.1) 5’-H 4’-H, 5’-H 
7’ 171.1   4’-H, 8’-H3 
8’ 20.5 2.03 s   
1.)*from HMBC/HSQC  2.) **no HMBC-Signal 3.)***covered from water  4.) 2D signals in brackets are week 
  
 
Table S2a: NMR data of simocyclinone D10 (3), angucycline and sugar part. (700 / 175MHz,  CD3OD, Temperature = 25°C, solvent as internal 
reference)  
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Table S2b
 
Pos. C* H (J Hz) COSY HMBC 
1’’ 168.3   2’’-H, 3’’-H 
2’’ 124.3 6.52 d (15.0) 3’’-H  
3’’ 143.8 7.44 dd (15.0, 11.8) 2’’-H, 4’’-H 5’’-H 
4’’ 134.9 6.68 dd (13.6, 11.8) 3’’-H, 5’’-H 2’’-H 
5’’ 140.9 6.79 m 4’’-H 6’’-H 
6’’ 134.8 6.79 m 7’’-H 5’’-H 
7’’ 134.6 6.62 dd (13.2, 11.8) 6’’-H, 8’’-H 9’’-H 
8’’ 145.7 7.34 dd (15.0, 11.8) 7’’-H, 9’’-H 6’’-H 
9’’ 122.7 5.95 d (15.0) 8’’-H  
10’’ 167.0   8’’-H, 9’’-H 
11’’ **    
12’’ **    
13’’ **    
13a’’ 115.7   14’’-H, 15’’-H 
14’’ 120.5 7.19 s br  15’’-H 
15’’ 116.7 7.19 s br  14’’-H 
16’’ 152.2   14’’-H, 15’’-H 
17’’ 115.7   15’’-H 
17a’’ 143.1   14’’-H 
1.)*from HMBC/HSQC  2.) **no HMBC-Signal 3.)***covered from water  4.) 2D signals in brackets are week 
 
 
Table S2b: NMR data of simocyclinone D10 (3), tetrane and aminocoumarin part. (700 / 175MHz,  CD3OD, Temperature = 25°C, solvent as 
internal reference) 
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Figure S3a: UV, MS and 
1
H NMR spectra of simocyclinone D10 (3). (A) UV spectrum of 3. (B) 
1
H NMR spectrum of 3 (700 MHz, CD3OD, 
25°C). (C) ESI-MS (neg. mode) of 3.  
A 
 
B 
 
 
C 
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Figure S3b: 2D NMR spectra of simocyclinone D10 (3). (A) COSY spectrum of 3 (700 MHz, CD3OD, 25 °C). (B) HSQC spectrum of 3 (700 
MHz, CD3OD, 25 °C). (C) HMBC spectrum of 3 (700 MHz, CD3OD, 25 °C).    
A 
 
B 
 
C 
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Figure S3c: Structure elucidation of simocyclinone D10 (3): 2D NMR correlations of 3. 
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Table S3a 
Pos. C* H (J Hz) COSY HMBC 
1 127.4 6.24 d (10.3) 2-H  
2 135.4 5.67 d (10.3) 1-H 13-H3, 4-Hb 
3 66.3   1-H, 4-Ha, 4-Hb 
4 44.2 Ha: 2.12 d (13.6) 
Hb: 1.76 d (13.6) 
4-Hb 
4-Ha 
2-H, 5-Ha, 5-Hb, 13-H3 
4a 70.5   1-H, 4-Hb, 5-Ha, 5-Hb 
5 39.6 Ha: 1.94 dd (12.9, 9.6) 
Hb: 1.80 dd (13.1, 6.0) 
5-Hb, 6-H 
5-Ha, 6-H 
4-Hb 
6 63.2 4.22 m 5-Ha, 5-Hb, 6-OH 5-Ha, 5-Hb 
6-OH  5.56 br d (6.7) 6-H  
6a 67.8   5-Ha, 5-Hb 
7 63.7 5.72 d (7.4) 7-OH  
7-OH  6.70 **   
7a 124.2   7-H, 8-OH, 11-H 
8 152.4   8-OH 
8-OH  9.56 s   
9 133.6   8-OH, 1‘-H, 2‘-Hax 
10 125.6 7.48 d (8.2) 11-H  
11 118.2 7.40 d (8.2) 10-H  
11a 128.5   10-H 
12 190.1   11-H 
12a 67.1    
12b 69.1   2-H, 5-Ha 
13 29.2 1.11 s  2-H, 4-Ha 
1’ 70.6 4.97 d (11.6) 2’-Hax 10-H, 2’-Hax 
2’ 36.5 Heq: 2.44 dd (14.7, 5.1) 
Hax: 1.58 dd (14.7, 11.7) 
2’-Hax, 3’-H  
1’-H, 2’-Heq 
 
3’ 71.6 5.19 ddd (11.3, 9.4, 5.1) 2’-Heq, 2’-Hax, 4’-H 2’-Hax, 4’-H 
4’ 74.1 4.76 dd (9.6, 9.6) 3’-H, 5’-H 3’-H, 5’-H, 6’-H3 
5’ 73.1 3.80 dq (9.6, 6.1) 4’-H, 6’-H3 4’-H, 6’-H3 
6’ 17.7 1.17 d (5.9) 5’-H  
7’ 169.7   4’-H, 8’-H3 
8’ 20.5 2.02 s   
*missing signal **signal covered from others 
 
Table S3a: NMR data of simocyclinone D11 (4), angucycline and sugar part. (600 / 150MHz, DMSO-d6, Temperature = 35°C, solvent as internal 
reference) 
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Table S3b 
Pos. C* H (J Hz) COSY HMBC 
1’’ 165.2   2’’-H, 3’’-H 
2’’ 121.1 6.02 d (14.4) 3’’-H  
3’’ 144.4 7.29 dd (14.4, 13.0) 2’’-H, 4’’-H  
4’’ 133.1 6.65 dd (13.0, 12.2) 3’’-H, 5’’-H 2’’-H 
5’’ 140.3 6.85 dd (12.2, 11.1) 4’’-H, 6’’-H 3’’-H, 7’’-H 
6’’ 139.0 6.86 dd (14.1, 11.1) 5’’-H, 7’’-H 4’’-H 
7’’ 134.2 6.72 dd (14.1, 11.6) 6’’-H, 8’’-H 9’’-H 
8’’ 140.9 7.31 dd (15.3, 11.5) 7’’-H, 9’’-H 6’’-H 
9’’ 124.8 6.60 d (15.3) 8’’-H  
10’’ 166.0   8’’-H, 10’’-H 
11’’ 158.8    
12’’ *    
13’’ *    
13’’-
OH 
 10.2 s   
13a’’ 115.4   13’’-OH, 14’’-H, 15’’-H 
14’’ 119.5 7.25   
15’’ 115.8 7.25  14’’-H 
16’’ 150.9   14’’-H, 15’’-H 
17’’ 114.6    
17a’’ 145.6   14’’-H 
*missing signal **signal covered from others 
 
 
 
Table S3b: NMR data of simocyclinone D11 (4), aminocoumarine and tetraene part. (600 / 150MHz, DMSO-d6, Temperature = 35°C, solvent as 
internal reference) 
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Figure S4a: UV, MS and 
1
H and 
13
C NMR spectra of simocyclinone D11 (4). (A) UV spectrum of 4. (B) ESI-MS (neg. mode) of 4. (C) 
1
H NMR 
spectrum of 4 (600 MHz, DMSO-d6, 35°C) (D) 
13
C NMR spectrum of 4 (600 MHz, DMSO-d6, 35°C). 
A 
 
B 
 
 
C 
 
D 
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Figure S4b: 2D NMR spectra of  simocyclinone D11 (4). (A) COSY spectrum of 4 (600 MHz, DMSO-d6, 35 °C). (B) HSQC spectrum of 4 (600 
MHz, DMSO-d6, 35°C).  (D) HMBC spectrum of 4 (600 MHz, DMSO-d6, 35°C).
A 
 
B 
 
C 
  
 V. APPENDIX  
23 
 
Figure S4c: Structure elucidation of simocyclinone D11 (4). 2D NMR correlations of 4. 
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Table S4a 
Pos. C 
a H 
a  COSY
b HMBCb 
1 196.8   (2-H)d, 13-H3 
2 122.4 5.89 13-H3 13-H3 
3 161.3   13-H3 
4 41.7 Ha: 2.69 
Hb: 2.39 
4-Hb 
4-Ha 
2-H, 13-H3 
4a 75.2   4-Hb 
5 28.5 Ha: 1.80 
Hb: 1.61 
5-Hb, 6-Ha, 6-Hb 
5-Ha, 6-Ha, 6-Hb 
6-Ha, 6-Hb 
6 23.4 Ha: 2.53 
Hb: 2.36 
5-Ha, 5-Hb, 6-Hb 
5-Ha, 5-Hb, 6-Ha 
5-Ha 
6a 73.4   5-Ha, 6-Hb 
7 70.5 5.34   
7a 125.7   7-H 
8 153.4   7-H, 1’-H 
9 135.8   1’-H 
10 127.9 7.43 11-H 1’-H 
11 119.4 7.38 10-H  
11a 129.4   7-H, 10-H 
12 194.3   11-H 
12a 64.7   5-Ha, 6-Ha, (7-H) 
12b 76.0   2-H, 5-Ha 
13 23.8 1.90  2-H4-Ha 
1’ 72.3 4.90 2’-Hax 10-H, 2’-Hax 
2’ 37.5 Hax: 1.48 
Heq: 2.41 
1’-H, 2’-Heq, 3’-H 
2’-Hax 
1’-H 
3’ 75.7 4.96 2’-Hax, 4’-H 1’-H, 2’-Hax, 4’-H 
4’ 74.8 3.30 3’-H, 5’-H 2’-Heq, 3’-H, 6’-H3 
5’ 77.0 3.53 4’-H, 6’-H3 4’-H, 6-H3 
6’ 18.3 1.31 5’-H 4’-H 
avalues taken from 2D-Spectra 
b2D signals in brackets are week 
cnot visible in HSQC/HMBC, no 13C NMR available 
donly visible at very high scale 
 
Table S4a: NMR data of simocyclinone D12 (5), angucycline and sugar part. (700 / 175MHz, CD3CN / HCOOH, Temperature = 25°C, solvent as 
internal reference)  
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Table S4b 
Pos. C 
a H 
a  COSY
b HMBCb 
1’’ 166.9   3’-H, 2’’-H, 3’’-H 
2’’ 123.6 6.01 3’’-H 4’’-H 
3’’ 144.6 7.34 2’’-H, 4’’-H 4’’-H 
4’’ 134.7 6.65 3’’-H, 5’’-H 2’’-H, 5’’-H 
5’’ 140.2 6.74 4’’-H, 6’’-H 3’’-H, 4’’-H, 7’’-H 
6’’ 144.4 7.42 5’’-H, 7’’-H 7’’-H 
7’’ 134.3 6.65 6’’-H, 8’’-H 5’’-H 
8’’ 144.0 7.42 7’’-H, 9’’-H 7’’-H 
9’’ 123.4 6.51 8’’-H 7’’-H 
10’’ 167.8   9’’-H 
11’’ c    
12’’ c    
13’’ 155.5   14’’-H 
13a’’ 116.6   14’’-H 
14’’ 120.0 7.22 15’’-H  
15’’ 112.5 7.14 14’’-H  
16’’ 154.3   15’’-H 
17’’ 121.0   15’’-H 
17a’’ 141.3   14’’-H 
avalues taken from 2D-Spectra 
b2D signals in brackets are week 
cnot visible in HSQC/HMBC, no 13C NMR available 
 
 
 
Table S4b: NMR data of simocyclinone D5 (5), aminocoumarine and tetraene part. (700 / 175MHz, CD3CN / HCOOH, Temperature = 25°C, 
solvent as internal reference) 
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Figure S5a: UV, MS and 
1
H NMR spectra of simocyclinone D5 (5). (A) UV spectrum of 5. (B) ESI-MS (neg. mode) of 5. (C) 
1
H NMR spectrum 
of 5 (700 MHz, CD3CN/HCOOH, 25°C).
A 
 
B 
 
C 
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Figure S5b: 2D NMR spectra of simocyclinone D5 (5). (A) COSY spectrum of 5 (700 MHz, CD3CN/HCOOH, 25°C). (B) HSQC spectrum of 5 
(700 MHz, CD3CN/HCOOH, 25°C) (C) HMBC spectrum of 5 (700 MHz, CD3CN/HCOOH, 25°C).
A 
 
B 
 
C 
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Figure S5c: Structure elucidation of simocyclinone D5 (5). 2D NMR correlations of 5.  
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Figure S6: Chromatogram of the HPLC-ESI/MS analysis of K. sp. ΔPKS mutant crude extract. Arrows indicate peaks corresponding to 
simocyclinones. 
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Figure S7: Chromatograms of the HPLC-ESI/MS analysis of: (A) crude extract of K. sp. with deleted smcKSII ; (B) crude extract of K. sp. with 
deleted smcKSII complemented with intact smcKSII; (C) crude extract of K. sp. with deleted smcKSII complemented with modified smcKSII; (D) 
crude extract of K. sp. wild type strain. Arrows indicate ions corresponding to simocyclinones. 
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   L         WT               ∆KS     p∆KS 
10 kb 
6 kb 5,9 kb 
A B 
Ex2 A13 simC1B hyg
R
 
loxP loxP 
AT DH ER KR 
Ex2 A13 simC1B 
hyg
R
 
aac(3)IV
R
 gusA 
loxP loxP 
2.5 kb 2.5 kb 
KS AT DH ER KR 
Figure S8a: S. antibioticus Tü6040 ∆KS mutant. (A) Generation of S. antibioticus Tü6040 ΔKS mutant via double crossover (DNA region 
encoding KS domain was replaced with a hygromycin-resistance gene). hyg
R
 – hygromycin resistance gene, aac(3)IVR  - apramycin resistance 
gene, gusA – β-glucoronidase gene, loxP – target site for Cre recombinase. (B) Nylon membrane after hybridization of S. antibioticus Tü6040 
wild type and S. antibioticus ΔKS chromosomal DNA with hph-zond. Red arrow indicates predicted 5,9 kb fragment in S. antibioticus Tü6040 
ΔKS mutant. L – DNA ladder, WT – wild type of S. antibioticus Tü6040, ΔKS - S. antibioticus Tü6040 ΔKS, pΔKS – pKGKSΔ cassette used 
for KS domen disruption. 
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Figure S8b: Chromatogram of the HPLC-ESI/MS analysis of S. antibioticus mutant crude extract. Arrows indicate ions corresponding to 
simocyclinones. 
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+ Cre recombinase 
hyg
R
 
aac(3)IV
R
 gusA 
loxP 2.5 kb 2.5 kb 
ORF7* 
hyg
R
 
loxP loxP 
2 3 4 6 7 8 
loxP 
5* 
aac(3)IV
R
 
2.5 kb 2.5 kb 
ORF7* 
gusA 
loxP 
P KSII B7 ORF7* KSI B5 B4 
P KSII B7 ORF7* KSI B5 B4 
P KSII B7 ORF7* KSI B5 B4 
Figure S9: Generation of K.sp. ORF7* mutant via double crossover. aac(3)IV
R 
– apramycin resistance gene; hygR – hygromacin resistance gene; 
gusA – β-glucoronidase gene; loxP – target site for Cre recombinase 
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Figure S10: Level of transcription of smc genes in NL5 and DNPM production media. In yellow are labeled genes involved in aminocoumarin 
biosynthesis, blue – genes involved in sugar unit formation, green – genes responsible for the angucyclic core synthesis, pink – genes putatively 
involved in modification of the polyketide chain precursor, dark grey – regulatory genes, dark blue – efflux, pale grey – genes of unknown 
function, white – smcP, smcKSI, smcKSII, orf7. 1-43 – number of the gene (see Table 1). 
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Table S5  
Primer Sequence (5’→ 3’) Restriction site 
KS_R_fus-f TTCGGCAGTATCTGAAGAAGGATATCGCGCAGCCCGAC
GCACCGGG
a
 
EcoRV 
KS_F_fus-r CCCGGTGCGTCGGGCTGCGCGATATCCTTCTTCAGATAC
TGCCGAA
a
 
EcoRV 
KS_R-SspI-r ACTAATATTCCGCCCCATGGGTCAGGACGA
a 
SspI 
KS_F-SspI-f ACTAATATTGGTCTGGCCGGGACGACGCTC
a
 SspI 
KSII_ff-EcoRI-f CCTGAATTCAAGTCCGGCCCGACGCTCGGCAG
a
 EcoRI 
KSII_ff-MCS -r CCCGATATCAACAATTGAAAGGCCTAATGTCCGCCGAC
GGGCTTCCGG
a
 
EcoRV, MunI, 
StuI 
KSII_fr-MunI-f CCCCAATTGAATCTGAACTACGCGATACAGCA
a
 MunI 
KSII_fr-XbaI-r CCCTCTAGAAATGCGCGTCTGTCGGCTGGCCG
a
 XbaI 
putPKS-562-f  ATCAAGCTTCGACCCCACTGGACCGACACC
a
 HindIII 
putPKS-562-r  ACGTCTAGACGCGGTGGCCTGGTGCAGCCG
a
 XbaI 
KSII-com-f ATATCTAGAATGTGCGGGCTCTAACACGTCCTAGTATGGT
AGGATGAGCAAGGTACCAAGCTTATTGGCACTAGTCGAG
CAACGGAGGTACGGACATGCCCGAGGCCCCGGGTCGG
a,b
 
XbaI 
KSII-com-r ATAGATATCATCACGCCGAAGGCCGATGCTT
a
 EcoRV 
KSII*21p-f.1 ATATCTAGAATGTGCGGGCTCTAACACGTCCTAGTATGGT
AGGATGAGCAACGAGCAACGGAGGTACGGACATGCCCGA
GGCCCCGGGTCGG
a,b 
XbaI 
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KSII*-r.1 TGGCGTAGTTCCCCGCCGACGCCGCCGTGGCCAGGGTCA
G 
- 
KSII*-f.2 CTGACCCTGGCCACGGCGGCGTCGGCGGGGAACTACGC
CA 
- 
KSII*21p-r.2 ATAGATATCATCACGCCGAAGGCCGATGCTT
a 
EcoRV 
ORF7-rev -f CCCGAATTCGTGACCGTGCGGTCGGGGAAG  EcoRI 
ORF7_rev- -r CCCGATATCCAATATTCCAATTGCAGGCCTTGGAGCAG
AACGCGAAAGCCGT
a
 
EcoRV, SspI, 
MfeI, StuI 
ORF7_for -f CCCAATATTCGGGCATGCCCTCCTCTACCA
a
 SspI 
ORF7_for-r CCCTCTAGAGTGGTCCCGGAACGGCTCGCC
a
 XbaI 
ORF7* –for1 CCCCCAATTGTATGAAGTATTTCGTCCTGGGa MunI 
ORF7*-rev1 ACGTCTCCGACTGGCCGCCCCCCGCCACATTGGCGGTCG
CCA  
- 
ORF7*-for2 GGCGGCCAGTCGGAGACGT - 
ORF7*-rev2- CCCTAGGCCTATCAGCGGAGATCGGCCAGCCC
a
 StuI 
hph-MfeI-f CCCCAATTGAGAATAGGAACTTCGGAATAGG
a
 MfeI 
hph-BamHI-r CCCGGATCCTCCGTATTTGCAGTACCAGCGT
a
 BamHI 
smcX5-21-XbaI CCCTCTAGATGTGCGGGCTCTAACACGTCCTAGTATGGTA
GGATGAGCAAGGAGGTACGGAATGATCGAGCAGCTGCTG
GCG
a,b
 
XbaI 
smcX5-HindIII CCCAAGCTTCTAAATCTCCGCTGTGCCGCC
a
 HindIII 
smcC3-A9-XbaI CCCTCTAGACCGGGCGGCTTCCTCATGCTTGACTTGACTA
GGATAAAGGGGGAGGTACGGAATGCATTCACCGCCCGTC
XbaI 
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TGG
 a,b
 
smcC3-BglII CCCAGATCTTCACCGGACAACTCCTCTCGT
a
 BglII 
SmcTet-KpnI-f CCCGGTACCTGTGCGGGCTCTAACACGTCCTAGTATGGTA
GGATGAGCAACTGGAGGCGGTCATGGCGGTTGTGACGCC
AGACGAA
a,b
 
KpnI 
SmcTet-rev CCCTCTAGACGGGCATGCCCTCCTCTACCA
a
 XbaI 
SmcA7_ff-
EcoRI-f 
ccaGAATTCTGTCAGGTCGGCGTCCAGGAGA 
 
EcoRI 
SmcA7_ff-MCS-
EcoRV-r 
CCCGATATCACAATTGCCAATATTACGAGCTCAGCCCC
GGCAAGGC 
EcoRV, MunI, 
SspI 
SmcA7_fr-MunI-
f 
CCCCAATTGTTCCCATGTCCTTCCGTTGTTC MunI 
SmcA7_fr-XbaI-r CCCTCTAGAAAGCGCTTCGAACCGGACCGTC XbaI 
SmcA9_ff-
EcoRI-f 
CCAGAATTCTCGACCTGCACGGACCCCAGCA EcoRI 
SmcA9_ff-MCS-
EcoRV-r 
CCCGATATCACAATTGCCAATATTAGCGTCGCACATCT
GGACGAAG 
EcoRV, MunI, 
SspI 
SmcA9_fr-MunI-
f 
CCCCAATTGTGCCGGGTGGAACACACCGTCG MunI 
SmcA9_fr-XbaI-r CCCTCTAGAAAGGAGTTCTCCTCGTCGAATG XbaI 
Hph-MunI-f CCCCAATTGAGAATAGGAACTTCGGAATAGG  MunI 
Hph-BamHI-r CCCGGATCCTCCGTATTTGCAGTACCAGCGT BamHI 
simA8-11F  TTGAATTCCACTCCTCTCTCCGTC EcoRI 
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simA8-11R  TTGATATCAACTCGTTCGGTGACG EcoRV 
simA8-21F  AAGATATCGTTGGTCGACGATCTCCA EcoRV 
simA8-21R AAAAGCTTCACCATCGACGACCTGAG HindIII 
simA8Forw ACAGGAGTTCTCCTCGTCGA  
simA8Rev CAAGGACCACGCCGAGCGTC  
a
 – restriction sites introduced artificially are marked in bold; b – promoter sequences introduced 
artificially are marked in italic 
 
Table S5: Oligonucleotides used in this study.
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Experimental section 
 
General  
NMR spectra were obtained on a Bruker Avance 500 MHz spectrometer equipped with a 5mm TCI 
cryoprobe (Bruker Biospin GmbH, Germany) and a Varian VNMR-S 600 MHz spectrometer (Varian, 
USA) equipped with 3mm triple resonance inverse probe. The spectra were indicated and referenced to 
residual 1H signals in deuterated solvents (MeOD: δH = 3.30 ppm, δC = 49.0 ppm, DMSO-d6: δH = 2.50 
ppm, δC = 39.5 ppm). HR-ESI-MS spectra were acquired using an UltiMate 3000TM rapid separation 
liquid chromatography system (Dionex RSLC) equipped with an UV/Vis diode array detector module and 
connected to an Orbitrap (Thermofisher scientific) or an UHR-TOF mass spectrometer (Bruker Daltronics, 
MaXis Q-Tof) in positive ion mode under the following conditions (Waters BEH C18 column, 100  
2.1mm, 1.7 µm, eluting with 0.55 mL/min 95% H2O/MeCN to 5% H2O/MeCN (with isocratic 0.01% FA) 
over 18 min. For HPLC separation UltiMate 3000TM rapid separation liquid chromatography system 
(Dionex RSLC) equipped with an UV/Vis diode array detector module and fraction collection unit was 
used (Thermofisher Scientific). Optical rotation values ([]D) were obtained on a Jasco J720 spectro-
polarimeter with a 1 cm cuvette at 20 C. IR-spectra were obtained with Bruker IFS 66V. Melting points 
were detected on a Mettler FP80 with heating table Mettler FP82 Hot Stage under a Nikon microscope 
511501, objective 10/0.21. CD-Spectra were measured on Chirascan spectrometer in 0.2 cm quartz-cuvette. 
Absorptions spectra were measured on Varian Cary 100 double beam spectrometer. As spraying reagents 
on TLC (KG 60 F254 0.20 mm, Merck) vanillin sulfuric acid and Orcin solution were used: Orcin solution: 
Solution A: iron(III)chloride (1 g) solved in conc. H2SO4 (100 ml). Solution B: orcin (6 g) solved in 
ethanol (100 ml). Before usage 10 ml of A were mixed with 1 ml of B. Spraying and heating the TLC with 
a heat gun at min. 100 °C. Brown-black spot indicate sugars. Vanillin sulfuric acid: The spraying reagent is 
made from 1.0 g vanillin diluted in 100 ml concentrated sulfuric acid. 
Fermentation and isolation of amycomycin C and D in NL5 medium 
Batch fermentation of strain Kitasatospora sp. was done in a 3-l fermenter, equipped with a turbine 
impeller system in NL 5 medium (1 liter NL-5 medium consists of NaCl 1.00 g, K2HPO4 1.00 g, MgSO4 × 
7 H2O 0.50 g, glycerin 25.0 g, l-glutamine 5.84 g, trace-element-solution 2.00 ml, pH 7.3; trace-element-
solution consists of ZnCl 40.0 mg, FeCl3 × 6 H2O 200 mg, CuCl2 × 2 H2O 10.0 mg, MnCl2 × 4 H2O, 
Na2B4O7 × 10 H2O 10.0 mg, (NH4)Mo7O24 × 4 H2O). The fermenter was inoculated with 5% by volume 
of a shake flask culture grown in a TSB medium at 28° C in 500 ml Erlenmeyer flasks with 4 baffles for 24 
h on a rotary shaker at 250 rpm. The fermentation broth was cultivated for 5 days (30° C, 180 rpm). The 
culture broth was centrifuged (30 min, 20° C, 7000 rpm, Beckmann-Coulter; Rotor JLA 8.1000) for 
separation of supernatant and biomass. The biomass was stirred with MeOH (20 min) and evaporated. The 
resulting residue was mixed with ethyl acetate (400 ml) centrifuged (15 min, 20° C, 7000 rpm, Beckmann-
Coulter; Rotor JLA 8.1000) and the supernatant was taken and evaporated. The biomass extract yielded 
3.00 g of an oily residue, which was chromatographed in portions of two times 1.50 g on a SiO2 column 
(KG 60, 3 cm × 22 cm, CHCl3/MeOH 9:1). Fractions were analyzed with spraying reagent vanillin sulfuric 
acid on SiO2-TLC (CHCl3/MeOH 9:1, fraction 4: Rf: 0.43, fraction 6: Rf: 0.21). Fraction 4 (17.7 mg) was 
purified via repeated size exclusion chromatography on sephadex LH 20 column (1 × 1 cm × 16 cm, 
MeOH, 2 × 0.5 cm × 13 cm, MeOH ) and led to 200 µg amycomycin D (2). Fraction 6 (7.65 mg) yielded 
after size exclusion chromatography on sephadex LH20 in 3.42 mg. Final semi preparative workup on 
HPLC (C18 column, Phenomenex Luna C18(2), 100 A, 250 × 10 mm, 5µm) with a 20 min gradient of 10% 
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B to 90% B (A: H2O, B: acetonitrile, retention time 12.2 min, detection-λ = 328 nm) resulted in 1.00 mg of 
amycomycin C (1).  
 
Cultivation and isolation of amycomycin D in DNPM medium 
A second cultivation of K. sp. (8.8 l) was done in 500 ml flasks containing 100 ml DNPM-medium (1 liter 
DNPM medium consists of dextrin 40.0 g, soy tone 7.50 g, fresh yeast 5.00 g, 4-
Morpholinopropanesulfonic acid (MOPS) 21.0 g, pH 6.8). The cultures were inoculated with 7 ml pre-
culture and cultivated for 5 days (28° C, 180 rpm). The pre-cultures were cultivated in 300 ml Erlenmeyer 
flasks (2 days, 28 °C, 180 rpm) filled with 50 ml TSB medium and 100 µl of sucrose-culture (1 l TSB 
consists of tryptic soybroth 30.0 g). The culture broth was centrifuged (30 min, 20° C, 7000 rpm, 
Beckmann-Coulter; Rotor JLA 8.1000) for separation of supernatant and biomass. The biomass was stirred 
with MeOH (20 min) and evaporated. The resulting residue was mixed with ethyl acetate (400 ml) 
centrifuged (15 min, 20° C, 7000 rpm, Beckmann-Coulter; Rotor JLA 8.1000) and the supernatant was 
taken and evaporated. The biomass extract, yielded 184 mg which were diluted in 2.4 ml (DMSO/MeOH 
1:4) and pre-separated through prep-HPLC (Waters C18 column, 150 × 19 mm, flow 25 ml/min; 200-300µl 
per injection) with a gradient from 10%B to 90% B in 30 min (A: H2O, B: acetonitrile, detection-λ = 328 
nm) Fraction 14 (1.6 mg, retention time = 21.8 min) led after semi-prep HPLC-isolation to 0.6 mg of 
amycomycin D (Phenomenex Luna C18, 250 × 10 mm, 5µm, flow: 3 ml/min, gradient 5% B to 100% B in 
20 min, A: H2O + 0.1% FA, B: CH3CN + 0.1% FA, detection- λ = 328 nm, RT: 18.5 min, injection 20-50 
µl, c = 4 mg/ml) – HR-ESI-MS: pos. 467.1330 [M+H] +, 321.0757 [M-sugar+H]+. 
Feeding experiment with alizarin and isolation of O-α-l-talosyl-1,2-dihydroxyanthraquinone 
The pre-culture was cultivated in 300 ml Erlenmeyer flasks filled with 50 ml TSB-medium (1 l TSB 
consists of tryptic soybroth 30.0 g) and 100 µl of K. sp. containing sucrose-solution (2 days, 30 °C, 180 
rpm). The pre-culture was platted and grown on MS-medium plates (3 days, 30 °C). The grown spores were 
covered with TSB-medium (4 ml) and scratched off. The spore-mixture was transferred into 300 ml 
Erlenmeyer flasks filled with TSB-medium (46 ml) and grown for 1 day (28 °C, 180 rpm). In each case 1 
ml of this second pre-culture was transferred into 100 ml DNPM-medium in 500 ml Erlenmeyer flasks (42 
×) and cultivated (30 °C, 180 rpm). The feeding started on cultivation-day 2 with the addition of 1 ml 
alizarin stock-solution (c = 0.25 mmolL-1) and went on during third and fourth day with addition of 500 µl 
of alizarin stock-solution (c = 0.25 mmolL-1). In total the alizarin concentration per sample reached c = 0.5 
mmol/l. The harvest started at day 5. The culture crude was separated into biomass and supernatant via 
centrifugation (30 min, 7000 rpm). The biomass was decomposed in MeOH (500 ml) evaporated and 
extracted with EtAc (300 ml). Evaporation of EtAc led to 94.2 mg biomass extract. The supernatant was 
extracted with EtAc (8 l) and resulted after evaporation in vacuum in 240 mg of an oily residue. The 
extracts from the feeding experiment were combined and loaded on Amberlite XAD16 column (500 × 3 
cm, water). The column was washed with water, water/MeOH 80:20, water/MeOH 60:40 and water/MeOH 
40:60 before elution of monoglycosylated alizarin started. The main fraction of monoglycosylated alizarin 
was eluted with pure MeOH and led to 209 mg pre-fraction which was purified further via semi-preparative 
HPLC (Nucleodur HTec, 250 × 10 mm, 5µm, A: CH3CN + 0.1 % FA; B: H2O + 0.1 % FA, detection λ = 
290 + 328 nm) using a 20 min gradient from 5% A to 95% of A, flow 3 ml/min, injection 100 µl/run 
(retention time: 16.8 min) The fraction was concentrated and extracted with ethyl acetate. The organic layer 
was washed with ammonium-formiat solution (50 mM), water (2 ×) and dried with Na2SO4. Fraction 4 led 
to 54.2 mg of a yellow powder related to glycosylated alizarin. The yellow powder was heated up in EtOH 
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(10 ml) and hot filtered through a sintered-glass funnel (porosity 4) to get rid of a kind of white insoluble 
compound. After removing the EtOH the yellow powder was recrystallized in MeOH and the solution was 
stored in the fridge ~ 2 weeks at 4 °C. Orange needles were achieved (28.4 mg). – Mp. 193-195 °C. – HR-
ESI-MS: pos. 387.1085 [M+H] +, 241.0495 [Alizarin+H]+. 
Sugar-cleavage of O-α-l-talosyl-1,2-dihydroxyanthraquinone and determination of d- and l-configuration  
The O-α-l-talosyl-1,2-dihydroxyanthraquinone (23.7 mg) was solved in dry MeOH (17.4 ml). Then Acetyl 
chloride (4.93 ml) was added and the solution was stirred at room temperature (16 h). The reaction control 
was done on TLC (SiO2, CHCl3/MeOH 4:1) using Orcin solution as spraying reagent. The finished 
reaction was evaporated under N2-stream and led to 31 mg of crude product. Column chromatography 
(SiO2, 1 × 16 cm, CH2Cl2/MeOH 7:4) led to three fractions. Fraction 1: mixture of Alizarin and sugar A, 
fraction 2: mixture of sugar A and B, fraction: 3 sugar B. Further column chromatography (SiO2, 1 × 16 
cm, CH2Cl2/MeOH 92:8) of fraction 1 and 2 with subsequent size exclusion chromatography on sephadex 
LH20 (1 × 16 cm, MeOH) led in total to 3.9 mg of sugar A, methyl-6-deoxy-α-l-talopyranosid. Fraction 3 
was purified via sephadex LH20 (1 × 16 cm, MeOH) and gave 0.4 mg of sugar B, methyl-6-deoxy-β-l-
talopyranosid (not pure). – Methyl-6-deoxy-α-l-talopyranosid: [α]20 = -100.85 (c = 2 mg/ml, MeOH), 
[α]20 = -87.35 (c = 2 mg/ml, H2O). – HR-ESI-MS: pos.179.0911 [M+H]+, 201.0731 [M+Na]+, 379.1571 
[2M+Na]+. 
 
Table S1: Physico-chemical properties of amycomycin C (1) and D (2) 
 1 2 
Appearance (solid) 
in MeOH (diluted) 
orange 
yellow 
violett 
red 
Molecular formula C31H32O13 C25H22O9 
Melting point °C 232 not determined 
HR-ESI-MS (m/z) 
Found [(M+H)+] 
Calcd [(M+H)+] 
 
613.1918 
613.1916 
 
467.1335 
467.1370 
UV λmax (ɛ) nm (MeOH) 224, 291 (1533), 312 (1727), 
420 (612) 
not determined 
CD: λmax (θ) (MeOH) 213 (+124), 223 (+118), 242 
(+77), 275 (+7), 311 (+41), 358 
(-303), 406 (+146), 451 (+234), 
510 (+100), 567 (+17) 
not determined 
IR ʋmax cm-1 3404, 2924, 2856, 2369, 1633, 
1459, 1363, 1284, 1235, 1102, 
1027, 974, 868, 812 
not determined 
 V. APPENDIX  
4 
 
Figure S1: UV-spectrum of 1 in MeOH (c = 25 mg/ml; 4.083∙10-4 mol/l) 
 
Figure S2: CD-spectrum of 1 in MeOH (c = 2 mg/ml; 3.27∙10-3 mol/l) 
 
Figure S3: IR-spectrum of 1 
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Figure S4. 1H NMR (500 MHz, 25 ºC, MeOD) spectrum of amycomycin C (1) 
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Figure S5. 13C NMR (500 MHz, 25 ºC, MeOD) spectrum of amycomycin C (1) 
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Figure S6. COSY (500 MHz, 25 ºC, MeOD) spectrum of amycomycin C (1) 
 
 
Figure S7. HSQC (500 MHz, 25 ºC, MeOD) spectrum of amycomycin C (1) 
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Figure S8. HMBC (500 MHz, 25 ºC, MeOD) spectrum of amycomycin C (1) 
 
 
Figure S9. TOCSY (500 MHz, 25 ºC, MeOD) spectrum of amycomycin C (1) 
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Figure S10. 1D TOCSY (600 MHz, 35 ºC, MeOD) spectrum of amycomycin C (1), excitation of 5.58 ppm  
 
 
Figure S11. 1D TOCSY (600 MHz, 35 ºC, MeOD) spectrum of amycomycin C (1), excitation of 5.82 ppm 
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Figure S12. band selective ROESY (600 MHz, 35 ºC, MeOD) spectrum of amycomycin C (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S13. band selective NOESY (600 MHz, 35 ºC, MeOD) spectrum of amycomycin C (1)
 
3‘-H/5‘-H 
5‘-H/3‘-H 
3‘‘-H/5‘‘-H 
5‘‘-H/3‘‘-H 
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Figure S14. 1H NMR (500 MHz, 25 ºC, MeOD) spectrum of amycomycin D (2) 
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Figure S15. COSY (500 MHz, 25 ºC, MeOD) spectrum of amycomycin D (2) 
 
 
 
 Figure S16. 1D-TOCSY (500 MHz, 25 ºC, MeOD) spectrum of amycomycin D (2), excitation of 
5.57 ppm 
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Figure S17. HSQC (500 MHz, 25 ºC, MeOD) spectrum of amycomycin D (2) 
 
 
Figure S18. HMBC (500 MHz, 25 ºC, MeOD) spectrum of amycomycin D (2)
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Figure S19. 1H NMR (500 MHz, 25 ºC, MeOD) spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
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Figure S20. 13C NMR (500 MHz, 25 ºC, MeOD) spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
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Figure S21. COSY (500 MHz, 25 ºC, MeOD) spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
 
 
 
Figure S22. HSQC (500 MHz, 25 ºC, MeOD) spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
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Figure S23. HMBC (500 MHz, 25 ºC, MeOD) spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
 
 
Figure S24. ROESY (500 MHz, 25 ºC, MeOD) spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
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Figure S25. 1H NMR (500 MHz, 25 ºC, CDCl3+CF3COOD) spectrum O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
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Figure S26. COSY (500 MHz, 25 ºC, CDCl3+CF3COOD) spectrum of O-α-l-talosyl-1,2-
dihydroxyantharquinone (3) 
 
 
Figure S27. NOESY (500 MHz, 25 ºC, CDCl3+CF3COOD) spectrum of O-α-l-talosyl-1,2-
dihydroxyantharquinone (3) 
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Figure S28. Expanded 1H NMR (500 MHz, 25 ºC, CDCl3+CF3COOD) spectrum O-α-l-talosyl-1,2-
dihydroxyantharquinone (3) 
 
 
Figure S29. Expanded NOESY (500 MHz, 25 ºC, CDCl3+CF3COOD) spectrum of O-α-l-talosyl-1,2-
dihydroxyantharquinone (3) 
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Figure S30. 1H NMR (500 MHz, 25 ºC, MeOD) spectrum of methyl-6-deoxy-α-l-talopyranosid
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Figure S31. COSY (500 MHz, 25 ºC, MeOD) spectrum of methyl-6-deoxy-α-l-talopyranosid 
 
 
Figure S32. HSQC (500 MHz, 25 ºC, MeOD) spectrum of methyl-6-deoxy-α-l-talopyranosid 
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Figure S33. Coupled HSQC (600 MHz, 25 ºC, MeOD) spectrum of methyl-6-deoxy-α-l-
talopyranosid, distance between crosspeaks result in 1J1’-C/1’-H = 171.8 Hz. 
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Table S2. MIC50 values (µM) against different pathogens and cell lines 
7 Amycomycin 
C (1) 
Amycomycin 
D (2) 
Monoglyc. 
Alizarin (3) 
Alizarin 
(reference) 
Bacillus subtilis >105 n.d. n.d. n.d. 
Micrococcus luteus >105 n.d. 13.2 86.7 
Staphylococcus aureus 
Newman 
>105 41.0 >105 No activity 
Mycobacterium 
diernhoferi 
>105 n.d. n.d. n.d. 
Candida albicans >105 n.d. >105 >105 
P.  anomala >105 32.0 >105 No activity 
Mucor hiemalis 94.2 9.21 >105 No activity0 
Chromobacterium 
violaceum 
>105 n.d. >105 >105 
E. coli 
 ToIC 
48.0 14.6 9.11 17.4 
E. coli DH5α >105 n.d. n.d. n.d. 
E. coli DSM116 n.d. n.d. >105 >105 
Pseudomonas aeruginosa 
PA14 
>105 n.d. >105 No activity 
Mycobacterium phlei n.d. n.d. >105 No activity 
HCT-116 >18.0 ~214 n.d. n.d. 
[a] Gram-positiv bacteria: M. luteus, St. aureus Newman; [b] fungi; [c] Gram-negative bacteria: 
E. coli; [d] human colon Carcinoma. n.d.: not determined.  
Biological Assay 
Bacterial Cultures. All microorganisms were handled under standard conditions recommended 
by the depositor. Overnight cultures of bacteria were prepared in EBS medium (0.5% peptone 
casein, 0.5% proteose peptone, 0.1% peptone meat, 0.1% yeast extract; pH 7.0) or TSB medium 
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(1.7% peptone casein, 0.3% peptone soymeal, 0.25% glucose, 0.5% NaCl, 0.25% K2HPO4; pH 
7.3). The latter medium was used for E. faecalis and S. pneumonia cultures. Yeast and fungi 
were grown in Myc medium (1% phytone peptone, 1% glucose, 50 mM HEPES, pH 7.0). 
Microbial Susceptibility Assay (MIC). Overnight cultures of microorganisms were diluted to 
OD600 0.01 (bacteria) or 0.05 (yeast-fungi) in the respective growth medium. Serial dilutions of 
compounds were prepared as duplicates in sterile 96-well plates. The cell suspension was added 
and microorganisms were grown overnight on a microplate shaker (750 rpm, 30°C or 37°C).  
Growth inhibition was assessed by measuring the OD600 on a plate reader. MIC50 values were 
determined as average relative to respective control samples by sigmoidal curve fitting.  
Cell Cultures. Cell lines were obtained from the German Collection of Microorganisms and Cell 
Cultures (Deutsche Sammlung für Mikroorganismen und Zellkulturen, DSMZ). All cell lines 
were cultured under conditions recommended by the depositor. Media were purchased from 
Sigma, fetal bovine serum (FBS Gold) from PAA, and other reagents from GIBCO (Invitrogen).  
Cytotoxic activity (IC50). Cells were seeded at 6 x 103 cells per well of 96-well plates in 180 μl 
complete medium and treated with compounds in serial dilution after 2 h of equilibration. Each 
compound was tested in duplicate as well as the internal methanol control. After 5 d incubation, 
20 μl of 5 mg-ml MTT (Thiazolyl blue tetrazolium bromide) [1] in PBS was added per well and 
it was further incubated for 2 h at 37°C. The medium was then discarded and cells were washed 
with 100 μl PBS before adding 100 μl 2-propanol-10 N HCl (250:1) in order to dissolve 
formazan granules. The absorbance at 570 nm was measured using a microplate reader (EL808, 
Bio-Tek Instruments Inc.), and cell viability was expressed as percentage relative to the 
respective methanol control. IC50 values were determined by sigmoidal curve fitting and values 
represent the average ± SD of two independent measurements. 
 
[1] Mosmann T (1983): Rapid Colorimetric Assay for Cellular Growth and Survival: 
Application to Proliferation and Cytotoxicity Assays. Journal of lmmunological Methods 65:55-
63. 
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Table S3. NMR spectroscopic data (500 MHz, 25 °C, MeOD) for amycomycin C (1) 
Pos. δC δH, mult, (J in 
Hz) 
COSY[a] HMBC[a] ROESY[a] bashdROESY[b] bashdNOESY[a,b] 
1 155.2 - - 2-H, 1’-H -   
2 113.6 7.26 d (1.1)  4-H 4-H, 3a-H3 (4-H), 1’-H, 
3a-H3  
  
3 143.4 - - 3a-H3 -   
3a 22.2 2.52 s 4-H 2-H, 4-H 2-H, 4-H   
4 121.2 7.32 s (br) 3a-H3, 2-H 2-H, 3a-H3, 
5-H 
3a-H3, 5-H   
4a 140.4 - - 4-H -   
5 118.5 7.75 s (br) - 4-H 2’’-H, 5-H   
6 153.6 - - 5-H 2’’-H   
6a 125.7 - - 5-H -   
7 189.2[a] - - - -   
7a 117.3 - - 11-H -   
8 162.8 - - 9-H, 10-H -   
9 124.2 7.24 dd (8.4, 
1.0) 
10-H 11-H 10-H   
10 137.7 7.69 dd (8.4, 
7.6) 
9-H, 11-H - 9-H, (11-H)   
11 118.3 7.46 dd (7.6, 
1.0) 
10-H 9-H 3’-H, 10-H   
11a 137.0 - - 10-H -   
12 187.9 - - 11-H -   
12a 141.4[a] - - - -   
12b 117.5 - - 2-H, 4-H, 5-
H  
-   
1’ 101.3 5.59 d (1.5) 2’-H 1J 2-H, 2’-H   
2’ 71.8 3.86 ddd (3.1, 
1.5, 1.5)  
1’-H, 3’-H, 
(4’-H) 
(1’-H) (3’-H) 1’-H 1’-H 
3’ 67.5 3.94 dd (3.2, 
3.1) 
2’-H, 4’-H 1’-H 2’-H, 4’-H, (5’-
H) 
11-H, 4’-H 11-H, 4’-H 
4’ 74.2 3.71 ddd (3.2, 
1.7, 1.5)  
(2’-H), 3’-H  5’-H, 6’-H 3’-H, 5’-H, 6’-
H 
5’-H, 3’-H, 6’-H 5’-H, 3’-H, (6’-H) 
5’ 69.9 4.15 d (6.7) 6’-H 1’-H, 6’-H 6’-H 3’-H, 4’-H, 6’-H 3’-H, 4’-H, 6’-H 
6’ 17.0 1.28 d (6.7) 5’-H 1J, 5’-H 4’-H, 5’-H   
1’’ 100.8 5.81 d (1.5) 2’’-H 5’’-H 4-H, 2’’-H   
2’’ 71.9 4.12 ddd (3.2, 
1.7, 1.5) 
1’’-H, 3’’-H, 
(4’’-H) 
1’’-H (1’-H), 3’-H, 
4’-H 
1’’-H, 3’’-H 1’’-H, 3’’-H 
3’’ 67.2 4.34 dd (3.4, 
3.2) 
2’’-H, 4’’-H 1’’-H 2’’-H,  4’-H, 
5’’-H 
5’’-H, 4’’-H 5’’-H, 4’’-H,  
4’’ 74.3 3.75 ddd (3.4, 
1.8, 1.7) 
(2’’-H), 3’’-
H  
(5’’-H), 6’’-
H 
3’-H, 5’-H, 6’-
H 
3’’-H, 5’’-H, 
6’’-H 
3’’-H, 5’’-H, (6’’-
H) 
5’’ 70.0 4.06 q (6.7) 6’’-H 1’’-H, 6’’-H 3’’-H, 4’-H, 6’-
H 
4’’-H, 3’’-H, 
6’’-H 
4’’-H, 3’’-H, 6’’-
H 
6’’ 16.9 1.21 d (6.7) 5’’-H 1J, 5’’-H 4’’-H, 5’’-H   
[a]weak signals are shown in brackets. [b] 600 MHz, 35 °C. 
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Table S4. NMR spectroscopic data (500 MHz, 25 °C, MeOD) for amycomycin D (2) 
Pos. δC δH, mult, (J in Hz) COSY[a] HMBC[a] 
1 155.9 - - 2-H, 1’-H 
2 113.2 7.15 s  4-H 1J, 4-H, 3a-H3 
3 144.2 - - 3a-H3 
3a 22.9 2.48 s 2-H, 4-H 1J 
4 121.2 7.22 s (br) 3a-H3, 2-H 2-H, 3a-H3, 1J 
4a 142.9 - - 4-H 
5 119.0 7.42 s - 4-H 
6 158.6 - - 5-H 
6a 139.6 - - 5-H 
7 194.7 - - - 
7a 117.3 - - 9-H, 11-H 
8 163.8 - - 9-H, 10-H 
9 125.0 7.27 d (8.3) 10-H, 11-H 1J, 11-H 
10 139.6 7.75 dd (8.3, 7.6) 9-H, 11-H - 
11 119.8 7.50 d (7.6) (9-H), 10-H 9-H 
11a 138.9 - - 10-H 
12 188.1 - - 11-H 
12a [b] - - - 
12b 118.1 - - 2-H, 4-H, 5-H  
1’ 101.8 5.57 s (br) 2’-H 1J 
2’ 72.4 3.87 ddd (3.1, 1.5, 1.5) 1’-H, 3’-H, 4’-H 1’-H, 4’-H 
3’ 68.2 3.94 dd (3.3, 3.1) 2’-H, 4’-H 1’-H 
4’ 74.2 3.72 s (br)  (2’-H), 3’-H  5’-H, 6’-H 
5’ 69.9 4.16 q (6.7) 6’-H 1’-H, 6’-H 
6’ 17.0 1.28 d (6.7) 5’-H 1J, 5’-H 
[a]weak signals are shown in brackets. [b] not detected from 2D-NMR HMBC spectra. 
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Table S5. NMR spectroscopic data (500 MHz, 25 °C, DMSO-d6) of 2-O-α-l-talosyl-1,2-
hydroxyanthraquinone (3) 
Pos. δC δH mult, (J in Hz) COSY[a] HMBC[a] ROESY[a] 
1 152.4   3-H  
2 149.8   1’-H, 3-H, 4’-H  
3 121.8 7.63 d (8.5) 4-H 1J 1’-H, (4-H) 
4 120.1 7.72 d (8.5) 3-H 3-H (3-H) 
4a 126.2   3-H,   
5 126.8 8.18 m 6-H 1J  
6 135.2 7.93 m 5-H 1J, 8-H  
7 134.3 7.93 m 8-H 5-H, 1J 8-H 
8 126.6 8.23 m 7-H 1J 7-H 
8a 133.3     
9 188.6   8-H  
9a 116.5   4’-H  
10 180.9   5-H, 4-H  
10a 132.9   6-H, 5-H, 8-H  
1’ 99.1 5.73 s (br)  (2’-H, 3’-H), 1J, (2’-OH) 2’-H, (2’-OH), 
3-H, 4-H 
2’ 70.0 3.85 m 2’-OH 3’-OH, 2’-OH, 1’-H, 4’-H,  3’-OH, 2’-OH, 
1’-H 
3’ 65.0 3.85 m 3’-OH (4’-H) (2’-H), 4’-H, 4’-OH, 3’-OH, 
2’-OH, 1’-H 
2’-H, 3’-OH 
4’ 72.0 3.59 d (6.5) 4’-OH, (3’-H, 4’-H) 3’-H, 5’-H, 6’-H3, 4’-OH, 
3’-OH 
3’-H, 4’-H, 4’-
OH, (3’-OH) 
5’ 68.5 3.85 m 6’-H3, (4’-H) 6’-H3, 4’-OH, 1’-H, 1J 4’-H, 4’-OH 
6’ 16.6 1.09 d (6.4) 5’-H 1J, 5’-H, (4’-H) 5’-H, (4’-H) 
1-OH  12.66 s (br)    
2’-OH  5.39 d (7.0) 2’-H  3’-H 
3’-OH  5.12 d (6.0) 3’-H  3’-H 
4’-OH  5.02 d (6.5) 4’-H  4’-H 
[a]weak signals are shown in brackets 
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Table S6. Band selective NMR data (500 MHz per 25 °C, CDCl3 + F3CCOOD ) for 2-O-α-l-
talosyl-1,2-hydroxyanthraquinone (3) 
Pos. δH mult, (J in Hz) COSY[a] NOESY 
1’ 5.83 s 2’-H 2’-H 
2’ 4.35 s (br) 1’-H 1’-H 
3’ 4.39 s (br) 4’-H 5’-H, 4’-H 
4’ 3.99 s (bs) (4.16), 4.39 5’-H, 3’-H, 6’-
H3 
5’ 4.16 q (6.5) 1.31 4’-H, 3’-H 
6’ 1.31 d (6.5) 4.16 5’-H, 4’-H 
[a]weak signals in brackets. 
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Table S7. NMR data (500 MHz per 25 °C, MeOD) for methyl-6-deoxy-α-L-talose gained from 
methanolic hydrolysis of 3. 
Pos. δC δH mult, (J in Hz) COSY[a] 
1’ 103.1 4.66 s (br) 2’-H 
1’-
OCH3 
55.0 3.36 s  
2’ 71.7 3.67 dd (3.3, 3.2) 1’-H 
3’ 67.1 3.69 m 4’-H 
4’ 74.0 3.59 dd (2.7, 1.5) 3’-H, 
5’ 67.7 3.84 q (6.6) 6’-H3, (4’-H) 
6’ 16.6 1.25 d (6.6) 5’-H 
[a]weak signals in brakets. R = OCH3 
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Figure S33. HR-ESI-MS spectrum of amycomycin C (1) 
EB_cb012inMeoh #362 RT: 4.14 AV: 1 NL: 1.55E6
F: FTMS + c NSI Full ms [200.00-2000.00]
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Figure S34. HR-ESI-MS spectrum of amycomycin D (2) 
eb000184-015_WatersF14 #799 RT: 5.45 AV: 1 NL: 1.53E6
T: FTMS + c NSI Full ms [50.00-1000.00]
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Figure S35. HR-ESI-MS spectrum of O-α-l-talosyl-1,2-dihydroxyantharquinone (3) 
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Table 1. Oligonucleotides used in this study 
 
Primer Sequence (5’→ 3’) Restriction 
site 
greTH-fF-SspI-f TTTAATATTCGTGCACGGGCGGACGGTGTT
a
 SspI 
greTH-fR-MCS-r TTTAATATTAAGCCGCCGCCGCCGAGGACG
a
 SspI 
greTH-fF-fus-r 
 
CGGCGGGGGAAAGGCTTATGGATATCTTCCGAGCC
TCCGTTGGGTG
a
 
EcoRV 
greTH-fR-fus-f CACCCAACGGAGGCTCGGAAGATATCCATAAGCCT
TTCCCCCGCCG
a
 
EcoRV 
greGT1-fR-f 
(fuz) 
CAGCACCGTACGGAGGCCTGAGATATCGCGGCACG
CCCGGACGGCCGG
a
 
EcoRV 
greGT1-fF-f CCCAATATTCCGGCCCGTTCCCCCTGACCG
a
 SspI 
greGT1-fF-r (fuz) CCGGCCGTCCGGGCGTGCCGCGATATCTCAGGCCTC
CGTACGGTGCTG
a
 
EcoRV 
greGT1-fR-r CCCAATATTGATCCGGAAGGCTCCAGGTCC
a
 SspI 
pCLY10-Gre-st TGGGCTGCAGGTCGACTCTAGAGGATCCGCGGCCGC
GCCCCCCGGATGGCGCGGCTGTGTGGTGCTTCAAAG
TGGC 
- 
pCLY10-Gre-end 
 
TCGCGCCCTCCATGAGGCGTACCCGAAGTTCACCGA
AGGTCGGACGCCGGGCCCCGGCCCGTCGATGCGCG
GCGGG 
- 
greR1-f GTGTGGTGCTTCAAAGTGGC - 
greR1-r GCCCCGGGCGGTGCTCACTG - 
greR3-f AGGGACCACCCCGTGAAAGC - 
greR3-r AAGCTTTATGTGCTCATGCC - 
greR2.1-f GGAGACCCGCCGGGTCCTGAT - 
greR2.1-r GGAACACGTTGATCATTTCGT - 
greR2.2-f CGGACTCCCACACGAGAGGAA - 
greR2.2-r GCCCTTCTCCACACGGATGGT - 
greR1-R2.1-f GTGGCCAACAACCCCGGCGCC - 
greR1-R2.1-r TAGAGGGTCAGCAGCGCCACC - 
greR2.1.-2.2-f CGGCTCGCCGAAGGAGCCCGA - 
greR2.1-2.2-r GGTGCCTTCGACGGTGGAGGC - 
greR2.2-R3-f ACTGGGCGGCGGAGCCCTGTG - 
greR2.2-R3-r GGCGCCGGTGCGTTCCCGCAG - 
‘a
 – restriction sites introduced artificially are marked in bold 
 
Table S2. Oligonucleotides used for sequencing pGRE 
 
Primer Sequence (5’→ 3’) 
gre-seq-51.2  AGACGGTCACGGACAACCTGC 
gre-seq-50.2 ATTCTGCTGGTCGTCTTCGGT 
gre-seq-49.2 TAACTCATGGGTAAGCCCTTA 
gre-seq-46.2 GGTGTACGTCGAAGGTGTTGA 
gre-seq-43.2  TATGTGCAGATGCAGCAGGTC 
gre-seq-41.2  AACCGTGGATGTACGAGAAGG 
gre-seq-39.2  AGCTGTACTTGGCCGACATCC 
gre-seq-36.2  AACTCTGTTCACTGCAAGCCG 
 VII. APPENDIX  
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gre-seq-35.2  TCAACTCCCTCACCCAGCACG 
gre-seq-34.2 AACTACACCAAGGTCCACAAA 
gre-seq-33.2  AACTCACCAACAGCGACATCA 
gre-seq-27.2  GGGTGATCGGCAACGACATCA 
gre-seq-24.2  AAGAACGCCATCGACTGGTTC 
gre-seq-23.2  AGAACTCCAAGGTCAGCAGCA 
gre-seq-18.2  GCTCATCAGCAGGTTCCTCTT 
gre-seq-12.2  AACATCACCATCAACAGCGTG 
gre-seq-7.1 TCATCGACACGAACCTCAACA 
gre-seq-4.1  TGGCCATGAAGCACCACGTGG 
gre-seq-1  ATCCGGTTGGTGTGTGATGTT 
gre-seq-2  ATAGCTTGCCAGGAGCAGTTC 
gre-seq-3  CGACGATGGGGCTCGACCAGG 
gre-seq-4  GGTCGGGCACTCTCTGGGCGC 
gre-seq-5 CCAGCGGAGTGGTCGTCAGCG 
gre-seq-6  CCGCGGCCACGGCGGCTTCAA 
gre-seq-7 CTGGTCAACAATGCGGGCCGC 
gre-seq-8 GTGAGAAGGACGAACGCATCC 
gre-seq-9 GCCGGTGTCGCCGAGGCCAGG 
gre-seq-10 CCGGCGCTTCGAACGGCTGGA 
gre-seq-11 GGCCTGCTGCTGAACATCTCC 
gre-seq-12 TCTTCATCATCCAGAGGGCGC 
gre-seq-13 GCTTCGGCGGACTGCTGCTGT 
gre-seq-14 GATCCGCTCGGCGCTGGGGGC 
gre-seq-15 GGAACGACGGCGGGCCGCTTC 
gre-seq-16 CGCCACCGAGATCCAGCACCA 
gre-seq-17 GACCGCTCGGACGACCCCGCC 
gre-seq-18 TCCTGATCCGCTCCCTGGCCAT 
gre-seq-19 GCACGGGCACCCGGCGGCACC 
gre-seq-20 GGCGGGATGCGAGCGGGCTAT 
gre-seq-21 CATTCCTGGAGGAGTGCCTCA 
gre-seq-22 CAGGCGCGGCTGCGAGGTCCT 
gre-seq-23 CCCCTGCGGGACGTGCTGTCC 
gre-seq-24 ACGCCGATCCGGCGACGGAGG 
gre-seq-25 GAGATGGAGGACGCCAACGCC 
gre-seq-26  CGCCCCGGCGCGACCCGGACG 
gre-seq-27 ACGCCGAACTCGCCGCGAGGG 
gre-seq-28 CCCGGCAGATCAACTACTCCG 
gre-seq-29 TCACCTACATCCCCCAGGACA 
gre-seq-30 CGTCCTGGACGGTGCCATGAT 
gre-seq-31 CCGAGAAGCTGATCCCGCTCT 
gre-seq-32 GGCTCCTCGGCCAACCTGCTC 
gre-seq-33 GGCTGCGGGAGGGACTGGACG 
gre-seq-34  GCCAAGGAGTTCGGCGGCGTC 
gre-seq-35 TCCTCGACACCGTGGAGCTGG 
gre-seq-36 CTCATGGAGAACGTGATGTTC 
gre-seq-37 CGGCGCTCGCCGCTGTCCTGC 
gre-seq-38   GCTGCACTACGCCAAGTACCT 
 VII. APPENDIX  
4 
 
gre-seq-39 GCCACCGGCCCCACCGCGCCC 
gre-seq-40 CGGCATGGTCTCCGGCCTCGA 
gre-seq-41 GCTGGCGCCCGGACGTCGTGG 
gre-seq-42 CCAGGAACTCCTGTCGAATCC 
gre-seq-43 GCCCCGGTGCTCGCGAAGTTC 
gre-seq-44 CGGAGGCCTGATGCGCGTCCT 
gre-seq-45 ACCCTCGCCCTCAACGGCGTA 
gre-seq-46 CCCGGAGACGGCCCGCCGTCC 
gre-seq-47 ACGCCTTCACGGCGGACTGCC 
gre-seq-48 CCGTGGCCGACGGGCCTCCTG 
gre-seq-49 AGTCTGTCGGGCTGTGCAGCC 
gre-seq-50 AAGGAGTTCGCCAAGGAGGGC 
gre-seq-51 GCCGGCTGCCGGCGGAGGCGG 
 
  
  
 
